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ABSTRACT

Erramilli, Satchal K. Ph.D, Purdue University, May 2016. Learning the ABCs of Ribose
Transport Using Biophysical Methods. Major Professor: Cynthia Stauffacher.
ATP-binding cassette transporters comprise a large superfamily of proteins that are
involved in a variety of biological phenomenon, from bacterial metabolism to cellular
homeostasis, antigen-presentation, and drug resistance. These proteins are implicated in a
variety of clinically relevant phenomenon, including the human diseases cystic fibrosis,
macular degeneration, and cancer. Understanding their structure-function can guide
therapeutics and contribute to our overall understanding of these biological phenomena.
This study focuses on understanding the motor protein of the bacterial ribose ABC
transporter in the context of transport. This complex is required for the uptake of the
nucleotide precursor, ribose. Using biophysical methods, we seek to better understand the
protein conformational changes and dynamics that link ATP utilization with ribose uptake.
We use site-directed spin-labeled electron paramagnetic resonance spectroscopy and
fluorescence binding studies to understand how the motor protein interacts with ATP, and
how conformational changes associated with this interaction fuel transport.
These studies reveal the motor protein, RbsA, is regulated from across the cell
membrane by the availability of the transported substrate. This regulation comes from the
form of a substrate-binding protein, RbsB, which binds ribose in the periplasm and delivers
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it to the membrane spanning permease, RbsC. Transmembrane signaling connects RbsB
arrival at RbsC with inward rotations of RbsA subdomains that stimulate ATP hydrolysis.
This leads to ribose delivery to the permease translocation channel. Post-hydrolysis,
outward rotation of RbsA subdomains then result in the release of RbsB from the transport
complex.
This process is completed by an unusual mechanism. Though the topology of RbsA
predicts two ATP binding sites, and ABC transporters typically possess two equivalent
ATP binding sites in their motor proteins, loss-of-function mutations have rendered one
site inactive. Fluorescence binding studies reveal both sites are occupied with ATP, yet
only one remains active. Thus, the conformational changes that drive active transport are
driven solely by one half of the motor.
These studies provide a model for how the ribose transporter functions. As more
ABC transporters, and in particular human proteins, are observed with similar halfmotors, these studies may provide a general mechanism that can be applied globally to
these systems. High-resolution structural information would provide a more complete
picture of ribose transporter function. In collaboration with the University of Chicago,
phage display experiments have identified several dozen crystallization chaperones in the
form of high-affinity synthetic antibodies that will aid crystallization of ribose transporter
proteins. Crystallization trials with these reagents are currently being pursued.

1

CHAPTER ONE: AN INTRODUCTION TO ABC TRANSPORTERS

1.1 Membrane Transporters: Cellular Gatekeepers
All cells are surrounded by semi-permeable membranes, which encase each cell in
a protective lipid bilayer built to not only hold its contents but also to protect and preserve
the treasures within. The costs of the protective function include special challenges for
moving substances across this lipid-filled moat, which is impermeable to most relevant
biomolecules except for the smallest of substances, such as oxygen and carbon dioxide.
Relevant biomolecules include not only toxins and wastes, which must be exported in a
timely manner, but also important cellular foodstuffs and critical ions, which must be
efficiently imported to meet cellular metabolic demands. As a means to overcome such
challenges, cells have evolved special classes of transport proteins. While costly to produce
in terms of time and resources, these proteins provide the cell virtually complete control of
everything that enters and exits its gates.
Broadly, these proteins can be classified as channels and primary and secondary
active transporters (FIGURE 1.1) (Lodish, et al. 2000). Channels provide pathways for the
passive movement of substances into or out of cells and their compartments. These include
the primarily alpha-helical channels (such as those for ions and water) as well as the betabarrel outer-membrane porins found in gram-negative bacteria. Entry to these channels is
carefully controlled by gates, which open and close in response to, for
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FIGURE 1.1: Schematic view of transport systems spanning the cell membrane (yellow).
(A) Left to right: Channels (blue) contain either intra- or extra-cellular gates that allow
control of opening and closing of passive transport pathways for substrates (green); Pumps
(maroon) utilize ATP hydrolysis to concentrate substrates (purple) on one side of the
membrane; Transporters (orange) utilize a mechanism of alternating access of substrate
binding sites to deliver substrates across membranes (bright red). (B) General transport
mechanisms. Left to right: Uniporters (teal) provide passive pathways for substrate
diffusion down concentration gradients; Symporters (light green) couple the favorable
transport of one substrate (black) with the unfavorable transport of another (orange), both
in the same direction across the membrane; Antiporters (royal blue) utilize a similar
coupling, except the direction of transport is opposite for each substrate.
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example, voltages and mechanical stress, and selectivity filters, which define cargo
specificity (Roux, et al. 2011). Specific channels exist, for instance, for water, sodium,
potassium, and calcium (Gouaux and MacKinnon 2005).
Transporters generally provide the ability to selectively concentrate substances
inside or outside of cells, a process requiring expenditure of energy, and are grouped by
energizing mechanisms (White 2009). Primary active transporters transport substances
against their concentration gradients by utilizing the free energy released by ATP
hydrolysis (Hobbs and Albers 1980). Examples include pumps such as the
sodium/potassium ATPase and traffic ATPases, which will be discussed below. Secondary
active transporters couple transport down favorable cellular gradients, such as those for
sodium ions or protons, to the unfavorable transport of relevant substances (Forrest,
Kramer and Ziegler 2011). These include uniporters, symporters, such as the sodiumglucose transporter, and antiporters, such as the sodium-calcium exchanger.

1.2 ABC Transporters: Powering the Processes of Life
Within these general classes of transport proteins exist conserved families that are
ubiquitously distributed and, as a whole, involved in nearly every imaginable biological
process (Higgins 1992). Over three hundred different families of channels and transporters
have been identified (Saier, Tran and Barabote 2006). Among these, two of the largest
superfamilies include the secondary transporter family known as secondary major
facilitators (MFS) and the primary traffic ATPases, or ATP-binding cassette (ABC)
transporters. ABC transporters are ATP-powered pumps, and broadly form one of the
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largest superfamilies of paralagous proteins known (Davidson, et al. 2008). ABC
transporters are found in nearly every species known, from the simplest of microorganisms
to man (Holland, et al. 2003). Fully five percent of the Escherichia coli genome codes for
ABC transporters, and nearly fifty have been identified in Homo sapiens (Rees, Johnson
and Lewinson 2009). Their prevalence and ubiquitous distribution both account for their
role in a variety of clinically-relevant phenomena (TABLE 1.1) including pathogenesis
and virulence (Lewis, Ween and McDevitt 2012), drug resistance in bacteria and cancer,
and the genetic diseases cystic fibrosis, Tangier disease, Stargardt disease, and age-related
macular degeneration (Borst and Elferink 2002). In total, thirteen known genetic diseases
have been directly linked to defects in fourteen human ABC transporters (Gottesman and
Ambudkar 2001).
The superfamily consists of three principal functional classes that likely diverged
at an early stage of evolution: importers, exporters, and non-transport proteins, which as a
group mediate an impressively diverse array of vital biological phenomena (FIGURE 1.2)
(Davidson, et al. 2008). Importers are typically prokaryotic and fulfill the uptake of a
variety of nutrients, including sugars, amino acids and peptides, ions, trace metals, and
vitamins (Cui and Davidson 2011). Exporters, found in all domains of life, deliver a similar
variety of substances out of cells and cellular compartments: peptides
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Table 1.1 – ABC transporters linked to human diseases and bacterial pathogenesis.
Adapted
from
Gottesman
and
Ambudkar
(2001)
and
http://www.genenames.org/genefamilies/ABC.

Disease
Age-related macular
degeneration
Cancer

Transporter
ABCR (ABCC7)

References
Allikmets, et al. 1997
Chen, et al. 1986

Cystic Fibrosis

MDR1 (ABCB1), MRP1
(ABCC1), MXR (ABCG2)
CFTR (ABCC7)

Riordan, et al. 1989

Dubin-Johnson Syndrome

MRP2 (ABCC2)

Paulusma, et al. 1996

Immune deficiency

TAP1/TAP2
(ABCB2/ABCB3)
MDR2 (ABCB4),
SPGP (ABCB11)

Momburg, et al. 1994

ABC1 (ABCA1)

Brooks-Wilson, et al. 1999

Wzt/Wzm (O-antigen,
many species), MsbA (lipid
A, many species), TagGH
(Teichoic acid, B. subtilis,
S. aureus)
HlyB (hemolysin, E. coli),
CylT (cytolysin, E.
faecalis)
DrrAB (doxorubicin, S.
peucetius), McjD (microcin
E. coli), MacB (E. coli),
LmrA (L. lactis) and
Sav1866 (S. aureus)
(polyspecific xenobiotic
exporters)
FbpABC (N. gonorrhoeae)
and HitABC (H. influenzae)
(iron acquisition)

Kauffmann 1947
Raetz, et al. 2007
Whitfeld, Cuthbertson and
Powers 2005

Progressive familial
intrahepatic cholestasis
Tangier disease and
Alzheimer’s Disease
Bacterial pathogenesis –
LPS production

Bacterial pathogenesis –
toxin secretion
Bacterial pathogenesis –
antibiotic/antimicrobial
resistance

Bacterial virulence

de Vree, et al. 1998

Blight and Holland 1990
Guilfoile and Hutchinson
1991
Choudhury, et al. 2014
Davidson, et al. 2008
Dawson and Locher 2006
Strange, Zola and
Cornelisson 2011
Adhikari, et al. 1995
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Figure 1-2: The diversity of ABC transporters. (A) Vitamin B12 is taken up in gramnegative bacteria by the outer membrane receptor BtuB, which is coupled to the energytransducing complex ExbBD-TonB. B12 is then captured in the periplasm by BtuF, which
delivers it to the inner membrane ABC transporter BtuCD for import. (B) Maltose diffuses
into the periplasm through maltoporins like LamB, where it is captured by MalE and
delivered to the ABC transporter MalFGK for cytoplasmic import. (C) ECF transporters
deliver micronutrients like folate using a unique mechanism. (D) ABC exporters, like HlyB
in E. coli, play a critical role in toxin export. HlyB complexes with a membrane fusion
protein (MFP) and the outer membrane protein TolC to extrude hemolysin toxin. (E) MsbA
is an ABC transporter that flips lipids from the inner to the outer leaflet of cell membranes
in many species. (F) Gram-positive bacteria use ABC transporters with a membraneembedded substrate-binding domain, like the zinc importer from S. aureus. (G) Pglycoprotein is a mammalian toxin exporter that has been implicated in cancer drug
resistance. (H) CFTR is an ABC transporter that functions as a chloride channel, and
contains a cytoplasmic regulatory domain and all other domains on a single polypeptide.
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proteins, lipids, polysaccharides, toxins, and hydrophobic drugs (Locher, 2009). A recently
identified third type of ABC transporter, termed energy-coupling factor (ECF) transporters,
is structurally and functionally distinct from typical ABC importers and is involved in the
uptake of trace metals and vitamins in prokaryotes (Slotboom, 2014). Finally, ABC
proteins not obviously associated with transporters are ubiquitous and thought to be
involved in mRNA translation and DNA repair (Hopfner & Tainer, 2003), although
recently characterized “orphan ABCs” may participate in transport either directly or
indirectly (Ferreira & de Sa-Nogueira, 2010). The latter two functional classes will be
discussed in greater detail later.

1.3 A Common Structural Organization
Despite the difference in substrate population and the direction of transport, both
importers and exporters share common structural features. All ABC transporters contain,
at minimum, two nucleotide-binding domains (NBD), present in the cytoplasm or lumen
of organelles, and two hydrophobic transmembrane domains (TMD), spanning either the
plasma or organellar membranes (Rees, Johnson, & Lewinson, 2009). These subunits
assemble to form the basic functional unit of an ABC transporter (FIGURE 1.3). In
prokaryotic importers, this assembly typically consists of each domain expressed as
separate polypeptides (Davidson, Dassa, Orelle, & Chen, 2008). Thus, ABC importers
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Figure 1-3: Organization of ABC transporters. Top: Importer organization. (A) ABC
importers, like the pictured Vitamin B12 transporter, are composed of homodimers of the
TMD (e.g. BtuC) and NBDs (BtuD). (B) The maltose importer is composed of
heterodimers of the TMD (MalF and MalG) and homodimers of the NBD (MalK). (C) ECF
transporters contain heterodimers of the TMD (EcfT and EcfS) and heterodimers of the
NBDs (EcfA and EcfA’). (D) In rare cases, importers such as the arabinose transporter are
composed of homodimers of the TMD and a fused NBD. (E) Typical exporters, like HlyB,
contain a fused N-terminal TMD with C-terminal NBD, which forms dimers as intact
transporters. (F) Some mammalian exporters contain all four domains on a single
polypeptide (e.g. P-glycoprotein). (G) Some transporters also contain additional regulatory
domains, like the cystic fibrosis transmembrane regulator (CFTR, RD is orange circle). (H)
Non-transport ABC proteins, like the DNA-repair enzyme Rad50, contain NBDs fused by
a linker region and additional domains involved in DNA recognition.
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normally exist as pairs of either homo- or heterodimers, as in the prototypical vitamin B12
and maltose transporters in E. coli. Exceptions to this organization exist and will be
discussed later. Exporters from all kingdoms usually possess a fused NBD-TMD
arrangement, with each present as independently folded domains on a single polypeptide.
These can be expressed as an N-terminal TMD with C-terminal NBD fusion, as in the case
of the of hemolysin transporter HlyB, or with the more rarely seen NBD-TMD arrangement
(Davidson, Dassa, Orelle, & Chen, 2008). An example of the latter organization is the
macrolide exporter MacB found in E. coli, which contains a membrane insertion signal
sequence following the N-terminal NBD (Kobayashi, Nishino, & Yamaguchi, 2001). The
fused protein then assembles also as a homo- or heterodimer to form the functioning unit
of the typical exporter. Notable exceptions include P-glycoprotein, a eukaryotic drug
exporter also known as MDR1 (Gottesman & Pastan, 1993), and the cystic fibrosis
transmembrane conductance regulator (CFTR), the chloride channel implicated in the
eponymous genetic disease, which both have all four domains expressed on the same
polypeptide (Dean, Hamon, & Chimini, 2001). In certain exporters, the NBDs are
expressed separately and assemble with the TMDs post-translation (Cuthbertson, Kos, &
Whitfield, 2010). Finally, ABC proteins not involved in transport typically consist of fused
NBDs and no associated TMDs (Hopfner & Tainer, 2003). These proteins are marked by
differences in conserved features, which will be discussed in the following section.
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1.4 Conserved Elements: The Nucleotide-binding Domain
All ABC proteins share highly-conserved sequence elements that are required for
the binding and hydrolysis of ATP (FIGURE 1.4A). Indeed, these features define and link
all members of this protein family. Structurally, each NBD is roughly L-shaped, with a
larger, RecA-like subdomain that is typical of P-loop ATPases and a smaller helical domain
that is unique to ABC proteins (FIGURE 1.4B). In the RecA-like domain, an aromatic
amino acid, usually tyrosine, and the Walker A motif [GXXGXGK(S/T)] form the ATPbinding site, with the aromatic positioning the ATP via ring-stacking and backbone amides
and the lysine amino group from the Walker A motif forming interactions with the β- and
γ-phosphates (Higgins & Hinton, The ATP switch model for ABC transporters, 2004). The
Walker B motif (φφφφDE, φ = any hydrophobic amino acid) is involved with hydrolysis,
with the conserved aspartate coordinating a magnesium ion and the glutamate coordinating
an attacking water molecule. This water is critical for hydrolysis, and supports the
traditionally accepted “general base” model for catalysis (Oldham, Davidson, & Chen,
2008). In addition, the H-loop contributes a conserved histidine that disrupts the stability
of the binding site once the bond between the β- and γ-phosphates is cleaved. For this
reason, it is also known as the switch histidine (Higgins & Hinton, The ATP switch model
for ABC transporters, 2004). The D-loop (SALD) stabilizes the binding site by interacting
with its cognate partner in the opposite monomer
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Figure 1-4: Structure and organization of ABC transporter nucleotide-binding domains. (A)
Schematic diagram of NBD protein sequence from N- to C-terminus with conserved
sequence motifs highlighted in color. (B) Cartoon representation of HlyB (hemolysin toxin
transporter) composite NBD dimer with bound ATP (brown) and Mg2+ (PDB ID: 1XEF).
RecA-like subdomain is shown in cyan and helical domain in light blue. Conserved
sequence motifs highlighted in color: Walker A (red), Walker B (magenta), ABC signature
(orange), Q-loop (blue), D-loop (dark blue), and H-loop (green).
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(Jones & George, 2012). The Q-loop, lying between the two subdomains, is the major site
of interaction with the TMD, and is critical for the signal transduction linking ATP
hydrolysis with substrate transport (Jones & George, 2002). ABC exporters contain an
additional short sequence motif (TEVGERV) in the structurally diverse helical region of
exporter NBDs that is also thought to be required for signal transduction between opposing
domains (Locher, 2009). Finally, the signature sequence (LSGGQ), unique to ABC
proteins and located at the N-terminus of a long alpha helix in the helical domain,
completes the binding site by directing the positive charges of the helical dipole towards
the γ-phosphate (ter Beek, Guskov, & Slotboom, 2014). Some NBDs also possess an
additional regulatory domain (RD) that mediates active transport depending upon the
abundance of the transported substrate, a process known as trans-inhibition (BiemansOldehinkel, Doeven, & Poolman, 2006).
The NBDs of ABC proteins typically function as dimers, with the canonical system
forming two equivalent ATP binding sites at the interface of the two monomers, related to
one another by pseudo two-fold symmetry. Structural and functional studies have revealed
distinct conformations of the monomers relative to one another, and in the absence of ATP
they remain separated in an “open” conformation. ATP binding results in the “closed”
conformation, where the signature sequence from one monomer moves close, via rigidbody rotations, to the Walker A and B motifs and the A-, H-, and D-loops of the opposing
monomer to form the intact binding site (Chen, Lu, Lin, Davidson, & Quiocho, 2003). In
essence, each monomer contributes a half-binding site, and dimerization results in two
equivalent ATP-binding sites, at least in canonical systems. Examples of such systems
include the well-characterized maltose, vitamin B12, and histidine transporters, which have
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been studied extensively both biochemically and structurally (Wen & Tajkhorshid, 2008).
These studies have revealed a closure of dimers upon ATP and magnesium binding, with
hydrolysis subsequently resulting in a “semi-open” conformation, as the bonds supporting
the γ-phosphate are broken (Orelle, Ayvaz, Everly, Klug, & Davidson, 2008). The NBDs
are then reset to “open” once ADP and magnesium are ejected. While it is tempting, given
the equivalency, to assume both ATPs are hydrolyzed per transport cycle, experimental
evidence is at best mixed for this model (Oswald, Holland, & Schmitt, 2006). A thorough
discussion of the stoichiometry of transport, the conformational changes in NBDs, and
deviations occurring in non-canonical systems can be found in subsequent sections.

1.5 Non-conserved Elements: The Transmembrane Domains
While the ABC protein provides the conserved elements that are hallmarks of this
protein family, the transmembrane domains exhibit little conservation with respect to the
sequence level (Davidson, Dassa, Orelle, & Chen, 2008). This is unsurprising: given the
diverse chemistry of substrates recognized and transported by ABC transporters, it should
be expected that each transporter contain binding pockets designed to recognize its specific
cargo. What is surprising is that the evidence for such binding pockets is hardly ubiquitous
for this family. Well-defined substrate-binding sites have been found in several cases, but
not all; importers such as the vitamin B12 transporter lack clear substrate-binding sites in
the TMDs (Korkhov, Mireku, & Locher, 2012), while the maltose transporter has a wellcharacterized maltose-binding pocket (Oldham, Khare, Quiocho, Davidson, & Chen, 2007)
(Oldham, Chen, & Chen, 2013). Perhaps more surprisingly, there exist several transporters,
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primarily exporters, which are each capable of recognizing a range of substrates, in some
cases with widely differing chemistries (Siarheyeva, Lopez, & Glaubitz, 2006). The most
well-known example of this promiscuity is found in the eukaryotic exporter P-glycoprotein,
which recognizes hydrophobic drugs, toxins, peptides, and proteins using a large and varied
patch of amino acids in the inner lining of its transmembrane cavity (Sharom, 2011).
What, then, can be considered a typical TMD for ABC transporters, and do any
shared features exist? Here it is most convenient to consider importers, exporters, and ECF
transporters separately (FIGURE 1.5). The simplest description can be made for exporters,
which typically consist of six core TM helices per TMD, forming translocation pathway
lined by twelve total TM helices in the dimer assembly (ter Beek, Guskov, & Slotboom,
2014). These helices typically extend far into the cytoplasm, positioning the NBDs nearly
25 Å from the membrane. (Importer NBDs lie much closer to the membrane.) Substrate
binding sites generally line the exposed cytoplasmic surfaces of
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Figure 1-5: Diversity of ABC transporter transmembrane domains. Grey bar is membrane.
(A) Type I ABC importers contain 6-8 TM helices per monomer, as shown with MalF
(yellow, 8 TM helices) and MalG (pink, 6 TM helices) (PDB ID: 2R6G). The core is
formed by 6 helices. (B) Type II ABC importers contain 10 TM helices per monomer, as
shown with BtuC2 (blue and green monomers) (PDB ID: 1L7V). (C) ECF transporters
(Type III ABC importers), such as the folate transporter (PDB ID: 4HUQ), contain 4 TM
helices in both the EcfT domain (yellow) and the EcfS domain (pink), each with different
amino acid properties. (D) ABC exporters, such as Sav1866 (PDB ID: 2HYD), contain 6
TM helices per monomer (blue and green), each with a large cytoplasmic region known as
the intracellular domain (ICD) or intracellular loop region (ICL).
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each TMD. The primary site of communication between the TMDs and the NBDs is the
coupling helix, also known as intracellular loop 1 (ICL1), which links TM helices 2 and 3
in crystal structures thus far solved (Prasad & Goffeau, 2012). In rare cases, the TMDs
contain only 4 putative TM helices, such as the E. coli macrolide exporter (Kobayashi,
Nishino, Hirata, & Yamaguchi, 2003); less is known about how such transporters function.
The picture is more complex for importers, including ECF transporters (Rice, Park,
& Pinkett, 2014). As crystallographic studies began to provide structural information of
ABC transporters, importers were segregated into two subtypes based initially on the
number of TM helices per monomer. Type I systems contained 6-8 TM helices per
monomer, with the lining of the pore formed by six core TM helices. The most well
characterized example of this importer subtype is the E. coli maltose transporter, which
contains a heterodimer of TMDs (Davidson, Dassa, Orelle, & Chen, 2008). Structural
studies have identified a clear maltose-binding pocket present in one of the two TMDs
(Oldham, Chen, & Chen, 2013). Transport is fulfilled by rigid-body rotations in the TMDs
relative to one another (Khare, Oldham, Orelle, Davidson, & Chen, 2009); these changes,
along with a more thorough description of importer subtypes, will be discussed more
thoroughly in a subsequent section.
Type II importers typically contain 10 TM helices per monomer and thus 20 in total
in the assembled dimer. Structures of the vitamin B12 transporter and molybdate transporter
initially shed light into the organization of these “large” ABC importers, which have more
voluminous translocation pathways with limited conformational changes to fulfill transport
(Rice, Park, & Pinkett, 2014). However, none these nor studies of additional Type II
importers revealed the presence of a clearly defined substrate binding site in the TMD.
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Rather, a hydrophobic surface forms the inner lining of the substrate pocket, preventing
interactions with the hydrophilic substrate to form a “Teflon-like” transport channel, with
the accessory binding protein providing the key regulatory step in the transport pathway
(Korkhov, Mireku, & Locher, 2012). The role of the binding protein will be elucidated in
the next section.
The inclusion of ECF transporters as a third type of ABC importer is recent, though
their existence has been known since the 1970s. Much like other ABC importers, ECF
transporters are critical for the uptake of nutrients in bacteria and archaea, and possess
dimers of NBDs to provide the energy required for active transport. ECF transporters
diverge at the TMD level: unlike ABC transporters, this group is obligatorily heterodimeric,
with each TMD unrelated to the other both functionally and structurally (Slotboom, 2014).
One TMD, termed the EcfT subunit, consists of a predicted 4 to 8 TM helices, although
recent crystal structures of intact transporters have 5. The other TMD is known as the S
component, an integral membrane protein with 6 core helices that binds the transported
substrate with high affinity, in the low nanomolar range. No translocation pathway exists,
and transport appears to be fulfilled solely by conformational changes of the S-component,
which appear to be sensitive to the presence of ATP. Each S-component contains a single,
extracellular binding site, which is capped by a loop between TM1 and TM2. Interestingly,
only the EcfT subunit, which contains two long cytoplasmic helices, appears to interact
with the NBDs, and in much the same manner and location as other ABC transporters (Xu,
et al., 2013). How ATP hydrolysis is linked to transport is still a matter under investigation,
not just for ECF transporters but also for other ABC importers and exporters, but cannot
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thoroughly be appreciated without first considering the critical role of the substrate binding
protein for the uptake of nutrients.

1.6 Not Just An Accessory After the Fact: The Substrate Binding Protein
A variety of pathways and complexes, including transport and non-transport related
systems, involve substrate binding proteins (SBP), or substrate binding domains (SBD). In
this section only the SBPs involved in ABC transporter systems will be considered. The
SBPs are critical components of ABC importers, as involved in the process as the TMDs
and NBDs. They are intracellular scavengers, capturing their prey – the substrates – with
high affinity (0.01 to 1 µM) and navigating promptly to the translocators, the TMDs, which
cajole them to finally release the substrate for transport (Davidson, Dassa, Orelle, & Chen,
2008). However, SBPs are not just specialized delivery systems that enable substrate
transport at low concentrations; even at high substrate concentrations, they are required for
uptake, and thus are active participants in the process of active transport (Shuman, 1982).
The interplay of the SBP, TMDs, and NBDs as they assemble and ultimately deliver their
cargo represents an elegant demonstration of signal transduction across the cell membrane,
tightly linking the hydrolysis of ATP with the presence of the transported substrate (Chen
J. , 2013).
Before describing the current mechanistic understanding of how the SBP interacts
with the TMD and how this information is communicated to the NBD, it is instructive to
consider the diversity of SBPs themselves. Much like ABC transporter TMDs, there is little
sequence conservation among SBPs, perhaps unsurprising given the diverse chemistries of
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their substrate. SBPs are, much like the TMDS, related at the structural level, and are
segregated into several distinct classes based on conserved three-dimensional folds
(TABLE 1.2) (Berntsson, Smits, Schmitt, Slotboom, & Poolman, 2010). The differences,
however, are subtle: all SBPs share the same basic architecture, a bilobal structure
connected by a hinge that causes the lobes to snap shut, thus capturing the substrate by a
“Venus fly trap” mechanism, where a single binding site exists between the two lobes (Mao,
Pear, McCammon, & Quiocho, 1982). Each lobe of the SBP must then interact with each
TMD monomer to reopen the trap and release the prey (Bohm, Licht, Wuttge, Schneider,
& Bordignon, 2013).
From this basic bilobal outline, six different clusters of SBPs arise (FIGURE 1.6),
each containing structural or chemical properties allowing for recognition of specific
substrates and transporter subtypes (Berntsson, Smits, Schmitt, Slotboom, & Poolman,
2010). The nature of classification and details of all six clusters, which include many SBPs
not involved with transport, can be found in the review by Berntsson et al; here we consider
only those relevant to ABC transporters.
Cluster A contains SBPs associated exclusively with ABC transporters and these
proteins are defined by an α-helix serving as the hinge region between the two lobes. This
confers rigidity to Cluster A SBPs, where limited rotation of the two lobes results in closure
upon substrate binding. For example, structures of BtuF, the vitamin B12 binding protein,
reveal only a 4° rotation from the apo to holo forms (Rice, Park, & Pinkett, 2014). All
Cluster A SBPs are involved with metal binding either directly, such as the iron, manganese,
and zinc binders, or indirectly in chelated form, such as the B12 and heme binders.
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Table 1-2: Substrate-binding protein classification, associated ligand specificity and
transporter type, and available PDB structures of representative proteins. Adapted from
Berntsson et al.
SBP
Cluster

Ligands

Association

Example SBPs
(PDB IDs)

A

Metal ions,
siderophores

ABC transporters only

BtuF (1N2Z, 1N4A, 1N4D,
2QI9)
MntC (1XVL)

B

Carbohydrates,
amino acids (L, I,
V),
small peptides

ABC transporters,
two-component signal
transducers,
receptors;
lacR homologs

MBP (1ANF, 1DMB,
1EZ9, 1EZ0, 1EZP…)
RBP (1BA2, 1DBP, 1DRJ,
1URP, 2DRI, 2FN8, 2FN9)

C

Arginine,
small peptides,
nickel

ABC transporters only,
large extra domain

OppA (3DRF, 3DRG,
3DRH,
3DRI, 3DRJ, 3DRK, 3FTO)

D

Carbohydrates,
thiamine,
oxyanions, iron

ABC transporters only
Carbohydrate binders have extra
domain

FbpA (1SI0, 1SI1, 1Q35)
PotD (1POT, 1POY)
TbpA (2QRY)

E

Sialic acid,
2-keto acids,
lactate,
ectoine

TRAP transporters only

SiaP (2CEY, 2CEX)
TTHA0766 (2ZZV, 2ZZW,
2ZZX)

F

Triognal planar
anions
methionine
amino acids

ABC transporters
ligand-gated ion channels
GPCRs

ArtJ (2PVU, 2Q2A, 2Q2C)
HisJ (1HPB, 1HSL)
ModA (2ONR, 2ONS)
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Cluster B contains SBPs that interact with ABC transporters, two-component signal
transducers, and certain peptide receptors, and are homologues of the lac-repressor type
transcription factors (Mauzy & Hermodson, 1992). Rather than a single helix, cluster B
SBPs contain three hinges between the two lobes, conferring greater flexibility. Indeed,
structures of cluster B SBPs reveal a significant rotation of the two lobes upon substrate
binding (Bjorkman & Mowbray, 1998). These proteins are involved in the binding of
simple sugars, such as arabinose, galactose, and ribose, as well as branched-chain amino
acids and small peptides.
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Figure 1-6: Representative structures of SBPs from each cluster. Hinge regions and distinct
features colored in brick red (A) Cluster A contains SBPs with helical hinge region, like
BtuF (PDB ID: 1N2Z). (B) Cluster B contains proteins with three loops forming a flexible
hinge, like RbsB (ribose-binding protein, PDB ID: 1BA2). (C) Cluster C contains proteins
with a large extra domain, which extends the substrate-binding site for larger substrates,
such as in OppA (oligopeptide-binding protein, PDB ID: 3DRF). (D) Cluster D contains
SBPs with short hinges, like in FbpA (iron-binding protein, PDB ID: 1S10). (E) Cluster E
contains SBPs of TRAP transporters with a large helical hinge, like SiaP (sialic acidbinding protein, 2CEY). (F) Cluster F contains SBPs with two hinges for greater flexibility,
like ModA (molybdate-binding protein, PDB ID: 2ONR).
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The bilobal forms with either rigid or flexible hinges represent the two extremes in
SBP structural diversity. All of the other clusters include designs similar to these, but with
slight variations. Cluster C also includes SBPs only associated with ABC transporters. This
group is marked by an additional domain that extends the substrate-binding site,
accommodating the larger oligopeptides that these proteins bind. Interestingly, not every
Cluster C SBP binds large substrates. Cluster D, which features a flexible hinge containing
two short strands (4-5 amino acids), also includes ABC transporter SBPs. Some of these,
such as the well-characterized maltose-binding protein (MBP) (Sharff, Rodseth, Spurlino,
& Quiocho, 1992), include an extra domain, while others are involved in the capture of
tetrahedral oxyanions. Cluster F includes some SBPs that participate in ABC-dependent
transport, and is marked by a two-stranded hinge consisting of 8-10 amino acids, which
allows greater flexibility to capture larger ionic substrates. Finally, Cluster E includes SBPs
that are components of tripartite ATP-independent periplasmic (TRAP) transporters.
While substrate-binding proteins are critical components of most ABC importers
and other transport and non-transport systems, they are not employed by ECF transporters
or by ABC exporters. Exporters contain substrate-binding sites within the cytoplasmic
portion of their TMDs. ECF transporters, as described earlier, contain the recently
characterized S-component, which binds substrates with pM to nM affinity (Berntsson, et
al., 2012). Domain-wide structural changes of the S-component, linked to ATP-hydrolysis
in the cytoplasm, lead to delivery of the substrate by a still-unknown mechanism.
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1.7 Structures of Intact Transporters: General Mechanisms and Major Differences
The past fourteen years represent a golden age for ABC transporter structural
biology, with thirty-three crystal structures solved of twenty different intact transporters,
including nine bacterial importers and one human mitochondrial exporter (TABLE 1.3).
In addition, two recent crystal structures have been solved for intact ECF transporters.
These structures have provided tremendous insight into the organization and assembly of
these transporters while guiding biochemical and biophysical studies that have elucidated
the mechanistic details of their function. While many open questions remain, it is useful to
consider what we have thus far learned from this structural information.
A simple two-state model (Jardetzky, 1966) can be used to describe the function of
a given transporter, provided three structural criteria are fulfilled: i) it must contain a cavity
to admit the transporter molecule; ii) it must be able to assume two different configurations,
alternately open to each side of the membrane; and iii) it must contain a binding site for
the transported molecule. Crystallographic studies have provided the structural basis for
this two-state transport model: alternating access of transmembrane helices that transfers
the substrate from one side of the membrane to the other (FIGURE 1.7). All ABC
transporters have a core of helices that form a translocation pathway for
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Table 1-3: Structures of intact ABC transporters.
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Table 1-3: Structures of intact ABC transporters (continued).
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Table 1-3: Structures of intact ABC transporters (continued). 1) (Locher, Lee, & Rees,
2002); 2) (Hvorup, et al., 2007); 3) (Korkhov, Mireku, & Locher, 2012); 4) (Hollenstein,
Frei, & Locher, 2007); 5) (Gerber, Comellas-Bigler, Goetz, & Locher, 2008); 6) (Pinkett,
Lee, Lum, Locher, & Rees, 2007); 7) (Tirado-Lee, Lee, Rees, & Pinkett, 2011); 8) (Oldham,
Khare, Quiocho, Davidson, & Chen, 2007); 9) (Oldham & Chen, 2011); 10) (Khare,
Oldham, Orelle, Davidson, & Chen, 2009) 11) (Chen, Oldham, Davidson, & Chen, 2013);
12) (Kadaba, Kaiser, Johnson, Lee, & Rees, 2008); 13) (Woo, Zeltina, Goetz, & Locher,
2012); 14) (Yu, Ge, Heuveling, Schneider, & Yang, 2015); 15) (Maruyama, et al., 2015);
16) (Dawson & Locher, 2006); 17) (Ward, Reyes, Yu, Roth, & Chang, 2007); 18) (Aller,
et al., 2009); 19) (Li, Jaimes, & Aller, 2014); 20) (Szewczyk, et al., 2015); 21) (Jin, Oldham,
Zhang, & Chen, 2012); 22) (Kodan, et al., 2014); 23) (Hohl, Briand, Grutter, & Seeger,
2012); 24) (Hohl, et al., 2014); 25) (Shintre, et al., 2013); 26) (Lee, Yang, Zhitnitsky,
Lewinson, & Rees, 2014); 27) (Srinivasan, Pierik, & Lill, 2014); 28) (Choudhury, et al.,
2014); 29) (Lin, Huang, & Chen, 2015); 30) (Perez, et al., 2015); 31) (Xu, et al., 2013); 32)
(Wang, et al., 2013).
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Figure 1-7: The alternating access model for ABC transporters. Grey bar is cell membrane.
(A) Cut-away surface representation of maltose transporter structure in apo- state without
maltose-binding protein (MBP) (PDB ID: 3RLF). Translocation channel faces cytoplasm
(red bars; inward-facing). (B) Cut-away surface representation of maltose transporter
structure with MBP and bound Mg2+-AMP-PNP (PDB ID: 3HF6). Translocation channel
faces periplasm (red bars; outward-facing). (C) Schematic diagram of alternating access
model showing rotation of TMDs upon ATP binding and hydrolysis.
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delivery of the substrate. Structures have revealed the number of core helices and the
degree of helical rotation differs for each type of transporter, with significant differences
related to the nature of the transported substrate (ter Beek, Guskov, & Slotboom, 2014)
(Rice, Park, & Pinkett, 2014). A common driving force fuels the alternating access of
transmembrane helices: hydrolysis of ATP by the NBDs, thus leading to active transport
of the substrate. This is also known as the Switch Model (Higgins, 1992).
What are the structural changes associated with this driving force? Here, we lean
on functional studies of the maltose transporter using electron paramagnetic resonance
(EPR) spectroscopy for insight into ABC domain function (Orelle, et al., 2010). These
studies focused on conformational changes of the NBD homodimers of MalK and revealed
a 10° rotation of each α-helical subdomain relative to the opposing RecA-like subdomain
upon the binding of ATP. The ATP binding, in turn, required the presence of MBP, forming
a key regulatory step in the transport pathway against futile hydrolysis cycles. Neither ATP
nor MBP alone could trigger this domain motion, suggesting the association of the αhelical and RecA-like subdomains is stabilized by interactions with the bound nucleotide.
In addition, the conserved Q-loop, which interacts with the coupling helix, was found to
engage with the active site upon ATP binding. The results also provided a pathway for
domain separation post-hydrolysis, when the interactions between the domains are likely
to be destabilized. These results were supported by high-resolution structures of the intact
maltose transporter with different ATP analogs bound, which revealed a network of
interactions from both domains coordinating ATP binding (Oldham & Chen, 2011),
including the Q-loop glutamine.
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Similar studies have yet to be performed on ABC exporters and ECF transporters
and crystal structures in different conformations for the same exporter have yet to be
determined at sufficient resolution to obtain mechanistic details. However, molecular
dynamics simulations have provided a similar framework for ATP-induced domain closure
of the NBDs (Wen, Verhalen, Wilkens, Mchaourab, & Tajkhorshid, 2013). These
experiments, along with extensive studies of importers, have shown related, yet slightly
different, transport pathways for each transporter type. For instance, the coupling helix is
a common structural feature of each transporter type, providing a physical link between the
TMDs and the NBDs and ability to “sense” the nucleotide state. The details of how
precisely this is accomplished are still under investigation and in the next sections we will
discuss what is known about the mechanisms of each type of transporter and how each
conforms to the criteria given by the membrane pump model.

1.8 ABC Exporters: A Guide for Leaving
The crystal structures of nine different ABC exporters have been solved to date
with resolution ranging from 2.5 Å for the glutathione-bound form of the Atm1 exporter to
5.5 Å for the closed-apo form of the MsbA structure. These structures include the first
human ABC transporter structure solved, a mitochondrial exporter, eukaryotic and
bacterial drug exporters, two peptide translocators, two lipid flippases, and one
heterodimeric archeal exporter. While none of the structures include the same exporter in
multiple conformations, based on the expected model of alternating access, different
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exporters have been captured in various conformations and their crystal structures provide
insight into the mechanical changes associated with transport.
The arrangement of monomers in ABC exporters is distinct and
significantly impacts how each interacts with the other in intact transporters. Unlike ABC
importers and ECF transporters, ABC exporters display domain swapping by intertwining
of transmembrane helices, with each subunit forming “wings” that pack tightly with the
opposite monomer (Bies, 2015). These wings are typically formed by TM segments 1 and
2, which pack against TM3-6 of the other subunit in the intact transporter (FIGURE 1.8A).
Further, each wing contributes an intracellular loop (ICL) that forms a short intracellular
helix (IH1) between TM2 and TM3. In tandem with a second short helix contributed by an
intracellular loop connecting TM4 and TM5 (IH4), these conserved structural features form
a salt bridge with the NBD Q-loop (FIGURE 1.8B) that serves as the couple between
membrane-spanning domains and the cytoplasmic domains ( (Jin, Oldham, Zhang, & Chen,
2012). While the substrate binding sites of exporters have not yet been clearly resolved,
the wings and intracellular helices provide a pathway to connect hydrolysis and transport
across both monomers.
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Figure 1-8: Structure and mechanism of ABC exporters. (A) Domain-swapping in exporter
TMDs, demonstrated in the crystal structure of MsbA (PDB ID: 3B60). TM 1 and 2 (red)
from one monomer primarily interact with TM 3-6 of the opposing monomer (grey). (B)
Interactions of exporter TMDs with NBDs. TM helix 1 (blue) and TM helix 3 (orange)
interact with the Q-loop of the NBD (grey). Interacting residues are represented as stick
models. (C) Exporter transport mechanism. The cycle begins in the inward-open
conformation (PDB ID: 4F4C). 1: Futile hydrolysis cycles set the exporter in the ADPbound outward-occluded configuration (PDB ID: 5C73). 2: Substrate (red) binding triggers
an exchange of ADP for ATP in the catalytic sites, setting the transporter in the outwardopen configuration (PDB ID: 2HYD). 3: ATP hydrolysis results in the outward-occluded
conformation. 4) The substrate is pinched from the core binding site within the TMDs,
leading to export.
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With respect to the model of NBD rotation proposed by Orelle et al (2010), the
structural changes associated with nucleotide binding in exporters remain unresolved.
Multiple structures of exporters in the inward-open configuration have been solved
(FIGURE 1.8C), and the NBDs are typically displaced far from one another, with the
interfacial distance spanning up to 45 Å. In addition, structures of the outward-open and
outward-occluded conformations of exporters have been solved, demonstrating, similarly
to ABC importers and isolated NBD structures (Zaitseva, et al., 2005), an association of
NBD monomers with bound nucleotides at their interface. These structures thus require a
significant rotation of NBDs with a radical rearrangement of TM helices to promote such
domain closure, which is triggered perhaps by substrate and subsequently ATP binding.
A key missing link was provided by three structures of the PglK lipid flippase from
C. jejuni (Perez, et al., 2015). In addition to two structures of the homodimer PglK in the
inward-open conformation, a third structure provided an unprecedented ADP-bound
outward-occluded state. These structures showed engagement of the NBDs post-hydrolysis,
and functional studies showed a full separation of the monomers, as expected based on
inward-open crystal structures, was not required for transport. Combined with the AMPPNP-bound structure of the bacterial peptide exporter McjD (Choudhury, et al., 2014),
these structures provide a pathway for substrate transfer to the extracellular/periplasmic
surface not requiring a complete displacement of NBDs after each successful transport
cycle, and form the basis of a three-state model that best represents the current
understanding for exporter function (FIGURE 1.8C). In this model, futile ATP hydrolysis
sets the transporter in the ADP-bound outward-occluded conformation. Substrate binding
triggers exchange of ADP for ATP and results in the outward-open conformation, which
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transfers the cargo through the cytoplasmic membrane (Dawson & Locher, 2006).
Hydrolysis then resets the transporter to the outward-occluded conformation, pinching the
substrate away from the transporter to complete delivery. Whether this model can
accommodate large substrates, including peptides and large protein toxins such as HlyA
(Olson & Gouaux, 2005), or simply small substrates such as lipids and hydrophobic drugs,
remains to be seen.

1.9 ABC Importers Types I and II
ABC transporters are ancient and efficient pumps for their respective substrates,
and given their ubiquity, likely segregated into functional types at an early stage of
evolution (Saurin, Hofnung, & Dassa, 1999), and only diverged ever once in evolution.
While eukaryotes contain only ABC exporters and prefer to use secondary active
transporters for uptake, prokaryotes maintained both systems, and have developed an
extensive and diverse system of binding protein-dependent importers.
Structures for nine different bacterial importers have been solved, including a few
in multiple conformations. These include the most detailed structural and functional
characterizations that have been performed for any transport system: studies of the E. coli
vitamin B12 and maltose transporters, which have provided tremendous insight into the
current understanding of all ABC transporters. Structures of these and other import systems
revealed a divergence of importers, which remains a point of investigation, based primarily
on the topology of TMDs and the mechanism of transport. We consider, compare, and
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contrast the mechanisms of transport for both types in the next subsections, and briefly
discuss the recent introduction of a third type of ABC importer, the ECF transporter.

1.9.1 Type I ABC Importers: Symmetry versus Asymmetry
Structurally characterized type I importers include the maltose transporter
MalFGK2, the methionine transporter MetNI, the molybdate transporters ModBC, the
amino acid transporter ArtN2Q2, and the alginate transporter AlgM1M2SS (TABLE 1.3),
all prokaryotic (FIGURE 1.9A). In general, these type I importers contain fewer TM
helices (5-8) than type II importers, and include TMDs which are heterodimers (such as
the maltose transporter TMDs MalF and MalG, with 8 and 6 TM helices, respectively).
Comparison of type I TMDs reveal a core of four TM helices that share a common topology
(Rice, Park, & Pinkett, 2014). Biochemical studies have shown these transportes show little
basal hydrolysis activity and are maximally stimulated in the presence of their respective
substrate-binding proteins (Davidson, Shuman, & Nikaido, 1992). In addition, all type I
importer structures with the exception of ArtN2Q2 and A. fulgidus ModBC contain
additional regulatory domains (RDs) attached to their respective NBDs. The RD, composed
of two beta-sandwich motifs, modulates the transporter by binding the transported substrate,
thus inactivating hydrolysis and subsequently shutting off transport.
In general, importers, like all other transporters, fulfil transport by the alternating
access mechanism. As in exporters, this alternating access is sensitive to the presence of
substrate and nucleotide. Transmembrane signaling is accomplished through the coupling
helices, which for importers consist of a single cytoplasmic loop of the TMDs (typically
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between TM4 and TM5 for type I importers, and TM6 and TM7 for type II importers).
Structures of the maltose transporter have provided the physical basis for alternating access
in type I importers (FIGURE 1.9B). Maltose-loaded maltose-binding protein initiates the
transport process by docking onto the nucleotide-free resting-state conformation of the
transporter MalFGK2 (J. Chen, 2013; Khare, et al. 2009; Davidson, Shuman and Nikaido,
1992). This promotes a closure of the NBDs and a pinching on the cytoplasmic side of the
TMDs via rigid-body rotations, although the periplasmic gate remains closed (Oldham &
Chen, 2011). ATP-binding subsequently induces domain closure between the two subunits
of MalK (Orelle, Ayvaz, Everly, Klug, & Davidson, 2008), which then promotes the
outward-facing state, MBP opening, and release of maltose to the TM binding site in MalF
(Oldham, Chen, & Chen, 2013). ATP is then
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Figure 1-9: ABC importers type I structure and mechanism. (A) Representative structures
of type I ABC importers (left to right): Outward-facing maltose transporter (MalFGK2) in
complex with MBP-maltose and bound ATP (PDB ID: 2R6G); Inward-facing methionine
transporter (MetN2I2) with bouth Met in RD (PDB ID: 3DHW); Inward-facing substratefree molybdate transporter (ModB2C2) in complex with ModA (PDB ID: 2ONK); Inwardfacing ATP-bound structure of arginine/glutamine transporter (ArtN2Q2) with bound
arginine in TMD cleft (PDB ID: 4YMU). (B) Type I importer mechanism based on maltose
transporter structures (left to right): resting-state substrate-free MalFGK2 (PDB ID: 36F6)
accepts maltose-loaded MBP (1) and transitions to occluded pre-translocation state (PDB
ID: 3PV0); Docked maltose-bound MBP promotes ATP binding and hydrolysis (2) and
transitions transporter to outward-facing conformation (PDB ID: 3RLF). Maltose is bound
in transient site in MalF. Post-hydrolysis state (no structure) results in MBP release and
transition to inward-facing conformation, leading to maltose uptake.
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hydrolyzed, reverting the transporter to the inward-state, destabilizing MBP-MalFG
interactions and thus delivering maltose to the cytoplasm (Bohm, et al., 2013). This
mechanism has been confirmed by the nucleotide-free resting-state structures of MetNI
and ArtN2Q2 and SBP-bound structures of ModABC (A fuldigus) and AlgM1M2SS, as well
as mechanistic studies showing SBP-induced ATPase activity. Finally, the structural basis
of inactivation by RDs was demonstrated by the tungstate-bound structure of ModBC
(Gerber, et al., 2008), which showed an unusually large separation of coupling helices upon
substrate binding to the regulatory domain. A structure of the maltose transporter bound
with two molecules EIIAglu protein demonstrated an additional means of allosteric
regulation for this protein family, although this mechanism may yet prove to be more
universal.
A prevailing theme of the type I importer structures, in addition to the significant
conformational changes, is symmetry: homodimers of NBDs and (generally) TMDs show
identical rearrangements during alternating access and the SBPs of these transporters
belong to Clusters B and F, which contain flexible hinge regions. At the functional level,
the hydrolysis of ATP at both binding sites is typically required for transport (Davidson &
Sharma, 1997), although measurements for the stoichiometry of ATP:substrate have not
consistently shown a 2:1 dependence per transport cycle (Procko, et al., 2009). However,
asymmetry in these proteins is also apparent: MalFGK2 contains only a single TMD
maltose-binding site (Oldham, et al., 2013), and recent EPR experiments demonstrate MBP
dissociates in an asymmetric manner (Bohm, et al., 2013). This leaves open a significant
question: if both the SBP and substrate interact with the transporter asymmetrically, how
is ATP hydrolyzed in a equivalent manner and how are symmetric NBD structural changes
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communicated in an asymmetric way? Future detailed studies of other type I importers may
provide the answer.

1.9.2 Type II ABC Importers: Subtle Movements and Complex Issues
Structural evidence for type II ABC importers is more limited; three structures of
intact importers have been solved (FIGURE 1.10A), and only one – the vitamin B12
transporter – in multiple conformations and complexed with its cognate binding protein.
However, all three structures have revealed a conserved TMD fold: ten transmembrane
helices per monomer and homodimers of the TMDs. In addition, the NBDs are typically
homodimers and lack regulatory domains. These transporters were first described as
“large”, alluding to the twenty total TM helices but also to the larger substrates of these
transporters, such as vitamin B12 and heme. However, the latter descriptor has since been
revised due to the discovery of type II small substrate transporters, such as the elucidation
of HI1470/1471 as a molybdate importer (Tirado-Lee, et al., 2011) and several other
putative type II transporters with small substrates.
Further revisions may accompany characterizations of other putative type II
importers. Of significance is the strict accompaniment of Cluster A SBPs, which contain a
rigid helical linker region, with type II importers. However, X-ray structures of putative
type II importers, such as the arabinose transporter, which has a Cluster B SBP, can revise
this model of exclusivity. As observed for type I importers, substrate specificity is defined
by the SBP, and type II importers uptake a range of substrates with diverse chemistries
(Rice, Park, & Pinkett, 2014). Despite the diversity, limited conformational changes upon
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substrate binding have thus far been observed for Cluster A SBPs for both large and small
substrates.
These subtle conformational changes are not limited to the SBPs and extend to the
core of type II importers. X-ray structures of type II importers have revealed
conformational changes are limited to TM helices 2, 3, 4, 5, 5a (a partial helix), and 10,
and thus are predominantly intra-domain movements, in stark contrast with the interdomain rigid-body movements found in type I importers. These helices combine to control
access to a central translocation channel formed at the interface of the two monomers. In
the outward-facing BtuCD-F structure (Hvorup, et al., 2007), the cavity has a maximum
diameter of 9 Å and an internal volume of 3400 Å3, which can accommodate vitamin B12
with some steric hindrance. In comparison, the outward-facing SBP-free structure of
HmuUV (Woo, et al., 2012), a heme importer, revealed a translocation pathway with a
maximum diameter of 15 Å but an overall smaller internal volume of 1300 Å3, enough to
contain the smaller substrate. Three gates, one periplasmic and two cytoplasmic, alternately
control access of the cavity to deliver the substrate. No
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Figure 1-10: ABC importer type II structures and mechanism. (A) Representative
structures of type II ABC importers (left to right): Outward-facing ATP-bound vitamin
B12 transporter (BtuC2D2, PDB ID: 1L7V); Inward-facing substrate-free
molybdate/tungstate transporter HI1470/1471 (ModB2C2, PDB ID: 2NQ2); Inward-facing
substrate-free heme transporter (HmuU2V2, PDB ID: 4G1U). (B) Type II importer
mechanism based on vitamin B12 importer structures (left to right): basal ATP hydrolysis
results in ATP-bound outward-facing state of BtuCD (1L7V), which promotes binding of
B12-bound BtuF to the core transporter (1) (PDB ID: 4FI3). Upon binding BtuF releases
B12 and subsequent hydrolysis results in its dissociation (2), promoting the substrate-free
inward-facing conformation (from HI1470/71, PDB ID: 2NQ2) and import of B12. In the
absence of substrate in the periplasm (3), BtuF stably associates with the substrate-free
conformation of the transporter in a resting state (PDB ID: 2QI9).
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substrate binding nor clear binding sites have been observed in these regions, unlike type
I importers. The structural differences between these type II importers also have subtle
mechanistic consequences (FIGURE 1.10B). For the vitamin B12, transport is initiated by
docking of the substrate-loaded binding protein, BtuF onto the outward-facing
conformation of the BtuCD (Lewinson, et al., 2010). This conformation is set by the
binding of ATP to BtuCD (Korkhov, et al., 2014), which opens cytoplasmic gate I and
closes cytoplasmic gate II. In general, it appears type II importers have higher basal
ATPase activity than type I importers, and do not show clear substrate-stimulated increases
in rates of hydrolysis (Rice, et al., 2014). Docking of BtuF onto the transporter results in
substrate release into the cavity and collapse of the periplasmic gate, as observed in the
structure of the outward-occluded BtuCD-F (Korkhov, et al., 2012). The movement of
periplasmic gating helices is more subtle for small substrate type II importers, both in
detergents (Rice, et al., 2013) and native lipid bilayers (Rice, Harrison, et al., 2014). ATP
is subsequently hydrolyzed, which results in dissociation of the the BtuD subunits, driving
apart the coupling helices and the cytoplasmic gate II. This pulls the transporter into a
symmetric inward-open conformation, visualized by the H. influenzae MolBC structure
(Pinkett, et al., 2007), allowing the substrate to enter the cytoplasm. This is proposed to be
a transient state, with the resting conformation a substrate- and ATP-free complex of
BtuCD-F (Hvorup, et al., 2007) featuring asymmetric closure of the cytoplasmic gate to
restrict access to the cytoplasm. In the small substrate transporters, the cytoplasmic gating
is not apparent from structures and biophysical experiments. Given the substrate size
differences, it is unsurprising that different uptake mechanisms have evolved.
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The nature of the substrate- and ATP-free complex of type II importers is of great
interest. BtuCD-F form a stable and long-lived complex in vitro in the absence of vitamin
B12 and nucleotide, and the interaction of BtuF with BtuCD is significantly destabilized by
the presence of both (Lewinson, et al., 2010). It is proposed that the tripartite complex
represents the resting state of the complex, and the availability of substrate awakens the
transporter, prompting it to activity. Additionally, the NBDs of these complexes lack RDs
found in type I importers or any other identified mechanism of post-translational
modulation, and instead regulation is likely fulfilled at the transcriptional level (Rice,
Harrison, et al., 2014; Chao, et al., 2005) by the transported substrate. Finally, the
observation of asymmetric gating in the apo BtuCD-F structure is unexpected and, much
like for type I importers, begets a still-unresolved questions: how is asymmetry achieved
in symmetric transporters?

1.9.3 ECF Transporters: Type III ABC Importers?
Despite their discovery in the 1970s, ECF transporters were only recently classified
as a third type of ABC importer (Rodionov, et al., 2009). Two intact structures of ECF
transporters have now been solved, and several structures of their isolated substratebinding S-components have been determined. Studies of these components have identified
proteins that are more modular in nature than other ABC importers. Multiple S-components
interact with the same core ECF transporter, formed by a single TMD (EcfT) that interacts
with dimers of NBDs (EcfA and EcfA’) in a similar fashion to other ABC transporters.
Unlike the typical ABC transporter organization, coupling with the NBDs is accomplished
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solely by the EcfT, which contains two long cytoplasmic helices that dock into the Q-loops
of the NBDs (FIGURE 1.11A) by forming an X-shape.
The current transport model is based entirely on two ECF transporter X-ray
structures and several isolated S-component structures. Most unexpectedly, structures of
whole ECF transporters showed S-components lying parallel to the plane of the membrane,
and substrate binding sites and NBDs unoccupied in both structures. In these structures,
TM helices 1,2, and 6 of EcfS primarily contact the EcfT domain, fitting into a groove
between the TM and cytoplasmic helices. Studies of isolated S-components suggested
these proteins span membranes in a perpendicular orientation. These observations led to a
hypothetical and unprecedented toppling transport mechanism (FIGURE 1.11B)
(Slotboom, 2014), where the substrate-free S-component first binds the core transporter.
ATP binding in the NBDs tilts the S-component perpendicular to the membrane, exposing
the substrate binding site to the extracellular/periplasmic surface. The substrate binds the
S-component and ATP is hydrolyzed by the NBDs, tilting the S-
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Figure 1-11: ECF transporter/ABC importer type III structures and mechanism. (A)
Structures of ECF transporters (left to right): Inward-facing folate ECF transporter with
bound S-component (PDB ID: 4HUQ); Inward-facing hydroxymethylpyridine ECF
transporter with bound S-component (PDB ID: 4HZU); Unbound biotin S-component
(PDB ID: 4DVE). (B) Mechanism of ECF transporters (left to right): Unbound outwardfacing structure of ECF transporter with substrate-specific S-component (speculative based
on isolated S-component structures). Substrate binding (1) triggers unknown
conformational changes, perhaps due to ATP binding and hydrolysis (2), resulting in
toppling of S-component to deliver susbtrate (3).
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component conformation back to the parallel orientation, wherein substrate is then
delivered to the cytoplasm. This model is speculative, and the connection between
hydrolysis and S-component conformation is currently unknown. Nevertheless, these
transporters have a distinct architecture, reflecting the diversity of ABC transporter
structure, function, and regulation.

1.10 Outstanding Questions
The “Golden Age” of ABC transporter structure determination has yielded a wealth
of information regarding their architecture and function while providing a glimpse at the
tremendous diversity lying just below the surface of our current knowledge of these
transporters. Despite these advances, the “mastodon-in-the-room” remains an elucidation
of the link between hydrolysis and transport. How precisely is substrate binding sensed by
the nucleotide-binding domains? How does hydrolysis in turn confer the structural changes
that drive transport? How do energetics drive active substrate transport? Structural and
functional studies have yielded nearly as many new questions as answers.
The diversity of ABC transporters may shed some light onto this quandry. Whether
two or one ATP are hydrolyzed simultaneously or processively and the structural
consequences of this process remain unclear, and biochemical studies of homodimeric
transporters have yet to yield a unifying answer. Evidence of positive cooperativity for
ATP binding exists in some (Davidson, Laghaeian, & Mannering, 1996), a 2:1
ATP:substrate ratio has been measured in one during transport (Patzlaff, van der Heide, &
Poolman, 2003), and still others have been engineered to transport with a single active site
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without deleterious effects (Tal, Ovcharenko, & Lewinson, 2013). However, genetic
studies have revealed a number of naturally-occurring ABC transporters that are formed
from heterodimers of NBDs or contain non-equivalent NBDs on a single polypeptide. This
non-equivalency arises from function-altering mutations present in one of two ATPbinding sites and has been shown to have interesting functional and structural
consequences. This will be discussed in more detail in the upcoming sections and chapters
as the motivation for the current study. What is clear is that transport can be fulfilled for
many ABC transporters by hydrolysis at a single active site. How this is understood and
how these transporters fulfill their respective delivery functions will be explored by studies
of an ABC transporter with an unusual architecture, the E. coli ribose transporter.

1.11 The Uptake and Processing of D-ribose, a Building Block for Life
In a publication over a half-century prior, it was found that the “penetration of
ribose into cells requires a permease and that the formation of this permease depends on
the presence of ribose in the medium” (Eggleston & Krebs, 1959). It was shown that cells
could not ferment ribose unless they had been grown in the presence of ribose, providing
the initial evidence for an inducible ribose transport system in E. coli. Selective permeation
systems had recently begun to be characterized (Cohen & Monod, 1957), and evidence for
ATP as the energizing mechanism for active transport was demonstrated several years later
when it was found ribose uptake was sensitive to Mg2+ availability and could be inhibited
by aresenate (Curtis, 1974). The proteins involved in uptake and processsing of ribose were
later identified as gene products mapped to the 84th minute of the E. coli chromosome
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(Lopilato, et al., 1984), and sequencing of this region revealed the existence of five genes,
rbsDACBK, involved in the high-affinity uptake of this metabolite under the control of
distally-located inducible repressor, rbsR (Groarke, et al., 1983; Bell, et al., 1986; Hope, et
al., 1986; Mauzy & Hermodson, 1992).
Detailed biochemical studies have identified the function of each gene product and
an overall pathway for uptake has been proposed (FIGURE 1.12). Ribose is captured in
the periplasm by ribose-binding protein (RBP), or RbsB, with an apparent affinity of 0.3
µM (Willis and Furlong 1974). RbsB is essential for the high-affinity uptake of D-ribose
(Lopilato, et al., 1984) and plays a critical role in chemotaxis, coordinating the taxis
towards ribose by interacting with inner-membrane receptor Trg (Binnie, et al., 1992).
RbsC and RbsA form an inner membrane energy-transducing complex and combine with
RbsB to form the intact ABC transporter for the import of ribose. Once inside the cell,
ribose is phosphorylated by ribokinase, or RbsK, completing the first step in ribose
utilization. Interestingly, from a survey of knock-outs, only rbsK was shown to be required
for E. coli to utilize ribose as the sole carbon source (Hope, et al., 1986),
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Figure 1-12: The ribose import pathway. Ribose (brown) diffuses into the periplasmic
space by an outer-membrane (OM) porin (blue), where it is captured by RbsB (green).
RbsB-ribose docks onto the core ABC transport complex in the inner membrane (IM)
formed by RbsC (red) and RbsA (orange). ATP is hydrolyzed by RbsA to drive active
uptake of ribose, where it is converted between furanose and pyranose forms by RbsD and
phosphorylated by RbsK. Ribose-5-phosphate is then shuttled to biosynthetic pathways,
and can also be synthesized by the pentose phosphate pathway in the absence of active
transport.
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suggesting the existence of alternative low-affinity uptake pathways. RbsD processes
ribose and ribose-5-phosphate by catalyzing the conversion between the pyranose and
furanose ring forms (Kim, et al., 2003), a process required for RbsK function, and appears
to enhance the uptake of ribose when overexpressed (Oh, et al., 1999). Ribose-5-phosphate
then proceeds into pathways leading to nucleotide and amino acid synthesis.
Genetic, biochemical, and structural studies in the Hermodson and Stauffacher labs
at Purdue University have elucidated rbs operon regulation, the function of proteins
involved in this pathway, and the protein-protein interactions that ultimately drive ribose
uptake. These studies have primarily focused on the tripartite ABC transporter complex
formed by RbsA, RbsB, and RbsC. In the next sections, we consider what has been learned
about each protein individually, starting from the periplasm and working our way into the
cell, and then review the studies of the intact transport complex that they form.

1.11.1 The Ribose-binding Protein, RbsB
RbsB is a member of the large family of SBPs previously discussed, and is
structurally classified as a Cluster B binding protein with a flexible hinge domain
consisting of three loops (Bjorkman, et al., 1994; Bjorkman & Mowbray, 1998). A 30º
rotation of the hinge region snaps the N- and C-terminal lobes of RbsB together, trapping
ribose in a Venus Flytrap-type manner. From this ribose-bound conformation, RbsB fulfills
its biological role by interacting with its specific transport complex to uptake
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Figure 1-13: Structure of ribose-binding protein (PDB ID: 1DRK). Ribose is bound in a
cleft between the N- and C-terminal lobes. Mutations affecting ribose transport and
chemotaxis colored in red. Inferior surface is likely site of interaction with transporter.
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ribose into the cytoplasm and participating in transmembrane signal transduction involved
in the chemotactic response (Bjorkman, et al., 1994).
RbsB is a 271-amino acid protein with an N-terminal localizing signal directing it
to the periplasm post-translation, much like all other SBPs in gram-negative bacteria.
Structures of its apo- and ribose-bound forms reveal a closure of 20 Å across the substratebinding cleft between the N- and C-terminal lobes. Like other SBPs of ABC importers,
RbsB interacts stably with the transmembrane homodimers formed by RbsC. While no
intact structures of the transport complex exist, functional residues of RbsB critical for
substrate binding and transport have been mapped to its surface (Binnie, et al., 1992)
(FIGURE 1.13), and mutation of any of these result in decreased or complete loss of
transport function. These residues are mapped in general to its inferior surface and likely
affect the ability of RbsB to interact with RbsC, although one has been shown to stabilize
the open form of RbsB (Bjorkman & Mowbray, 1998). Interestingly, the mutations are
disproportionately located on the N-terminal lobe; this suggests an asymmetry of
interaction and function that will be discussed later. Many of the same residues critical for
transport are also critical for chemotaxis, likely affecting interactions with the chemotaxis
receptor Trg. Two additional residues on the superior surface of RbsB are also critical for
the chemotactic response. These positions are conserved for other SBPs with dual
transport-chemotactic functions (Bjorkman, et al., 1994; Kondoh, Ball, & Adler, 1979).
Finally, as an excellent demonstration of the efficiency of evolution, RbsB is
structurally related to the LacI-type rbs operon repressor, RbsR (Mauzy & Hermodson,
1992). Homology modeling reveals a similar two-domain hinged binding region in RbsR
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and an additional N-terminal DNA binding domain. Following ribose binding, RbsR
releases its grasp on the operator region, although how ribose is sensed is not yet known.

1.11.2 The Transmembrane Domain, RbsC
While homology is evident for SBPs and NBDs, and can be used to infer a common
functional mechanism for these components in ABC transporters, less is definitively
known about TMDs. As has been discussed earlier, four separate folds of TMDs have been
identified, revealing the majority of ABC transporters contain 5-10 TM helices per
monomer. In addition, two types of importers have been identified, one containing 6 core
TM helices and TM substrate-binding sites, with the other containing 10 helices and no
obvious binding sites.
No structure of the 321-amino acid protein RbsC is currently available, although
sequence-based analysis shows 21% identity with BtuC. Topological studies of RbsC,
using cysteine-scanning mutagenesis, revealed a structural model with 10 TM helices
(Stewart & Hermodson, 2003) (FIGURE 1.14). While RbsC was generally tolerant of
cysteine mutations introduced by this technique, the few inactivating mutations mapped
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Figure 1-14: Topology of RbsC. Cysteine-scanning mutagenesis predicts 10 TM segments
per RbsC monomer. Regions of limited accessibility – likely TM helices, shown as red bars
– are indicated as red bars with numerical labels for starting and ending amino acids. The
conserved EAA motif is shown as a short cytoplasmic helix. N- and C-termini are labeled
as shown.
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nearly entirely to predicted periplasmic regions, suggesting the importance of RbsB-RbsC
interactions for transport.
In addition to identifying TM regions and potential sites of RbsB-RbsC interactions,
the study also revealed the position of the coupling helix, based on the presence of the
conserved EAA motif, as a cytoplasmic loop between TM helices 6 and 7. Much like the
prediction of 10 TM helices, the location of the coupling helix also resembles the
architecture of type II importers. No evidence of a ribose-binding site in the TMDs is
readily apparent from analysis of the RbsC primary structure.
Finally, tests of the oligomeric state of isolated, detergent-solubilized RbsC using
analytical ultracentrifugation demonstrate it also functions as a dimer, much like other
ABC transporters (Clifton, et al., 2016). No changes in oligomeric state are apparent due
to presence of ribose. These studies also suggest RbsC assembly and interactions in the
intact transporter complex are canonical, although an in vivo study using RbsA-RbsC
chimeras suggests alternative mechanisms are possible (Zaitseva, et al., 1996).

1.11.3 The Motor Domain, RbsA
RbsA is a 501-amino acid protein required for the high-affinity transport of ribose
in E. coli. Analysis of its sequence identified it as ATP-binding cassette transporter NBD,
based on the presence of the aforementioned conserved motifs (Walker A and B, ABC
signature, etc.) albeit with an atypical organization (Buckel, et al., 1986). This primary
structure analysis (FIGURE 1.15) showed homologous N- and C-terminal domains
present in RbsA; thus, rbsA likely formed as a duplication of the primordial gene resulting
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in a protein with fused NBDs connected by a short linker. This organization is uncommon
for bacterial importers, but such end-to-end fusions of proteins gave rise to MDR
transporters (Chen, et al., 1986), the aforementioned CFTR (Riordan, et al., 1989), and
many other eukaryotic and bacterial exporters. However, as discussed in earlier sections,
the former two proteins are formed from N-TMD-NBD-TMD-NBD-C fusions and typical
exporters contain N-TMD-NBD-C and occasionally N-NBD-TMD-C fusions (Davidson,
et al., 2008). RbsA, based on its sequence, and a few similar bacterial NBDs contain the
rarely seen N-NBD-NBD-C arrangement.
A three-dimensional structure of the full-length RbsA protein is currently
unavailable. The 2.5Å crystal structure of the 259-amino acid RbsA N-terminal NBD
represented the first successful structural study of an ABC transporter (Armstrong, et al.,
1998) (FIGURE 1.16). This structure revealed the L-shaped NBD that is now considered
typical for ABC proteins, with the mixed α/β RecA-like subdomain and the helical
subdomain containing the conserved motifs that are hallmarks of this protein family.
Interestingly, Mg2+ and ADP were found bound in the RecA-like subdomain, inidicating
active hydrolysis, although no non-crystallographic symmetry or evidence of dimerization
was evident from the crystal structure. A similar effort to obtain the crystal
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Figure 1-15: Sequence alignment between the N and C terminal domains of RbsA.
Sequences were aligned using ClustalW. Identical residues are shown in blue, highly
similar in orange, and similar in green. Conserved sequences are boxed including the
Walker A domain in black, the signature sequence in red, the Walker B in blue, and the
conserved histidine in purple. Adapted from (Clifton, et al., 2016).
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Figure 1-16: Crystal structure of RbsA N-terminal domain (residues 1-259), reported to
2.5-angstrom resolution (Armstrong, Tabernero, Zhang, Hermodson, & Stauffacher, 1998).
Conserved regions are color-coded and labeled. Structure includes bound ADP (yellow)
and magnesium (black). RecA-like subdomain in cyan, helical subdomain in light blue.
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structure of the C-terminal NBD proved unsuccessful and the structure of the full-length
protein remains elusive. These efforts will be discussed in the fourth chapter.
An analysis of the primary structure reveals an apparent non-equivalency of the
NBDs. While both contain the conserved motifs that are typical of ABC family proteins, a
clear asymmetry arises in the C-terminal NBD. The Q-loop, which contains a conserved
glutamine (Q86 in the N-terminal NBD) that completes the active site, is substituted with
a glutamate (E334) in the C-terminal NBD. The conserved lysine of the Walker A motif is
replaced with arginine in the C-terminal NBD; while the chemical properties are similar,
this may affect the geometry of the binding site. Most critically, the conserved switch
histidine (H199 in the N-terminal NBD) has been substituted for a serine (S453) in the Cterminal NBD. Mutagenesis studies of RbsA have demonstrated only a single active site
of ATP hydrolysis is present, and that these mutants have interesting and varied functional
consequences both in the context of substrate transport and bacterial chemotaxis
(unpublished data from Hermodson and Stauffacher laboratories), providing direct
evidence of signal transduction in the tripartite complex. These studies will be discussed
in greater detail in the following chapters.

1.11.4 Isolating and Characterizing the Intact RbsABC Transporter
Prior to crystallographic structural analysis of ABC transporters, biochemical
studies, notably in vitro assembly experiments, provided the initial evidence for the
arrangement of domains in intact transport complexes (Sharma, et al., 2005; Borths, et al.,
2005; Liu & Ames, 1998; Vigonsky, et al., 2013). These experiments have been performed
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by overexpressing and isolating detergent-solubilized transporters, and varying the
presence of nucleotides and substrates to determine which promote assembly of complexes.
Critical to these studies has been the observation that orthovanadate (V3O4) inhibits the
ATPase function by mimicking the “ADP+PO4” state and locking the NBDs in a bound
conformation (Sharma & Davidson, 2000) so that they may be stably co-purified. Nonhydrolyzable ATP analogs have also provided useful cofactors. These studies have also
contributed to the understanding of type I and type II ABC importers: while the presence
of nucleotides and substrates promotes complex formation in type I importers, it has a
destabilizing effect on the assembly of components, notably the SBP, in type II importers.
Similar studies have also been performed on the ribose transporter and have
observed a divergent phenotype [ (Clifton, et al., 2015), (Clifton, 2005) (FIGURE 1.17).
In these studies, RbsA and RbsC have been overexpressed together on a single plasmid,
while RbsB is expressed and purified separately. The RbsA-RbsC complex is purified by
detergent extraction, using n-dodecyl-β-D-maltoside, in the presence of Mg2+, ATP or
ADP, and orthovanadate. Addition of RbsB to the assembly mixture allowed purification
of the intact complex, RbsABC, by utilizing a poly-histidine tag on any of the three
components, typically RbsC. The RbsAC complex could be isolated as above without the
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Figure 1-17: Complex assembly studies of the ribose transporter using affinity
chromatography and his-tagged RbsC. Data shown is 15% SDS-PAGE of elution fractions
from cofactor-varied assembly experiments. Lanes with numbered gel bands is molecular
weight marker, in kDa. Figure is adapated from (Clifton, et al., 2015). (A) Lane 1 – purified
RbsA; 2 – Purified RbsB; 3 – purified RbsC; 4 – RbsAC with Mg-ATP-VO4; 5 – RbsABC
with Mg-ATP-VO4; 6 – RbsABC with no cofactors (only RbsBC co-elute); 7 – MW
marker. (B) RbsAC with Mg-ADP and MW marker. (C) RbsABC with ribose along as
cofactor (only RbsC elutes) and MW marker.
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addition of RbsB or using Mg2+ and ADP as the cofactor combination. In the absence of
cofactors, the previously unobserved SBP-TMD complex of RbsB-RbsC could be isolated.
The requirement of nucleotide for the isolation of the TMD-NBD complex had not
previously been observed as these components had typically been shown to assemble and
co-elute without addition of cofactors in similar transporters, and suggested a weak
interaction between RbsA and RbsC. This was the first evidence of atypical behavior in
the ribose transporter.
When these experiments were repeated in the presence of the transported substrate,
ribose, a destabilization between the RbsB and RbsC complex was observed. Thus, when
ribose was added in the presence of nucleotide, only the RbsAC complex could be isolated.
In the absence of nucleotides and the presence of ribose, only his-tagged RbsC could be
isolated by affinity purifcation. Unlike the atypical behavior of the RbsA-RbsC complex,
this substrate-induced destabilization resembled observations of type II importers. Further,
it was demonstrated that binding of RbsB to RbsC resulted in substrate release (Simon,
2011). Combined with the observation that RbsC contains 10 TM helices per monomer,
this initially led to the characterization that RbsABC was perhaps a poorly-behaved type II
importer.
However, other lines of evidence clashed with this observation. SBPs cluster along
clear lines with their cognate transporters: type I importers utilize clusters of SBPs with
flexible hinges, marking more significant conformational changes, while type II importers
interact with SBPs with rigid hinges, in line with the more limited conformational changes
observed in their structures. RbsB is a cluster B SBP with a flexible hinge, and structures
of its closed and open forms support the notion of significant conformational changes upon
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ribose binding (Bjorkman & Mowbray, 1998). EPR experiments, utilizing the placement
of spin probes opposite one another in both the N- and C-terminal lobes of RbsB,
demonstrate the same conformational changes are observed during the function of the
intact transporter (FIGURE 1.18; (Erramilli, et al., 2016); Simon, 2011). In these
experiments, distance measurements between the spin probes revealed a RbsB lobe
opening of over 20 Å in the vanadate-trapped RbsABC state, while in the RbsBC state the
lobe-separation was less than 8 Å. Further, previous results demonstrated a RbsB- and
ribose-stimulated increase in ATPase activity in RbsA (Clifton, et al., 2015).This provided
a pathway for ATP-dependent substrate transport in the manner of type I ABC importers.
The evidence thus far suggests a mechanism of ribose transport by a hybrid type Itype II approach, with RbsB releasing substrate upon docking to RbsC, and subsequent
hydrolysis in RbsA accelerating the dissociation of RbB from the core transporter
(FIGURE 1.19). Following hydrolysis, it appears RbsA then dissociates from RbsC,
although this observation may not be biologically relevant given cellular concentrations of
ATP and magnesium (typically 1-10 mM). However, not all evidence supports this
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Figure 1-18: EPR spectra of doubly labeled RbsB. (A) Apo (green, PDB ID: 1BA2) and
ribose-bound (blue, 2DR1) structures of RbsB with N41 and I132 represented as colorcoordinated spheres in apo and ribose-bound forms. Bound ribose represented as red
spheres. (B) EPR spectra of spin-labeled N41C/I132C RbsB in: cofactor free conditions
with RbsC (black) and RbsAC (green); vanadate-trapped conditions with RbsAC (red);
trapped with non-hydrolyzable ATP analog (blue); Mg2+ and ADP with RbsAC (gold).
All cofactors used at 1 mM. All spectra are background-subtracted and amplitude
normalized. Adapted from (Erramilli, Simon, Clifton, & Stauffacher, 2016) and (Simon,
2011).
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Figure 1-19: Proposed model for ribose transport. (A) RbsB (green) captures ribose via an
induced-fit mechanism. In the absence of substrate, RbsA (orange) is dissociated from
RbsC (red). (B) Ribose-loaded RbsB binds RbsC and samples multiple conformations
based on EPR results, leading to ribose release. (C) Mg-ATP bound RbsA binds RbsBC,
which promote hydrolysis, leading to the open conformation of RbsB and the outward
facing state of the transport complex. (D) Post hydrolysis, the complex resets to an inward
facing conformation, leading to the closed conformation of RbsB and subsequent release,
allowing it to scavenge additional molecules of ribose. Adapted from (Erramilli, Simon,
Clifton, & Stauffacher, 2016).
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model, as substrate-induced rate increases and a clear RbsB lobe-opening upon hydrolysis
provide a clear link between ATP utilization and substrate release from the binding protein.
On balance, it appears RbsABC contains features typical of both canonical importer
subtypes, suggesting a distinct transport mechanism.

1.12 Outstanding Questions
While the current model provides some detail of the biochemistry and
conformational changes related to transport, there remains the unanswered question of how
a single functional active site contributes to this model. In importers characterized thus far,
equivalent sites of hydrolysis lead to substrate uptake. An engineered version of the vitamin
B12 transporter demonstrated that a single active site could fulfill transport in this system,
while a similar approach could not do so for the maltose transporter. The current
explanation for this discrepancy is that molecules required in trace quantities can be taken
up by single-site hydrolysis, while those required in abundance require hydrolysis of both
ATPs for efficient substrate accumulation. As it has been observed that E. coli can subsist
on ribose as the sole carbon source, this model does not satisfactorily address the energetics
of substrate transport for the ribose transporter. Addressing this question will thus lead to
a broader understanding of ABC transporter function in a naturally-occurring system.
In chapter two of this thesis, we address whether RbsA binds one or two molecules
of ATP. While it appears only one ATP is hydrolyzed in a given cycle, whether both are
bound remains unclear. Studies of other transporters have provided an intriguing and
relevant model, which will be discussed in detail in that section. In order to conduct this
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study in a natural environment, the transporter has been reconstituted into nanodiscs, and
this chapter explores the details of this process.
In chapter three, we explore the conformational changes in the full-length RbsA
protein during transport. As different complexes have been identified, it has been inferred
from cofactor combinations and the conformation of RbsB how different stages of the
transport cycle can be structurally modeled. The conformation of RbsA can be then
deduced from studies of other ABC transporters. However, as has been discussed, the
arrangement of NBDs in RbsA is atypical and no study has thus far been undertaken to
address the function of such a protein. Using homology modeling and EPR spectroscopy,
we explore the conformational changes in both the active and inactive NBDs in the context
of transporter function. The impact of catalytic mutations will also be explored in the
context of conformational changes both in RbsA and in RbsB.
Three-dimensional structures of ribose transporter proteins, with the exception of
RbsB and the N-terminal NBD of RbsA, remain elusive, despite extensive crystallization
trials. These trials have been pursued in a variety of cofactor combinations and using
complex-stabilizing mutations, which have shown to be successful in the crystallization of
other ABC transporters. Details of these trials will be reported in chapter four. In addition,
a new approach, utilizing synthetic antibodies from phage-display selection, has yielded
potential crystallization chaperones. The rationale for this approach and the crystallization
chaperones obtained and characterized thus-far will be reported. In addition, these synthetic
antibodies have been shown to not just bind with high affinity, but to also be
conformationally selective. We will discuss what these antibodies tell us about ribose
transporter assembly and function.
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Finally, in chapter five we will conclude with an update of ABC transporter
understanding by applying lessons learned from studies, including this one, of the ribose
transporter and other asymmetric ABC transporters.
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CHAPTER TWO: FUNCTIONAL STUDIES IN MEMBRANE ENVIRONMENTS

2.1: An Enduring Question: One or Two ATP?
The mechanism of ATP hydrolysis in ABC transporters is still unresolved. Elegant
structural and functional studies have provided working models for the choreography of
the transport mechanism, but gaps remain in our knowledge. Many of these missing details
surrond the mechanics of ATP binding and hydrolysis, in particular how conformational
changes in the NBDs drive changes in the TMDs and how these ultimately lead to substrate
transport.
An enduring question is whether one or two ATP are hydrolyzed per transport cycle,
one that remains unanswered despite a surplus of biochemical data from a variety of ABC
systems (Patzlaff, van der Heide, & Poolman, 2003; Sharma & Davidson, 2000; Lewinson,
Lee, Locher, & Rees, 2010). This can in part be ascribed to the difficulty of making such
measurements, including the amount of substrate transported and the amount of ATP
hydrolyzed per transport cycle due to basal ATP hydrolysis. Still, at the heart of this answer
lie the mechanics of the transport process and our fundamental understanding of how the
transporter interacts with the transported substrate.
In general, the core transporter consists of NBD sandwich dimers, which bind ATP
at their interface, and TMD dimers, which form substrate translocation pathways. Prior to
the availability of crystal structures, biochemical studies of exporters provided the basis
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for a transport model derived from Jardetzky’s predictions for transmembrane transporters.
This model was known as the twin-cylinder model, and posited that each hydrolysis event
contributed to the transport of one substrate molecule (Jones & George, 2012). In this
model, the transport pathway consists of high- and low-affinity substrate binding sites in
the TMDs, with each TMD contributing one such pathway. Substrate accessibility to the
high-affinity site is thus coupled to an inward-facing ATP-bound state of the transporters.
Upon binding of a substrate molecule to the high-affinity site, hydrolysis occurs at one
NBD site, resulting in conformational changes that rearrange the TMDs and flip the
substrate to a low-affinity site, completing transport. A second substrate molecule can then
be transported using the second ATP and translocation pathway, before the entire
transporter is reset to an inward-facing state by an exchange of ATP for ADP/Pi.
While this model is generated for exporters, a similar model can be readily
imagined for importers. Here, the ATP-bound state sets the transporter in an outwardfacing configuration, primed to receive substrate-loaded SBP. Upon docking of the SBP,
the substrate is released to a transient substrate-binding site in the TMDs and signal
transduction events lead to ATP hydrolysis at one site. This results in rearrangements of
the TMDs such that the substrate is flipped to a low-affinity site in the ADP-bound inwardfacing state of the transporter and subsequently imported. Protein-protein interactions on
the outside are destabilized, leading to SBP release. The process then resumes with a
second substrate-loaded SBP docking onto the transporter.
While this model readily accommodates the “one ATP per substrate” concept, it is
in conflict with crystallographic evidence that has become available since its development.
For both importers and exporters, the balance of evidence suggests that TMD substrate-
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binding sites, when present, are limited to one per TMD dimer. The NBDs appear to act in
an equivalent manner, as demonstrated both by nucleotide occupancy of NBDs in intact
transporter crystal structures (ter Beek, Guskov, & Slotboom, 2014) and by biophysical
studies of protein conformational changes (Orelle, et al., 2010). A two-state model is
readily apparent, with an ATP-bound closed-NBD dimer state and an ADP/Pi-bound openNBD dimer state. NBD dimerization induces changes in TMD gating to allow substrate
access to the translocation pathway. Sequential hydrolysis then drives conformational
changes in the TMDs to facilitate substrate transport by a dissociation of NBDs, which then
resets the transporter for the upcoming cycle, much like an on/off switch. Hence, this is
popularly known as the ATP Switch model (Linton & Higgins, 2007) and provides the
basis for a “2 ATP per substrate” transport cycle (FIGURE 2-1A).
These seemingly clear-cut observations have been challenged by molecular
dynamics simulations of ABC transporters, guided by high-resolution crystal structures
solved in multiple states (Wen & Tajkhorshid, 2010). These simulations demonstrate a
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Figure 2-1: Switch versus Constant Contact Models. A) The Switch Model for ATP
hydrolysis. ATP are bound cooperatively and hydrolyzed processively to complete a
catalytic cycle. Two ATP are hydrolyzed per transport cycle. B) The Constant Contact
Model. ATP are hydrolyzed one at a time and exchanged for ADP, with helical domains
rotating away to facilitate exchange. The NBDs remain in contact during the catalytic cycle,
and the model leaves open the possibility for one ATP hydrolyzed per transport cycle.
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dissociation of NBDs after each hydrolysis event, allowing for an asymmetric substrate
translocation process that is not readily apparent from most crystal structures and ensemble
data from biophysical studies. Alternatively, each site might hydrolyze ATP processively
to fully complete a single trnalocation event. From these studies, a second model for NBD
function, termed the “Constant Contact Model”, has been proposed (FIGURE 2-1B). In
this model, ATPs are hydrolyzed processively, as in the Switch Model, but a complete
dissociation of NBDs is never observed. Instead, partial disengagement of the first
hydrolysis site allows release of products, which are exchanged for ATP while hydrolysis
occurs in the second site. The partial disengagement drives changes in the TMD gating
regions, allowing for substrate transport. In addition to MD simulations, the rapid exchange
and occupancy of each site rationalizes biochemical affinity measurements for ATP with
cellular ATP concentrations, which are an order of magnitude or more in excess. In this
view, crystal structures of apo forms of the transporters can be thought of as nonphysiologic states.
While this model is appealing, particularly for exporters, it remains incongruent
with experimental evidence. However, recent crystal structures of an unusual
heterodimeric exporter provide compelling visual evidence for a Constant Contact-type
translocation pathway. We will discuss this in the next section, and how this model applies
to the ribose transporter and guides the experiments described in this chapter.
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2.2 The Archaeal Exporter, TM287/288
Until recently, all crystal structures solved of ABC transporters contained fully
equivalent nucleotide-binding sites – all formed from homodimers of NBDs. These
included exporter TMD-NBD homodimers and importer NBD-NBD homodimers that
assembled with TMDS to form intact transporters. As expected, these nucleotide-binding
sites behaved as pairs, all either occupied or unoccupied by nucleotides, and always both
with the same nucleotides bound (either ATP, ADP, or some non-hydrolyzable analog). As
described earlier, biophysical studies demonstrated a functional equivalency of the two
sites.
In 2012, an AMP-PNP bound crystal structure of a heterodimeric archaeal ABC
exporter was determined at high-resolution and produced an unexpected result (Hohl,
Briand, Grutter, & Seeger, 2012). The drug transporter is formed by heterodimers of TMDNBD fusion proteins, as is typical for exporters, known as TM287 and TM288. Sequencebased analyses of the heterodimers revealed degeneracy in the nucleotide-binding sites,
with substitutions present for the catalytic glutamate (aspartic acid) and the switch histidine
(glutamine) in the NBD of TM287. These mutations implied reduced or abolished activity
of this NBD, as is the case for several human ABC transporters, including the
aforementioned CFTR, the peptide transloctor TAP1/TAP2, and the ion channel regulator
SUR1. Similar mutations impair the function of the C-terminal NBD of the ribose
transporter ATPase subunit, RbsA, most notably a serine substitution for the switch
histidine. Unexpectedly, the crystal structure revealed the degenerate site occupied by
AMP-PNP and the consensus site unoccupied with partial disengagement of the NBDs
where the nucleotide was absent (FIGURE 2-2). Biochemical analyses revealed the
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degenerate site bound nucleotide preferentially. This suggested the bound AMP-PNP
stabilized the interactions of the degenerate site, replacing some of the interactions
normally provided by the Q-loop and switch histidine. In addition, the D-loop, which
stabilizes the closed state of NBDs by contacting with the opposing D-loop, contained an
unusual SNVD sequence (consensus: SALD), with the asparagine located within hydrogen
bonding distance of the AMP-PNP γ-phosphate. This analysis was supported by studies of
TM287/288 conformational changes, which demonstrated that the NBD1 D-loop and
catalytic residues experienced significant motion during hydrolysis while NBD2 was
restricted (Hohl, et al., 2014). This provided the structural basis for allosteric cooperativity
in the consensus site and a transport model where conformational changes across the intact
half of the protein drove substrate export (FIGURE 2-3). The unusual mechanism then
suggested the possibility that the constant contact model could be applied in certain cases,
such as to heterodimeric exporters and atypical human ABC proteins such as CFTR and
SUR1. Appealingly, this demonstrated structurally how hydrolysis of a single ATP could
lead to transport. Whether this model can be universally applied remains to be determined
and requires analysis of other and varied systems. Recent MD simulations of CFTR using
a homology model based on TM287/288 found
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Figure 2-2: X-ray structure of AMP-PNP bound TM287-288 solved to 2.6 Å resolution.
Bound AMP-PNP is colored orange. Grey bar represents schematic of cell membrane.
AMP-PNP is bound at degenerate site (top, inset), and unoccupied consensus site (bottom,
inset) demonstrates disengagement of NBD relative to occupied degenerate site.
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Figure 2-3: Proposed transport and catalytic cycles for asymmetric TM287-288 exporter.
Left: Following hydrolysis, partial disengagement of helical domain of NBD1 allows
exchange of nucleotide. NBD2 remains bound with ATP and lacks, through naturallyoccurring mutations, the requisite catalytic residues. Right: Substrate (blue) docks onto
binding cleft in inward-facing state. NBD1 is stimulated to bind ATP, resulting in
engagement of binding interface and structural rearrangement of TMDs to outward-facing
state, allowing transport of substrate. Subsequent ATP hydrolysis in NBD1 resets
transporter to inward-facing state.
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the asymmetric inward-open conformation of the latter could rationalize experimental
evidence of CFTR gating with the proposed model (Corradi, Vergani, & Tieleman, 2015).
These models may provide a guide for understanding common gating-defects in CFTR that
cause its eponymous disease. Further studies of similar systems, particularly those from
bacterial sources that are readily expressed and purified, can provide us more detailed
insights into how these proteins function.

2.3 The Curious Case of RbsA
Much like TM287-288, CFTR, and many other asymmetric eukaryotic ABC
transporter NBDs, RbsA contains both consensus and degenerate nucleotide-binding sites.
While a full-length three-dimensional structure for RbsA is not available, sequence-based
analyses followed by biochemical studies have revealed its functional asymmetry. As
described in the previous chapter (FIGURE 1-15), the RbsA primary structure contains
several deviations in conserved domains from what are commonly thought of as canonical
ABC protein sequences. In addition to the aforementioned deviations in the Q-loop and Hloop of the C-terminal NBD (E334 and S453, respectively), several other variations exist.
In the Walker A motif of the C-terminal domain, the conserved lysine and serine at the Cterminus of the sequence are mutated to arginine and threonine, respectively. Whether
these impact ATP binding is unclear and remains to-be-determined. In the N-terminal
Signature Sequence, rather than the canonical LSGGQ, RbsA contains an LSIGDNQ
sequence (LSGGNQ in the N-terminal domain). As this motif stabilizes the phosphate
groups of ATP, primarily via hydrogen bonds formed by the conserved serine and
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glutamate, it is unclear how these substitutions impact the binding of ATP. Finally, the
conserved D-loop, which stabilizes interdomain interactions once ATP is bound, is
peppered with mutations in both NBDs of RbsA. In the N-terminal NBD, the canonical
SALD motif is instead DALT, while in the C-terminal NDB contains a more radical
departure, RGVD. Since its primary role in catalysis is to stabilize, through hydrogen
bonding, the catalytic glutamate from the Walker B motif, it is possible the D-loop is
unaffected by these substitutions.
In addition to the analysis of primary structure, biochemical and in vivo studies of
RbsA catalytic mutants have provided the most persuasive evidence for ribose transport
via hydrolysis at a single active site. A summary of several of these mutations and their
impact on activity, transport, and cell growth can be found in Table 2-1. A full list of
mutations and strains produced for this project can be found in the APPENDIX. Of
significance are the two mutations that have previously been shown to have the most
dramatic impact on ATPase activity in similar ABC transporters. The initial structures of
BtuCD were produced from crystallization of an inactivating and complex-stabilizing
mutation of the conserved Walker B glutamate, required for the currently-accepted general
base catalysis mechanism, to glutamine (E159Q in that system) (Locher, Lee, & Rees,
2002). In this state, ATP was shown to be bound but could not be hydrolyzed, and
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Table 2-1: Impact of catalytic mutations on RbsABC complex assembly in the presence of
the cofactors Mg-ATP-VO4, ATPase activity of the intact transporter, and ribose transport
into vesicles. ATPase activity measured by NADH-coupled enzyme assay. Ribose uptake
into vesicles measured using C-14 labeled ribose.

RbsA Species

Mutation
Position

Complex Assembly ATPase
Ribose
(with Mg-ATP-VO4) Activity Transport

wild-type

-

ABC

100

100

K43R

Walker A

AC (some ABC)

0

10

S44A

Walker A

BC

0

10

Q86A

Q-loop

AC (some BC)

50

60

E167Q

Walker B

ABC

0

0

H199A

H-loop

ABC

0

0

R291K

Walker A
(C-terminal)

ABC

50
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the success of this stabilization led to a similar effort employed to produce the first welldiffracting crystals and subsequent structure of the maltose transporter (Oldham, et al.,
2007). In addition to the critical glutamate, mutation of the switch histidine, which
coordinates and positions the ATP γ-phosphate, has also been shown to impact function.
Structures of the hemolysin transporter HlyB NBDs complexed with ATP were achieved
by an inactivating mutation of this histidine (H662A) (Zaitseva, et al., 2005).
Since single mutations in a fused NBD could theoretically produce an active
ATPase if both sites were functional, it was tested whether these RbsA mutants retained
any functionality, both in the context of hydrolysis and transport. Further, the impact of
these mutations on E. coli growth using ribose as a carbon source was tested in strains that
lacked wild-type RbsA. ATPase activity was measured by a phosphate-based detection
method (Baykov, et al., 1988) and transport was assayed by accumulation of C-14
radiolabeled ribose in vesicles containing RbsAC, with RbsB and ribose added outside.
The E167Q (the N-terminal positions of the aforementioned catalytic residues) mutation
abolished nearly 100% of ATPase activity compared with the wild-type when measured by
this method and no ribose accumulation could be detected in vesicles. Transformation of
the mutation-carrying plasmids into cell lines lacking endogenous RbsA resulted in
phenotypes unresponsive to ribose availability as the sole carbon source, consistent with
the ATPase and transport assays. Interestingly, while the H199A mutation severely
impaired ATPase activity, both transport and cell responsiveness proceeded at detectable,
albeit significantly reduced, levels. This may point to a more significant role for the
catalytic glutamate via this mechanism or compensation for the absence of the switch
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histidine by other residues. In either case, the data strongly support hydrolysis by a single
active site in the intact RbsA protein.
What then, is the role of the second site? Does it provide allosteric cooperativity by
binding ATP, much like the NBDs of TM287-288? Or is it a mere bystander, a useless and
vestigial limb dragged on through the millenia by bacteria that have long learned to get by
efficiently and effectively through more parsimonious means? In this chapter the role of
the second site is explored by ATP-binding studies of the transporter in modular membrane
bilayers known as nanodiscs. Reconstitution and characterization of the ribose transporter
into functional nanodiscs are described, followed by the details and results of the binding
studies.

2.4 Nanodiscs: Membrane Modules for Functional Studies
A variety of membrane-based media exist for studies of membrane proteins in
native environments. Their development is motivated by the inability of detergents,
required for membrane protein extraction, purification, and solubilization, to faithfully
replicate the native cell membrane. A significant aspect of membrane protein stability
concerns the lateral pressure profiles of native lipid bilayers, as well as acyl chain length
to provide a “hydrophobic match” to membrane-spanning helical segments (Cantor,
Lateral pressure in cell membranes: a mechanism for modulation of protein function.,
1997). These properties are defined by the type and composition of cell membranes, and
are subject to local fluctuations that can accommodate a diverse array of membrane
proteins (Cantor, 1999). Screening detergents during purification can result in one or a
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combination of two or more than produce a stable reconstitution; the choice is generally
made through empirical characterization following extraction from native membranes
during protein purification (Seddon, Curnow, & Booth, 2004).
Despite their usefulness, detergents are poor membrane mimetics, and have
contributed to the significant lag of membrane protein structure determination progress
compared with the field as a whole (Zhou & Cross, 2013). This problem will be addressed
in greater detail in Chapter 4. In addition to the difficulties of solving membrane protein
structures, the inability of detergents to faithfully stabilize membrane proteins also
contributes to challenges for functional studies of these systems. A variety of methods have
been developed to better replicate the membrane environment, including liposomes
(Rigaud, et al., 1995), bicelles (Durr, et al., 2012), and, more recently nanodiscs. A
nanodisc is a modular membrane bilayer surrounded by an engineered protein derived from
the apolipoprotein A-1 scaffold proteins (Ritchie, et al., 2009) (FIGURE 2-4). The efficacy
of nanodiscs in membrane protein functional studies is well-documented and widespread,
including biochemical experiments of ABC
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Figure 2-4: Nanodiscs are modular lipid bilayers enveloped by an amphipathic membrane
scaffold protein that forms a belt around the hydrophobic segments. The size of the
nanodisc is restrained by the length of the belt protein and the particle diameter can vary
from 10 – 17 nm. Figure represents a schematic diagram and is adapted from the Atkins
Lab: http://depts.washington.edu/wmatkins/nanodiscs.html.
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transporters (Alvarez, et al., 2010), and the technology has more recently been applied to
modern structure determination techniques (Kim, et al., 2015). Unlike liposomes, they
offer no orientation bias, although this may be considered a limitation for transport assays.
Unlike bicelles, they do not require maintenance of high concentrations of lipids and
detergents to preserve their integrity, and thus are most convenient for biochemical and
biophysical studies where substrate accumulation is not the primary objective.
Nanodiscs are assembled spontaneously by the combination of the membrane
scaffold protein (MSP), lipids, and the target membrane protein following removal of
detergent. Each disk is formed by two copies of MSP encapsulating a circular bilayer to
form a modular membrane system. Variants of MSP have been engineered to produce
nanodiscs with diameters ranging from 9.6 to 17 nm. Lipid content can be varied as desired
to find arrangements suitable to particular membrane proteins, adding to a range of
customizations that are possible within the nanodisc framework. The number of copies of
the target membrane too can be varied by altering the lipid:target ratio during nanodisc
assembly, allowing for optimization in cases where one target protein per disc is desired.
Previously, a protocol for reconstitution of an ABC transporter, the maltose
transporter, has been described (Alvarez, Orelle, & Davidson, 2010). In this study,
nanodiscs of ~13 nm diameter were produced using soybean L-α-phosphatidylcholine
(1,2-Diacyl-sn-glycero-3-phosphocholine) as the lipid medium and the MSP variant
MSP1E3D1, which carries three additional helical segments than MSP1. In this chapter, a
method to reconstitute the ribose transporter derived from this protocol is described.
Nanodisc-reconstituted RbsABC was then utilized in biophysical experiments to
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characterize the binding of fluorescent ATP substrates to the transporter. The background
for these experiments is described in the following section.

2.5 TNP-ATP as a Probe for Nucleotide Binding Sites
Trinitrophenyl-ATP (TNP-ATP) is a modified nucleotide analog carrying a
fluorescent moiety on the ribose ring (FIGURE 2-5), allowing it to function as robust
sensor for protein-nucleotide binding and enabling the determination of kinetic and
equilibrium constants. TNP-nucleotides generally act as non-hydrolyzable nucleotide
analogs that fluoresce weakly in solution and can bind proteins with generally higher
affinity than natural nucleotides. The quantum yield of fluorescence increases greatly when
bound to the more hydrophobic environment of a protein’s substrate binding site, making
TNP-nucleotides sensitive probes for binding. These probes have been shown to have great
utility for the determination of thermodynamic binding isotherms for a variety of systems,
including kinases (Stewart, et al., 1998), F1-ATPases (Yamagata & Tainer, 2007), and
recently ABC transporters (Bao & Duong, 2013).
In aqueous solutions, TNP-ATP demonstrates a single fluorescence emission
maximum at 561 nm following excitation at 408 nm. This maximum is blue-shifted and
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Figure 2-5: TNP-ATP carries the trinitrophenyl moiety on the ribose ring of ATP, resulting
in a weakly fluorescent molecule with a maximum emission output of 561 nm. Adapated
from manufacturer’s website (Jena Bioscience).
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accompanied by a 75-fold increase in quantum yield when TNP-ATP is placed in an
organic solvent; thus, the wavelengths of absorbance maximum of TNP-ATP depend
strongly on solvent polarity. This property is exploited to gain information about the probe
environment, notably by studying changes in absorption properties during binding and
dissociation of TNP-ATP from nucleotide binding sites.
Here we utilize TNP-ATP to determine the binding properties of the ribose
transporter NBD, RbsA. The data described above strongly suggest RbsA hydrolyzes ATP
using only its single active site. However, whether a model of allosteric cooperativity can
be applied to RbsA in a similar fashion as TM287-288 is unclear, and more information
about the binding stoichiometry is required to draw such a conclusion. This information
can then be exploited to refine the current transport model for RbsABC. Reconstitution of
RbsABC into nanodiscs allows for the study of nucleotide binding in natural environments.
The reconstitution experiments and subsequent binding and kinetic studies are described
in the following sections.

2.6 Methods and Materials
The expression, assembly, and purification of the various ribose transporter
complexes and individual components have been previously described (Clifton, et al.,
2015;, Simon, 2011; Clifton, 2005; Barroga, et al., 1996; Binnie, et al., 1992) and these
sources should be consulted as detailed references for these protocols. These protocols has
been employed with slight variations throughout this study. These variations will be
described when applicable, but the readers are referred elsewhere for complete details.
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2.6.1 Expression and Purification of Ribose Transporter Complexes
The complexes were expressed as described (Clifton, et al., 2015) with slight
modifications. Plasmids bearing RbsAC (pTATHC) or RbsC (pTCH-14) were transformed
into BL21-AI (Invitrogen) cells and plated on LB media containing ampicillin (100 µg/mL
final concentration). Colonies for expression were selected the following day and grown
overnight in 10 mL LB liquid media supplemented with ampicillin. The overnight cultures
were used the following morning to inoculate 1 L 2XYT media supplemented with
ampicillin as above. Growth was monitored by spectrophotometer (Ultraspec 3100 pro)
and cells were grown (37°C with shaking at 230 RPM) until an OD600 of 0.6, after which
they were briefly cooled to 16°C. The cultures were induced with 0.01% arabinose
(Narayanan, et al., 2011) and grown for 20 h post-induction (16°C with shaking at 200
RPM). The cells were harvested the following morning by centrifugation (5000 RPM for
10 min). Transport complexes were purified as described using the appropriate cofactor
combinations (Clifton, et al., 2015). Following purification, imidazole was removed by
overnight dialysis (Buffer A: 20 mM Tris, pH 8.0, 200 mM NaCl, 20% glycerol, 0.05%
DDM, and appropriate cofactors) or by two rounds of buffer exchange using 10DG
desalting columns (Bio-Rad). Vanadate-trapped RbsABC could be produced, by this
method, to yields of 10-15 mg purified protein per liter of 2XYT cell culture. Expression
was previously optimized by varying cell lines, induction conditions (optical density, time,
and temperature) and inducer concentration [IPTG (100 µM – 1 mM) and arabinose (0.01
– 0.1 %)] (FIGURE 2-6). Ribose transporter complexes were concentrated to 50 µM and
stored at -20°C for long-term storage.
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2.6.2 Expression and Purification of MSP
Membrane scaffold protein (MSP) variants MSP1D1 and MSPE3D1 were purified
as previously described (Ritchie, et al., 2009) with slight modifications during the column
washing procedure. These are described in Alvarez et al (2010). Following purification
and dialysis, the poly-histidine tag was removed by overnight TEV protease digest using a
1:100 TEV:MSP ratio in 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, and 2 mM
2-mercaptoethanol. TEV protease was purified as described in the APPENDIX. Following
digestion, EDTA was removed by dialysis into the same buffer lacking EDTA. The
digested sample was then reversed purified as previously described (Alvarez, et al., 2010)
using 10 mL of TALON cobalt affinity resin (Clontech). Samples were analyzed by SDSPAGE. Samples containing digested MSP were pooled, dialyzed into buffer (20 mM TrisHCl pH 8.0, 100 mM NaCl), and concentrated to approximately 100 µM, aliquoted and
subsequently stored at -20°C for long-term storage. By this method, purified and digested
MSP could be recovered up to 90-100 mg protein per L of Terrific Broth cell culture.

2.6.3 Lipid Preparation for Nanodisc Assembly
Soy lipids were prepared as previously described (Alvarez, et al., 2010) with slight
modifications. One-hundred mg of soy phosphatidylcholine (Sigma) were suspended in 8.5
mL of buffer (50 mM Tris-HCl, pH 8.0) and sonicated on ice with 5-10 one-minute cycles
(1 sec on/1 sec off), allowing solution to cool on ice in between cycles. Once the solution
became clear and yellow, 1.5 mL of a 10% DDM solution was added, producing a mixed
micelle solution containing final concentrations of 10 mM soy PC and 30 mM DDM, which
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was subsequently used for nanodisc assembly. A separate lipid solution made from a
mixture of chicken egg PC (Avanti) was prepared as previously described (Dominik &
Kossiakoff, 2015), producing an identical mixed micelle solution containing 10 mM egg
PC and 30 mM DDM.

2.6.4 Nanodisc Assembly and Purification
Nanodiscs were assembled using a protocol adapted from those previously
described (Alvarez, et al., 2010; Dominik & Kossiakoff, 2015; Ritchie, et al., 2009). Prior
to reconstitution, Bio-beads (Bio-Rad) were activated by methanol followed by washing
with copious amounts of water. A 50% Bio-beads suspension was made with water and
could be stored for several months at 4°C. The requisite amount of beads was washed with
buffer and then dried immediately prior to usage for assembly experiments.
Nanodisc preparation was optimized by varying the ratios of transporter:MSP and
MSP:lipid, and the type of lipid used. In general, the experiments were designed to produce
an excess of empty nanodiscs relative to transporter-incorporated discs. This ensured a
maximum of one transporter per disc is produced. For initial experiments, ratios of 1:5, 1:8,
and 1:10 transporter:MSP, and ratios of 1:50, 1:80, and 1:200 MSP:lipid were utilized.
These were later optimized to 1:5:325 transporter:MSP:lipid, as will be discussed during
the RESULTS section.
The amount of transporter added to the experiments was calculated to ensure the
final glycerol concentration in the assembly mixture was less than 3% (Ritchie, et al., 2009).
The assembly mixture was designed for a total volume of less than 1.5 mL. Larger volume
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mixtures resulted in inefficient assembly of nanodiscs. Transporter was first combined with
excess buffer (Buffer A, as above with appropriate cofactors but excluding glycerol) and
incubated on ice for 10 minutes. The lipid solution was then added and the resulting mixture
was incubated on ice an additional 20 minutes. MSP was added and, following a brief
incubation on ice, the mixture was transferred to dried Bio-beads, triggering the assembly
reaction. Reconstitution mixtures were incubated overnight at 4°C with agitation.
The following morning, the assembly mixture was removed from Bio-beads (the
remaining beads were washed once with 0.5 mL of buffer and added to the assembly
mixture) and transferred onto 2 mL of Ni-NTA resin (Qiagen) pre-equilibrated with buffer
(Buffer A, as above with appropriate cofactors but lacking DDM). The suspension was
placed on a rocker at 4°C and allowed to bind with shaking for approximately 1.5 hours.
The suspension was then transferred to 14 mL PD-10 columns (Bio-Rad) and the resin was
allowed to settle. Flow-through was collected and the column was washed with 10 column
volumes (Buffer A with 25 mM imidazole, no DDM) and proteins were subsequently
eluted with 6 column volumes (same buffer but with 250 mM imidazole). Fractions (2 mL
each) were collected and analyzed by SDS-PAGE using 15% gels.
Fractions containing transporter-incorporated nanodiscs were pooled and dialyzed
against Buffer A (no DDM), then concentrated for size-exclusion chromatography using a
50 kDa MWCO centrifugal spin filter (Amicon). Prior to nanodisc injection, the column
was calibrated by the injection of standards of 673, 158, 67, 44, and 18 kDa. The
concentrated sample (~500 µL) was then injected onto a Superdex200 10/300 GL column
(GE Healthcare) pre-equilibrated with 2 CVs of Buffer A with appropriate cofactors (no
detergent and no glycerol) and run at 0.5 mL/min (maximum column pressure was 1.5
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MPa). Fractions (1 mL) were collected in 1.5 mL Eppendorf tubes and peak fractions were
analyzed by SDS-PAGE. Samples containing reconstituted nanodiscs were pooled,
concentrated to 5-10 µM, and transferred to a storage buffer (as above with 20% glycerol)
for storage at -20°C.

2.6.5 Activity Assays with Nanodiscs
ATPase activity of the transporter-incorporated nanodiscs was tested using an
NADH-coupled enzyme assay utilizing pyruvate kinase (PK, Sigma) and lactate
dehydrogenase (LDH, Sigma) as previously described [ (Alvarez, Orelle, & Davidson,
2010), (Kiianitsa, Solinger, & Heyer, 2003)]. The assay utilizes a regeneration system: PK
uses phosphoenolpyruvate (PEP) to convert ADP to ATP while also producing pyruvate,
which is subsequently converted to lactate by LDH while oxidizing NADH to NAD.
Following NADH oxidation by the decline of absorption at 340 nm allows the real-time
monitoring of steady state ATP hydrolysis. As an added convenience, the assay is readily
adaptable to a high-throughput, 96-well format.
Crude nanodiscs from Ni-NTA purifications were used for the activity assays. The
concentration of nanodiscs was determined by Bradford or BCA assays, since ATP
interfered with the direct measurements of protein absorbance. Cofactors used during
purification were removed by overnight dialysis followed by several rounds of buffer
exchange into Buffer A (minus cofactors). The concentration was re-evaluated following
this procedure by the same methods. Typically, 1-3 ug of nanodisc-reconstituted RbsAC
were added to the reaction solution (50 mM Tris-HCl, pH 7.5, 100 mM KCl, 10 mM MgCl2,

94
4 mM PEP, 0.3 mM NADH, 60 µg/ml PK, 32 µg/ml LDH, and the presence or absence of
100 µM ribose and 5 µM RbsB). In addition, ATP was added in a series of concentrations
from 0 – 500 µM, producing a typical total reaction volume of 200 µL. All reactions were
performed at 37°C and in triplicate. Reactions were performed in 96-well UV-transparent
plates (Corning) and measured using a microplate reader with temperature control and
automated shaking (BioTek). The turnover of ATP was calculated as previously described,
using the equation below (Kiianitsa, Solinger, & Heyer, 2003):

Here, Kpath is the molar extinction coefficient of NADH at 340 nm and a given path length.
Kinetic parameters were subsequently determined using the graphing software, Prism
(GraphPad) and Michelis-Menten kinetics.

2.6.6 TNP-ATP Binding Assays
TNP-ATP binding assays were carried out as previously described (Stewart,
VanBruggen, Ellefson, & Wolfe, 1998) with modifications for this particular system. Both
wild-type RbsAC and the catalytic mutant transporter, RbsA(E167Q)C, were reconstituted
into nanodiscs (as described above). The choice of the catalytic mutant was made to control
for the possibility of hydrolysis of TNP-ATP. While it is generally assumed TNP-ATP is
non-hydrolyzable, there are many published reports of non-hydrolyzable analogs that are
actually “weakly hydrolyzable”, such as ATPγS (Jones & George, 2012). As a control,
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RbsABC assembly experiments were performed using TNP-ATP instead of AMP-PNP as
previously described (Clifton, et al., 2015).
Titrations were performed using RbsA, nanodisc-reconstituted RbsAC and
RbsA(E167Q)C, and detergent-reconstituted RbsAC, all at three different protein
concentrations. All experiments were performed in identical buffer conditions (25 mM
Tris-HCl pH 7.5, 100 mM KCl, and 10 mM MgCl2). Additionally, in experiments
involving transport complexes, RbsB was added at 5 µM final concentration.
Experiments were performed using a Jobin Yvon Fluoromax-3 fluorimeter
(Horiba). Samples were incubated at room temperature and stirred constantly. Using a
reaction volume of 2.5 mL and protein concentrations of 0.5, 1.0, and 2.0 µM, titrations of
TNP-ATP (Molecular Probes) were performed over a range of concentrations, from 0.01
to 5 µM. Control reactions without protein were also performed. TNP-ATP fluorescence
was stimulated by an excitation wavelength of 403 nm with a pathlength of 2 nm.
Fluorescence emission was monitored over a range of 480 – 650 nm using the same
pathlength. Spectra were background corrected using the buffer-only titrations and proteinonly control measurements. The peak emission wavelength was chosen and normalized
fluorescence at this wavelenght was plotted against substrate concentration for each protein
concentration tested. Using a previously described method (Stewart, VanBruggen, Ellefson,
& Wolfe, 1998), the amount of bound nucleotide per transporter molecule could be
calculated using the equation below.
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Every given normalized fluorescence point includes contributions from bound and
unbound nucleotide. By measuring TNP-ATP fluorescence for a series of transporter
concentrations, the amount of unbound nucleotide at each titration point could effectively
be determined from the data series (Bujalowski & Klonowska, 1993). Thus the slope of a
series of normalized fluorescence values could be determined and extrapolated to
saturation to determine the binding stoichiometry.

2.7 Results
The results of the nanodisc assembly, activity assays, and binding studies are
presented in separate sections below, with associated data figures and tables.

2.7.1 Optimization of RbsAC Expression
To facilitate structural studies, a variety of expression conditions and cell lines were
tested to optimize expression. These included typical expression cell lines, such as BL21DE3 and BL21-C43, and the less typically used cell line BL21-AI. Cells were grown in
LB, 2XYT, and TB media, and allowed to grow to cell densities ranging from 0.6 – 2.5
prior to induction. Cells were induced with either IPTG, at 0.1 – 1.0 mM final
concentrations, arabinose, at 0.01-0.1% final concentrations, or a combination of IPTG and
arabinose. A variety of induction temperatures were tested from 37°C to 16°C, with
induction times ranging from 3 h to 20 h. A summary of several successful conditions can
be found in FIGURE 2-6, judged by the final yield of RbsABC from 1 liter of cells. The
highest yield was obtained using 0.01% arabinose to induce at cell densities of 0.6-1.0
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followed by a 20 h induction at 16-18°C. Glycerol stocks were made and maintained for
the cell lines with the highest yields, typically 15-20 mg RbsABC per liter of cells.

2.7.2 Purification and Removal of His-tag from MSP
MSP was purified as described above and the fractions from affinity
chromatography were analyzed by SDS-PAGE (FIGURE 2-7A). Elution fractions were
estimated to be over 80% pure. Fractions were pooled and digested overnight using a 1:100
molar ratio of TEV protease. The digested sample was applied to 10 mL cobalt-charged
TALON resin and reversed purified following 1.5-hours of incubation with rocking to
allow binding to resin. Fractions were collected and analyzed by SDS-PAGE (FIGURE 27B). Digested MSP samples could be found in the flow-through and wash fractions, and
are over 90% pure based on SDS-PAGE analysis. A lack of MSP in the
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Figure 2-6: Improving ribose transporter expression. All conditions evaluated by yield of
purified protein complex, RbsABC, of which RbsAC are co-expressed using a T7 promoter
system. Purified RbsB is added separately in the presence of cofactors to form the intact
transport complex. LB = Luria Broth, TB = Terrific Broth. A) 0.2 mM IPTG, 3 h induction
at 37 deg in LB. B) 0.5 mM IPTG, 3 h induction at 37 deg in LB. C) 0.5 mM IPTG, 3 h
induction at 37 deg in TB. D) 0.5 mM IPTG, 0.01% arabinose, 5 h induction at 25 deg in
TB. E) 0.01% arabinose, 12 h induction at 25 deg. F) 0.01% arabinose, 20 h induction at
16 deg. D-F correspond to the “restrained expression” method using arabinose as the
inducer.
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Figure 2-7: SDS-PAGE of purification and his-tag cleavage of MSP1D1. A) MSP1D1
purified from 1 L TB media by TALON affinity chromatography. FT = flow-through; W
= wash; E = elution. Standards molecular-weight given in kDa. B) MSP1D1 reverse
purified following overnight TEV protease cleavage. I = input mixture post reaction; FT =
flow-through; W = wash; E = elution. TEVp = TEV protease. Bands visualized by
Coomassie staining.
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elution suggested the TEV protease digest was run to near completion. The MSP fractions
were pooled and concentrated as described in the METHODS section.

2.7.3 Assembly of Ribose Transporter-Nanodiscs
Nanodiscs were assembled as described and initially purified by affinity
chromatography. Fractions were collected and analyzed by SDS-PAGE (FIGURE 2-8).
Fractions containg transporter-incorporated nanodiscs could be found in the elution due to
the presence of a poly-histidine tag on RbsC. Visual inspection of the band intensity
suggested the ratio of RbsC to MSP was 1:1, implying one molecule of transporter was
reconstituted per nanodisc. Based on the intensity of RbsA and RbsC bands in the flowthrough and wash, the reconstitution was determined to be about 50% efficient. Efforts to
improve the efficiency significantly were unsuccessful. The protocol could not be scaled
to larger sample volumes, and was most efficient at 2 mL or less for the assembly mixture
volume.
Based on SDS-PAGE analysis of affinity chromatography, the most successful
reconstitution occurred using MSP1D1 to form nanodiscs. Nanodiscs made from
MSPE3D1 were also analyzed by SDS-PAGE. The transporter bands were found to be
more faint by comparison with 1D1 reconstitutions (data not shown). Elution fractions
from MSP1D1 and E3D1 reconstitutions were pooled and concentrated to 500 µL or less
samples volumes and subsequently injected into a Superdex200 10/300 GL gel-filtration
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Figure 2-8: SDS-PAGE of purification of nanodiscs using Ni-NTA affinity
chromatography following assembly reaction. His-tag is on RbsC. Left to right: MW
marker, flow-through (FT), wash (W), elution 1 (E1), and elution 2 (E2). Ribose transporter
proteins and MSP are labeled. Bands are visualized by Coomassie staining.
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column. Successful reconstitutions using MSP1D1 eluted in well-defined peaks
approximately at 11.5 mL while empty nanodiscs from both 1D1 and E3D1 eluted at 12.5
mL (FIGURE 2-9). Samples from E3D1 reconstitutions did not produce well-defined
peaks and eluted in a diffuse manner, suggesting poor reconstitutions. Efforts to optimize
reconstitutions using E3D1 failed. Sizes of RbsABC nanodiscs were estimated by
comparison to the elution profile of gel filtration standards (FIGURE 2-10).

2.7.4 ATPase Activity of RbsAC Nanodiscs
ATPase activity was evaluated by the NADH-coupled enzyme assay described
above. Experiments were performed using a series of ATP concentrations and in triplicate
using 200 µL reaction volumes in a 96-well plate. The oxidation of NADH was monitored
and then used to calculate the rate of hydrolysis for each concentration using the equation
above.
Reconstituted RbsAC demonstrated a significant RbsB- and substrate-stimulated
rate of ATP hydrolysis (FIGURE 2-11, circles), calculated to be 420 ng ATP/min/mg
RbsA. Hydrolysis in the absence of ribose and RbsB was limited (squares) and calculated
to be 30 ng/min/mg RbsA. The activity for RbsA alone was too low to be measured by this
method (data not shown). The data compare favorably to the rates measured in liposomes
for RbsAC with RbsB and ribose added, suggesting a successful

103
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Figure 2-9: Gel filtration of RbsABC-reconstituted nanodiscs following affinity
purification using Superdex200 10/300 GL column. SEC buffer: 20 mM Tris-HCl pH 7.5,
200 mM NaCl, 1 mM Mg-ATP-VO4. Red curve – injection of empty MSP1D1 nanodiscs
formed from 1:130 MSP:Lipid ratio. Blue curve – injection of RbsABC in MSP1D1 using
1:5:325 RbsABC:MSP1D1:soyPC ratio. Orange curve – ratio of 1:5:400. Cyan curve –
ratio of 1:5:600. All injections following purification of nanodiscs using affinity
chromatography.
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Figure 2-10: Elution profile of RbsABC nanodiscs compared with gel-filtration standards
(GE Healthcare). Molecular weight of ribose transporter in nanodiscs was estimated based
upon the standard curve for thyroglobulin (670 kDa), aldolase (158 kDa), and albumin (67
kDa).
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Figure 2-11 (above): ATPase activity of ribose transporter reconstituted into MSP1D1
nanodiscs. Hydrolysis was measured for 60 minutes at 2-minute intervals using an NADHcoupled assay. Activity was determined from the rate of hydrolysis using a range of ATP
concentrations given above. Activity of transporter with RbsB and ribose (circles) and
without (squares) is shown. All assays performed in replicates of four.

Table 2-2 (below): Kinetic data for activity assays of RbsAC in nanodiscs in the presence
and absence of RbsB and ribose, as described. All values given in nmoles ATP hydrolyzed
per minute per mg transporter.
Vmax
Vmax Error
Km
Km Error Replicates
RbsAC + RbsB and ribose
114.7
6.35
26.71
5.77
4
RbsAC
9.72
0.80
22.30
7.35
4
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reconstitution. Previous experiments in detergent did not demonstrate a RbsB- and ribosestimulated rate of hydrolysis for RbsAC (data not shown). Kinetic constants for RbsAC in
1D1 nanodiscs with and without RbsB and ribose are reported in Table 2-2. Similar
constants in experiments previously performed in liposomes were not calculated (Clifton,
et al., 2015).

2.7.5 Complex Formation Experiments with TNP-ATP
As a control to ensure binding and behavior as a non-hydrolyzable analog, TNPATP was used as a substitute for AMP-PNP to repeat RbsAC complex formation
experiments (Clifton, 2005). Due to cost, TNP-ATP was used at 100 µM concentrations
rather than 1 mM as had previously been used. As before, magnesium chloride was added
as a required cofactor for ATP binding.
SDS-PAGE analysis of the fractions (FIGURE 2-11) collected from affinity
chromatography revealed the presence of both RbsA and RbsC in the elutions fractions, a
signature for successful complex formation. The band intensity was judged to be roughly
1:1 RbsA to RbsC, suggesting an efficient complex formation between the two proteins.
This demonstrated both that RbsA bound TNP-ATP in an expected manner, but also
promoted complex formation with RbsC, which carries the affinity tag for such
purifications. TNP-ATP was subsequently used for binding experiments.
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2.7.6 Fluorescent Analog Binding Experiments with RbsA
Binding of TNP-ATP with RbsA was shown to promote a 1.5-2-fold increase in
fluorescence intensity compared with measurements made in the absence of protein
(FIGURE 2-12). Fluorescence intesity was measured over a 10-fold concentration range
above and below the target protein concentrations. Each titration was performed at a fixed
RbsA concentration. Background-corrected intensity values demonstrated saturation in the
increase of fluorescence emission at higher substrate concentrations in the presence of
protein. For each experiment, fluorescence intensity values were normalized to the
maximum measured fluorescence emission for the particular replicate.
Titration data were collected in replicates for all three RbsA concentrations.
Average intensity values were plotted against TNP-ATP concentrations for each protein
concentration (FIGURE 2-13), revealing saturation kinetics for all three concentrations
during the course of the experiment. These best-fit results provided the total binding and
total fluorescent output, including unbound nucleotide.
To remove contributions of unbound nucleotide, fluorescence measurements at
each TNP-ATP concentration were compared for each protein concentration, and
normalized intensity was plotted against nucleotide concentration for a given RbsA
concentration. The slope of each line corresponded to the amount of nucleotide bound per
RbsA molecule (FIGURE 2-14), as described in the experimental methods section and in
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Figure 2-12: Increase in fluorescence emission of TNP-ATP due to protein binding.
Emission intensity following stimulation at 410 nm was monitored in buffer (blank, blue)
and in the presence of protein (red). Increase in emission was also accompanied by a blue
shift.
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Figure 2-13: Fluorescence-monitored titration of RbsA with TNP-ATP. Three different
RbsA concentrations were tested (0.5, green; 1.0, red; and 2.0; blue; all values in
micromolar). For each titration, the average fluorescence values were normalized with the
highest measured intensity for that set.
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Figure 2-14: For each measured intensity value, the total nucleotide concentration versus
the protein concentration were plotted. The slopes of these lines were determined to
calculate binding stoichiometry. Five different intensity values are shown here (0.1, circles;
0.25, squares; 0.5, triangles; 0.75, inverted triangles; 0.9, diamonds).
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FIGURE 2-15: Relative fluorescence values versus TNP-ATP per RbsA molecule. Data
are plotted over a range of values and fit using linear regression. Extrapolation of the data
to saturation (normalized fluorescnence = 1) reveals a binding stoichiometry of 1.9.
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the method by Bujalowski (1993). The average slope values were then plotted against
normalized intensity values and extrapolated to saturation (Y=1, FIGURE 2-15). These
revealed an average binding stoichiometry of 1.9 TNP-ATP molecules per RbsA molecule.
Binding isotherms were determined by non-linear regression using a two-site
cooperative binding model and one-site binding model. Both the shape of the curves and
the binding analysis suggest that both NBDs of RbsA do not contribute equally to the
spectral changes and that the first site generates a greater change than the second.
Macroscopic dissociation constants were determined for each site using the binding models.
The first site Kd was calculated to be 0.035±0.019 mM with a Bmax of 0.502. The second
site Kd was calculated to be 0.97±0.68 mM with a Bmax of 0.728. Neither value could be
determined with greater precision.

2.8 Discussion
This chapter described the reconstitution of the ribose transport complex into
nanodiscs and subsequent validation efforts using activity assays. Subsequently, nanodiscs
and isolated RbsA were used to assess the stoichiometry of ATP binding. This data filled
in gaps in the transport model: how the NBDs of RbsA interact with one another to fulfil
hydrolysis.

2.8.1 Tools for Biophysical and Biochemical Analyses
The long-term goal of this study is to provide detailed structural information about
an unusual ABC transporter and to use this information to improve our understanding of
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this well-studied yet incompletely understood protein superfamily. This endeavor is greatly
aided by improving yields of protein purifications and by utilizing modern technology for
the study of membrane proteins in native environments.
This chapter described efforts to improve the yield of the ribose transporter RbsAC
complex through optimization of expression conditions. This involved many variables to
identify an optimum condition. The most suitable condition utilized the technique
“restrained expression”, which takes advantage of the repressor-operator relationship to
reduce the amount of target mRNA produced. This method has previously been shown to
increase yields of both soluble and membrane-embedded proteins. For this system, the
RbsAC complex could be produced at 10-15 mg of purified protein per L of 2XYT cell
culture. This represented an increase of 10-15 times in yield from the IPTG-based method
that had been used previously.
Nanodiscs have been shown to be a robust platform for the study of integral
membrane proteins in vitro and can be optimized to successfully mimic the native
environments of a variety of membrane proteins (Ritchie, et al., 2009). These modular
membrane mimetics can be applied to biochemical and biophysical experiments, and have
recently been adapted for use in Cryo-EM structure determination (Kim, et al., 2015).
Here it has been shown that RbsAC can be successfully reconstituted into nanodiscs
formed from MSP1D1 and a soybean phosphotidylcholine lipid mixture, which form
nanodiscs roughly 10 nm in diameter. Analysis of gel band intensity suggests the nanodiscs
form with a ratio of 1 MSP to 1 RbsC molecule. In addition, RbsABC-reconstituted
nanodiscs (formed in the presence of cofactors) elute at 11.5 mL on a Superdex200 10/300
GL gel filtration column. Comparison of the elution volume with known standards suggests
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a particle size in between 158 and 670 kDa in size. Empty nanodiscs eluted at
approximately the same position as the 158 kDa standard. The molecular weight of the
RbsABC complex has previously been determined to be roughly 150 kDa (Clifton, et al.,
2016). This would suggest a particle size of 300 – 330 kDa in size if one transporter is
incorporated per nanodisc.
Although two transporters per nanodiscs would yield a size falling within the range
provided by the molecular weight standards, this is unsupported by the intensity of bands
in SDS-PAGE. However, estimating band ratios from such analysis is notoriously
inaccurate, particularly for membrane proteins that cannot be adequately solubilized by
SDS. Given this, the number of transporters per nanodisc is ambiguous and requires
additional analysis.
NADH-coupled activity assays demonstrated conclusively that the integrity of the
transmembrane domains is preserved in the nanodiscs. RbsAC nanodiscs showed a
significant stimulation of activity in the presence of RbsB and ribose, a demonstration of
signal transduction that is not achieved for this system in detergent reconstitution. The data
compare favorably to results of the maltose transporter in nanodiscs, which also shows a
binding protein- and substrate-stimulated increase in hydrolysis activity.
Finally, it is noteworthy that the smaller nanodiscs were the most accommodating
for RbsC. Previously nanodiscs made from the larger MSPE3D1 had shown utility for
several other ABC transporter systems. The larger, ~13 nm nanodiscs have been thought
ideal for systems with 6-10 TM helices per monomer. The significance of this result in the
context of existing data will be discussed in Chapter 5.
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2.8.2 Fluorescence Titrations Reveal 2 ATP binding sites in RbsA
The behavior of unusual ABC transporters has been sparsely studied, and the lack
of detailed understanding of these has contributed to the overall insufficiency of the current
global models. Currently, Type I and Type II ABC importer models have been derived
from transporters with functionally equivalent NBDs. The implications for importers with
non-equivalent sites remain largely unstudied. Yet, these systems may address basic
questions about the energetics of transport and whether some organisms have exploited a
potential efficiency for improved evolutionary fitness. This is largely speculation.
Fluorescence titration experiments described here reveal both NBDs of RbsA are
able to bind ATP, albeit with non-equivalent capabilities. The results suggest a cooperative
mode of binding, with the affinity of one site for ATP an order of magnitude higher than
the other. Evidence of cooperativity is apprent in activity assays, which demonstrate an
increased rate of hydrolysis as ATP concentrations increased. Both curves also carried the
characteristic “S-shape” that is a signature for cooperativity. The non-equivalent binding
could be a consequence of Walker A mutations, specifically the substitution of the
conserved lysine for an arginine, which may retard the ability of that site to bind ATP. As
the titrations proceeded to completion, both sites became saturated. Given cellular
concentrations of ATP and the respective affinity constants of both sites, it is reasonable to
expect that this result is physiological.
These results provide the basis for a model of the catalytic cycle of RbsA. The first
site captures ATP, promoting closure of one NBD and an overall reduction in distance
between both lobes of RbsA. This allows the second site to bind ATP efficiently, perhaps
setting the transporter in the most efficient position for alternating access. ATP in one site
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is subsequently hydrolyzed, alternating access occurs, and ribose is delivered to the
cytoplasm. ADP is released from the consensus site, and the transporter is reset for the next
transport process.
There, however, remains an unanswered question – which is the higher affinity site?
Like TM287-288, does the degenerate site become readily saturated, allowing the
consensus site to function optimally? Does the bound ATP replace some of the interactions
lost by degeneracy? Of significance are mutations in the C-terminal Walker A and D-loop
motifs, which direct both ATP binding and completion of the intact site.
Or is binding at the second site an artifact of this experiment, and does it hang listlessly
like a vestigial appendage during the hydrolysis cycle? No parallel is currently available
for the ribose transporter, and the application of an exporter model to an importer is
questionable. This question and many others cannot be resolved without a better
understanding of the conformational changes of RbsA during transport. This is pursued in
the next chapter, which describes EPR experiments for the study of conformational changes
in the NBDs.
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CHAPTER THREE: PROBING RBSA CONFORMATIONAL CHANGES
USING EPR SPECTROSCOPY

3.1 The ABCs of ABC Transporters
All ABC transporters contain a basic functional unit comprised of two
transmembrane domains (TMDs) and two cytoplasmic nucleotide-binding domains
(NBDs). The cytosolic domains, also known as the ATP-binding cassette, have a conserved
topology that has been observed ubiquitously from the X-ray structures of over 50 different
NBDs (Haffke, et al., 2010).
This topology consists of two distinct portions, as described earlier: a RecA-like
subdomain and a helical subdomain. The RecA-like subdomain is formed from α-helices
and typically two β-sheets, and contains several conserved motifs. These include the
Walker A motif that interacts with the β- and γ-phosphates of ATP, the Walker B motif
that contains the catalytic glutamate, the switch histidine (or H-loop), the D-loop, and the
A-loop, which contains a conserved aromatic amino acid involved in π-stacking
interactions with the adenine base of ATP.
The helical subdomain consists of an α-helical bundle that is a signature for ABC
transporter-type NBDs. Indeed, the ABC signature motif is located in this subdomain, part
of a long α-helix that directs its helical dipole towards the γ-phosphate of ATP. The NBDs
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of ABC transporters form sandwich dimers, where the RecA-like subdomain of one NBD
binds ATP at its interface with the helical subdomain from the opposing NBD. In this
manner, each NBD contributes half of a nucleotide binding site (NBS), each one
complementing the other, and the typical ABC transporter forms two catalyticallyequivalent NBS (FIGURE 1-4).
Recently the structural changes and ATP binding of heterodimeric NBDs with nonequivalent NBS have been characterized. In these NBDs, catalytic residues at one
nucleotide binding site impaired its function. For instance, the conserved glutamate is often
an aspartate, and the switch histidine is typically a glutamine. This substitution pattern has
been observed in clinically important ABC transporters, such as CFTR (Csanady, et al.,
2013), SUR1, TAP1/2 (Grossmann, et al., 2014), and several others. The mutations result
in hydrolysis only at a single active site.
The functional consequences of these substitutions have only begun to be
understood and, as discussed earlier, have structurally only been characterized in a single
intact system. The TM287-288 exporter studies showed the catalytic cycle typical for ABC
transporters during substrate delivery was observed only in the consensus site, which solely
contributed to alternating access of the transmembrane domains to complete transport
(Hohl, et al., 2012; Hohl, et al., 2014). The degenerate site remained bound for the majority
of cycles and rarely turned over (Bukowska, et al., 2015). A similar model has been
developed for CFTR (Grossmann, et al., 2014).
Can these same principles be applied to importers such as the ribose transporter?
While alternating access is a general principle of ABC transporters, importers utilize signal
transduction across membranes in a manner not required for exporters. This
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transmembrane signalling links docking of the SBP with ATP binding and hydrolysis in
the NBDs, which is then communicated to the SBP to promote dissociation. Further, the
NBD-TMD interface of importers, linked by a single coupling helix from one TMD, is
rather different than exporters, which utilize coupling helices from both TMDs to link
hydrolysis with transport. We discuss in the next section what is known about importer
NBD conformational changes and whether any of this knowledge can be applied to
RbsABC.

3.2 Maltose Transporter NBD Dynamics
The maltose transporter remains the best studied ABC transporter, and detailed
structural and functional analyses of this system have provided the general principles for
ABC transporter conformational changes. These studies have revealed that maltosebinding protein (MBP) initially docks onto the inward-facing transporter, and stimulates
ATP binding by NBD domain closure. This closure involves a rotation of the helical
subdomain towards its complementary RecA-like subdomain (Orelle, et al., 2010), and
provides direct structural evidence for MBP-stimulated ATP hydrolysis observed for this
system (Davidson, et al., 1996). While positive cooperativity is observed in this system for
ATP hydrolysis, no evidence of asymmetric conformational changes has been found in Xray structures or from biophysical studies of protein dynamics. Similar subdomain rotations
are observed in exporter NBDs, suggesting this is a global phenomenon (Dawson & Locher,
2006). A possibility remains that ATP are hydrolyzed consequtively, a model that would
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fit well with both cooperativity and the observed conformational changes driving
alternating access.
However, an engineered MalK dimer with only a single active site showed severely
impaired transport compared to wild-type transporter (Davidson & Sharma, 1997). While
conformational changes were not studied for this system, no MBP-stimulated increase in
hydrolysis rate was observed for this system, showing cooperativity between NBD subunits
was required for transmembrane signalling to function like normal. Interestingly, a similar
study with the vitamin B12 transporter demonstrated normal levels of substrate transport,
although conformational changes were not probed (Tal, et al., 2013). The authors argued
that molecules required in trace amounts, like vitamin B12, can be taken up without
detriment by a transporter with a single active site. This assessment stands in contrast to
empirical observations of RbsABC function, which drives normal E. coli growth on media
with ribose as the sole carbon souce despite hydrolysis at a single consensus site of RbsA.
Although not discussed in the paper, a second possibility is that hydrolysis of both
ATP molecules is necessary to drive with efficiency the conformational changes required
for MBP to release maltose. In contrast, BtuF is rigid and small rotations drive its substrate
binding and release. Further, it has been demonstrated that docking of BtuF onto the
transporter is sufficient to drive vitamin B12 release, and hydrolysis destabilizes its
otherwise tight interactions with the TMD interface. The free energy of a single ATP
hydrolysis may be sufficient to drive this release.
Could dynamics of NBD rotation be impacted by an impaired NBS? How are these
structural changes then contributed to symmetric TMDs and a SBP with MBP-type
conformational changes? These questions remain unanswered and require a more detailed
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analysis of RbsA and RbsC. In this chapter, the conformational changes that occur in RbsA
during its catalytic cycle will be probed using EPR spectroscopy and site-directed spinlabeling. EPR spectroscopy has proven to have great utility in the study of ABC transporter
function in solution state. A similar approach will be applied to this system to harness this
powerful technique. Before discussing experimental methods, the theory of EPR
spectroscopy, spin-labeling, and applications to protein structural research will be briefly
discussed.

3.3 Basic Theory of Electron Paramagnetic Resonance Spectroscopy and Spin Labeling
EPR spectroscopy has proven to be a robust structural biology technique (Klug &
Feix, 2008). At first glance, its applications to the study of proteins would appear to be
limited. EPR spectroscopy measures the absorption of microwave radiation by unpaired
electrons, which are generally in limited supply as stable species in biological systems.
Except for the relatively few proteins with certain transition metal prosthetic groups, few
obvious examples of proteins with stable free radicals exist. However, advances in
molecular biology techniques led to the development of spin traps colocalized to reactive
labels that can recognize specific biological chemical moieties, typically thiol groups on
cysteine residues in proteins (Columbus & Hubbell, 2002). These advances led to the full
embrace of EPR spectroscopy as a structural biology tool, and have spurred the
development of a sophisticated array of techniques that can be harnessed by the modern
structural biologist.

122
Site-directed spin-labeling (SDSL) EPR spectroscopy involves the covalent
attachment of a spin probe to the protein backbone. The most commonly used spin label is
2,2,5,5-tetramethyl-1-oxyl-3-methyl methanethiosulfonate (FIGURE 3-1), a thiol-reactive
nitroxide label that contains an unpaired electron primarily localized to the pz orbital of the
14

N. The spin label can be introduced to cysteines, allowing for a specific probe of the local

environment that can follow conformational changes and protein dynamics. Ideally, these
cysteines will be placed using molecular biology techniques at sites of interest, and thus
the technique requires the mutation of native cysteines to unreactive side chains, such as
serine, alanine, and methionine, or that the cysteines are rendered unreactive due to
participation in disulfide bonds.
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Figure 3-1: 2,2,5,5-tetramethyl-1-oxyl-3-methyl methanethiosulfonate (MTSL) spin label
with nitroxide label. The label reacts specifically with sulfhydryl groups of cysteine
residues.
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EPR spectroscopy measures the absorption of microwave radiation by unpaired electrons
at specific resonance frequencies. Unpaired electrons exist in one of two spin states, either
+1/2 or -1/2. In the absence of a magnetic field, no statistical preference exists for either
state. Once an external magnetic field is applied to the sample, the spins separate into two
well-defined low- (-1/2) and high-energy (+1/2) spin states, the relative amounts of each
given by the Boltzmann distribution (Equation 3-1).
(Eq. 3-1)
The distribution dictates that, at room temperature, the higher energy state has a
slightly smaller population than the lower energy state (ratio of 0.998). This segregation of
unpaired electrons into discrete energetic states due to the magnetic field is known as the
Zeeman Interaction (Equation 3-2). The energy required (ΔE) for the transition between
the two states is proportional to the strength of the applied magnetic field (H0) (FIGURE
3-2) (Equation 3-3).
(Eq. 3-2)
(Eq. 3-3)
Here, ms is the electronic spin number, ge is the electron g-factor (an intrinsic
property of electrons depending on their environment), and µB is a spectroscopic constant
known as the Bohr magneton. The traditional EPR spectroscopy experiment uses a constant
frequency of microwave radiation while sweeping across a range of magnetic
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Figure 3-2: Application of an external magnetic field to an unpaired electron leads to
separation of energy levels. This separation is proportional to field strength. Absorption of
microwave radiation at the resonance frequecy, Hres, results in transition from low- to highenergy level. The first derivative of this absorption is plotted as a function of field strength.
Figure adapted with permission from Michael J. Simon.
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field strength. Thus, when the energy difference between the two spin states matches the
frequency of the incident microwave radiation, microwave energy is absorbed by the
sample and the transition from low- to high-energy spin state occurs (Equation 3-4).
(Eq. 3-4)
This is the fundamental equation of EPR spectroscopy.
When no interacting nuclei are present near the spin label, a single transition occurs,
as is depicted in FIGURE 3-2. In the EPR tradition, the first derivative of the absorption
signal is plotted as a function of magnetic field strength. This is due to the relatively broad
spectral lines produced due to absorption, and lead to loss of information that will make
the choice of this convention apparent in the following segment.
The presence of certain nearby nuclei can induce splitting of the energy levels. This
is known as the hyperfine interaction, A. For nitroxide spin labels, the presence of the
nitrogen nucleus leads to a splitting that depends on the nuclear spin number (Equation 35).
(Eq. 3-5)
Here, mI is the nuclear spin number. Thus, for spin labels with the predominant 14N
nitrogen nucleus, the I = 1 nucleus gives rise to 2I + 1 energy levels, or three quantized
energy levels, leading to a three-line EPR spectra (FIGURE 3-3) corresponding to
transitions due to each spin state (+1, 0, -1). As a consequence of this
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Figure 3-3: Hyperfine splitting of the nitroxide spin label. The nearby N-14 nuclei
has a net nuclear spin (I=1), resulting in three distinct energetic states (2I+1). These
transitions are labeled +1, 0, -1, in accordance with the three nuclear spin numbers for N14.
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condition, nearby nuclei such as 16O or 12C will produce no such splitting of energy levels
(both have nuclear spin numbers of 0).
In SDSL EPR spectroscopy, the phenomenon of most interest is typically the
motion of the spin-label chain. This is sensitive to the local environment of the label, and
can thus be used to probe protein folding, dynamics, and conformational changes. The
effects of motion on spin labels can be dramatic and spectra can be interpreted by casual
inspection using qualitative measures such as “mobile” or “immobile”.
For the case of isotropic motion, an electron is sampling all possible states at a
given time. As a result, all electrons contribute equally and the result is three sharply even
spectral lines, as see in FIGURE 3-3. However, the spin label motion is not typically
isotropic, and thus has different amplitudes in different directions. Anisotropic motion
results in asymmetric orbitals, leading to sampling of a limited number of states. The
absorbance of radiation will then depend on how the electron is oriented relative to the
magnetic field, given by the anisotropic hyperfine interaction. This will result in many
different energetic transitions, leading to broad spectral lines (FIGURE 3-4).
The degree of peak splitting correlates to the rotational freedom of the label, and
can be interpreted in the context of protein secondary structure, tertiary interactions, or
quaternary structure depending upon the placement of the spin label. In addition to
qualitative inspection, assessment of mobility can also be performed using the inverse of
the center line-width, known as the mobility parameter (Perozo, Cortes, & Cuello, 1998).
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Figure 3-4: Spectral broadening of the nitroxide spin label due to limitations of side chain
mobility. A) Isotropic motion resulting from fast motion of the spin label. This spectra is
typical of a spin label free in solution. B) Spectral broadening due to slowing motion. This
spectra is typical of a spin label attached to a protein. C) Inhomogenous spectral broadening
and splitting caused by anisotropic hyperfine interactions resulting from further immobility.
Two spectral features are apparent, denoting a sharp mobile portion and a broad immobile
portion. D) Increase of immobile portion of spectrum caused by decreased spin label
mobility. Figure adapted with permission from Michael J. Simon.
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This is proportional to spin label mobility and is typically normalized relative to the most
mobile spectrum recorded for a given data set, and the parameter is typically reported on a
scale of 0 to 1.
Other quantitative measures using spin labels to probe protein structure can be
obtained using pairs of unpaired electrons in relatively close proximity to make distance
measurements. When in close proximity, unpaired electrons can undergo dipolar coupling,
resulting in additional peak splitting depending upon the degree of dipole-dipole
interactions (Equation 3.6).
(Eq. 3.6)
Here, θ represents the angle between the two dipoles, and r represents the distance
between the two dipoles. The splitting results in significant broadening of spectral lines,
and can be described mathematically as a convolution between the probability of
interaction, known as the Pake Function, and the non-interacting portion of both spectra
(Pake & Purcell, 1948). Experimentally, this interaction serves to flatten the spectrum,
increasing the peak area of the +1 and -1 field lines while decreasing the area of the centerfield line (Equation 3.7).
(Eq. 3.7)
These interactions can thus be assessed qualitatively (FIGURE 3-5) and
quantitatively using the relationships described above. In practice, interpretation of this
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Figure 3-5: The effects of spin-spin interactions on EPR spectral lines. Top – noninteracting spectrum of anisotropic doubly-labeled protein sample. Middle – spin-spin
interactions result in broadening of spectral lines. Bottom – normalized interacting
spectrum (red) overlayed onto non-interacting spectrum. Red spectrum normalized using
peak-peak height of center line.
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interaction is complicated by sample heterogeniety, which can lead to broad distributions
of dipolar distances. Nevertheless, the technique has been employed routinely and has
shown to be a powerful tool in ABC transporter research.

3.4 Shots in the Dark: Sites for Labeling RbsA
It should be readily apparent from the previous section that the optimum strategy
for the design of SDSL EPR experiments is using a high-resolution protein structure as a
starting point to guide sites for cysteine mutagenesis and susbequent spin-labeling. No
crystal structure of the full-length RbsA protein is currently available, and approaches
using simply secondary structure prediction algorithms can prove to be haphazard
endeavors. Fortunately, NBDs of ABC transporters share a conserved three-dimensional
topology, and homology models can provide reasonable guides for developing a SDSL
strategy.
The primary motivation of this study is three-fold. One, the conformational changes
of the consensus site of RbsA are of interest. It has been shown through mutagenesis of
catalytically-important residues that RbsA contains a single, consensus ATPase site.
Studies of other ABC transporters have provided the structural basis for conformational
changes in the RbsA consensus NBS; these changes were thus probed by EPR spectroscopy
in this study by placing labels across the NBS interface on the opposing domains.
Two, the conformational changes of the degenerate site of RbsA were also be
probed by EPR spectroscopy. Here, no precedence exists for this study in importers, as no
well-studied examples exist. The aforementioned heterodimeric exporter currently
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provides the only framework to understand RbsA degenerate site function. Whether this
model is sufficient to describe an asymmetric importer NBD function has yet to be
determined. These conformational changes were also probed by the placement of labels
across the dimer interface of the degenerate site.
Three, the association of RbsA with RbsC was probed by the placement of labels
near the primary sites of interaction of RbsA with RbsC. In addition to the asymmetry, an
unusual property of the ribose transporter relative to other importers is the observed
dissociation of RbsA from RbsC in the absence of magnesium and nucleotide. The
physiological relevance of the dissociation remains unclear, as does the conformation of
RbsA immediately before and after. Given that RbsB stimulates ATP hydrolysis by RbsA,
the current model can be described as “open” RbsA binding to RbsBC and becoming
“semi-open” ATP-bound RbsA, which is rapidly converted to “closed” RbsA, primed for
hydrolysis. Hydrolysis leads to RbsB dissociation followed by cycling of the transporter to
an inward-facing conformation. No direct evidence of these conformations was available
prior to this study. RbsA then presumably dissociates from RbsC. What is less clear is how
an asymmetric ABC interacts with a symmetric TMD, and whether any conformational
memory or residual interaction exists that cannot be captured by co-purification
experiments.
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3.5 Methods and Materials
The following sections describe the strategy for modeling, mutating, labeling, and
collecting EPR spectroscopic measurements for RbsA in the context of transporter function,
and the appropriate controls required to determine the relevance of these measurements.

3.5.1 Homology Modeling RbsA
RbsA was modeled using the Phyre2 web server by allowing the server to identify
the best homology (Kelley, et al., 2015) using the entire RbsA amino acid sequence from
the E. coli K-12 strain (Bell, et al., 1986). This models proteins using a combination of
sequence-based homology modeling and secondary structure prediction. In addition,
potential ligand-binding sites were predicted by the 3DLigandSite Server (Wass, et al.,
2010). This server identifies patterns of amino acids commonly found in ligand binding
sites from the PDB and analyzes a given model for these patterns. The best model was
chosen based on the scoring algorithm provided by the Phyre2 server.

3.5.2 Mutating Native Cysteines
Three cysteines are present in the ribose transporter: two in RbsA (C208 and C264)
and one in RbsC (C227). All three were mutated to serines using the PCR-based Quick
Change method (Stratagene). Primers were typically designed with 30-40 bases, GC
contents between 40-60%, melting temperatures over 70°C, and the mismatched bases at
the center of the primer to introduce the desired mutation. Mutagenesis was performed on
the pTATHC plasmid as a template, which expresses RbsA and RbsC using separate T7
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sites, by mutating each cysteine by turn. Reactions were setup according to the
manufacturer’s protocol for the Phusion enzyme. Typical PCR protocols used 35 cycles of
98°C for 30 s, 55°C for 60 s, and 72°C for 6 min. Parental strands were digested after PCR
by adding 0.5 µL restriction enzyme Dpn1 directly to the PCR reaction mix and incubating
at 37°C for 3 hours. Digestion reactions were cooled briefly on ice and 5 µL was used to
transform 20 µL of DH5α competent cells. Following recovery and 2-3 hours growth in
LB media, cells were plated on LB solid media supplemented with 200 µg/mL ampicillin.
Colonies (at least 3 per plate) were selected the following morning and used to inoculate 5
mL of LB-ampicillin liquid media. Cultures were grown for 8-12 h. Mutant plasmids were
prepared from 5 mL cultures using the Qiagen kit and protocol. Mutations were confirmed
by sequencing using primers designed specifically for either RbsA or RbsC.

3.5.3 Activity Assays for Cysteine-free RbsAC
Cysteine-free RbsAC (cf-RbsAC) was expressed and purified in the same manner
as the wild-type transporter. Imidazole and cofactors were removed by multiple rounds
buffer exchange following purification. ATPase assays for the cysteine-free RbsAC
transporter were performed as described in Chapter 2 using an NADH-coupled colorimetric
assay, except done in detergent and without RbsB and ribose. It has previously been shown
that assays in detergent show RbsC-stimulated rate of hydrolysis, but no increase is
observed due to RbsB and ribose (Simon, 2011). Assays were run for 60 minutes at room
temperature, as previously performed. Hydrolysis rate over time was compared with wildtype levels as a necessary control step.

136
3.5.4 Engineering Cysteines for EPR Spectroscopy
Cysteines were introduced to RbsA at sites of interest for EPR spectroscopy using
the plasmids for cf-RbsAC as the template. The site locations were guided by the homology
model produced by the Phyre2 server and by results from previous studies of ABC
transporters (Orelle, et al., 2008; Orelle, et al., 2010; Lewinson, et al. 2010; Hohl, et al.,
2014). Cysteines were introduced both singly and in pairs by the same PCR-based methods
described above. Mutant plasmids were transformed and purified as described. All
mutations were confirmed by sequencing. Sites of mutation and rationale for sites will be
discussed in more detail in the RESULTS section below.

3.5.5 Expressing, Purifying, and Spin-labeling Mutant Proteins
All mutant proteins were transformed, expressed, and purified in BL21-AI cell lines
as previously described (Clifton, et al., 2015) for the wild-type transporter, except for the
presence of 1 mM β-mercaptoethanol. Typically, mutant RbsAC were co-purified using
magnesium, ATP, and orthovanadate. Imidazole and β-mercaptoethanol were removed
after purification by buffer exchange. The exchanged buffer contained 25 mM Tris-HCl
pH 7.0, 200 mM NaCl, 20% glycerol, 0.05% DDM, and 1 mM each of cofactors. MTSL
spin label (Toronto Research Chemicals) was dissolved in acetonitrile to a final
concentration of 200 mM and stored in black 1.5 mL Eppendorf Tubes to shield the label
from light. Immediately prior to labeling, the stock solution was diluted to 2 mM in TrisHCl buffer, pH 7.0. This spin label solution was then added to a final 20-fold molar excess
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of label to transporter in 15-mL Falcon tubes wrapped in aluminum foil. The reaction
mixtures were then incubated at 4°C with rocking for overnight labeling.
The following morning, samples were centrifuged to remove precipitates,
concentrated to 500 µL, and subsequently injected onto a Superdex200 10/30 GL column
pre-equilibrated with buffer with cofactors. This removed both excess label and any
aggregates produced during labeling. 1-mL fractions were collected and analyzed by SDSPAGE. Fractions containing RbsAC were pooled for the next step.

3.5.6 DTNB Assay for Labeling Efficiency
The DTNB reagent was prepared as previously described (Simon, 2011). Samples
were tested in plate format and reagents optimized for 100 µL reaction volumes. A standard
curve was generated using DTT samples prepared in 0 – 500 µM final concentrations. Free
sulfhydryl concentration was measured for all protein samples and compared with a
standard curve. Total sulfhydryl concentration was determined by extrapolating from
protein concentration, which was first determined using the BCA assay, as described in an
earlier chapter. These two measures were used to determine labeling efficiency. Samples
with at least 80% efficiency were used for spectroscopic experiments.

3.5.7 ATPase Assays of Mutant Experiments
All mutants were tested for activity using the protocol previously described. Prior
to experiments, cofactors were removed by several rounds of buffer exchange into buffer
lacking cofactors. ATPase measurements were performed as described above in a plate-
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based format. Samples with at least 50% of wild-type activity were used for spectroscopic
measurements.

3.5.8 EPR Spectroscopy of Ribose Transporter Mutants
Prior to EPR experiments, samples were prepared to test several different cofactor
and protein combinations. All samples were prepared with the following four
cofactor/protein combinations: 1) RbsAC with 1 mM Mg-ATP-VO4; 2) RbsABC with 1
mM Mg-ATP-VO4; 3) RbsAC with Mg-ADP; and 4) RbsABC with ATP-EDTA. Samples
with cofactor combinations different from the Mg-ATP-VO4 were prepared by several
rounds of buffer exchange. Samples with RbsB were prepared by the addition of a molar
excess of RbsB (1.25:1). All samples were concentrated to 50 – 100 µM prior to
measurements using 30 kDa MWCO spin filters (Amicon).
EPR measurements were collected using an X-band Bruker EMX plus with the
high-sensitivity cavity ER4119HS. Instrument settings for all measurements are listed in
Table 3.1. 20 µL samples were loaded into 50 µL glass capillaries and placed in quartz
sample tube held in place in the cavity.
EPR spectral files were initially processed using WinEPR to remove the buffer
baseline. Double integration of spectra was used to calculate the concentration of spin label
for each sample. Amplitudes were exported to MS Excel for further processing. Specta
were normalized for each mutant using the sample with highest spin label
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Table 3-1: Instrument settings for data collection using Bruker EMX Plus.

Modulation Frequency

100 kHz

Modulation Amplitude

3.00 Gauss

Modulation Phase

0 degrees

Offset

0%

Time Constant

20.48 msec

Conversion Time

60 msec

Sweep Time

122.88 sec

Resolution in X

2048

Number of Scans

30

Field Width

250 Gauss

Static Field

3415.797 Gauss

Microwave Bridge Frequency

9.85 GHz

Microwave Bridge Attenuation

10 dB

Microwave Bridge Power

20 mW
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concentration to calculate a correction factor foe all other samples. These correction factors
were applied to those samples from each set. Normalized spectra were then plotted using
Prism (GraphPad).
For distance measurements, amplitudes were exported into ASCII files and
processed using Short Distances, a LabView program written and distributed by Christan
Altenbach (Altenbach, et al., 2001). The data files required for this included a “Sum of
Singles Spectra” and the double mutant spectral files. The singles spectra was collected
using the double mutant proteins and labeling them with a combination of a diamagnetic
probe in excess of the paramagnetic spin label (4:1 excess). The mutant samples were
labeled as before, evaluated as described, and the spectra were collected as above. Data
were processed as above and used to produce a file containing amplitudes in a single
column. These two files were used by Short Distances to perform a spectral deconvolution
to yield contributions only from interacting spins. These yielded a distribution of distances
based on the degree of dipolar coupling, as described earlier. Distances were compared for
each set of mutations and each cofactor combination.

3.6 Results
The following sections describe the results from homology modeling, discuss the
rationale of position of mutations, results from evaluating mutations, and finally EPR
spectroscopy.
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3.6.1 Homology Modeling RbsA Using Phyre2 Web Server
Several homologous proteins were used to generate models of RbsA that resulted
in scores with 100% confidence by the Phyre2 server (Kelley, et al., 2015). These
homologous proteins had percent identities with RbsA ranging from 22 – 32%. These
proteins included both traffic ATPase NBDs and DNA repair enzymes. Although many
models were the same, based on alignment of the generated PDBs, the chosen model was
based on BtuD, an ABC transporter NBD.
Analysis of secondary structure prediction revealed conserved domains were
modeled as expected, based on structures of similar ABC proteins. Overall, the protein was
modeled with 40% alpha helical content, 22% beta strand content, and 8% disorder, within
a range typical for ABC transporter NBDs. Twenty amino acids could not be modeled. As
expected, many of these were located at the region linking the C-terminal and N-terminal
NBDs, for which no homologous structure currently exists.
In addition, ligand-binding sites were predicted for the model using the
3DLigandSite application within the Phyre2 server. This application modeled, with 96%
confidence, the presence of a single ligand binding site at the NBS formed by the NTD,
which contributes the Walker A and B motif along with catalytic residues, and the CTD
Signature sequence. Bound ATP was modeled into this site. No second site was modeled
by this server. The basis for modeling ligand binding was the conservation of the site found
in 34 proteins of known structure, most of them other ABC proteins. The list of side chains
participating in ligand binding were canonical residues found in ABC proteins.
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3.6.2 Sites of Mutation in RbsA
The chosen Phyre2 model was used to identify sites for engineering cysteines. This
was based on conformational changes of NBDs from crystal structures and functional
studies, as described in the Methods section. The labeled sites are indicated in Figure 36.
Three pairs of mutations were used for EPR experiments to probe RbsA
conformational changes during the transport cycle. A pair of mutations was placed at the
predicted contact interface between RbsA and RbsC (H85C and S333C, colored in
magenta). In crystal structures of the maltose transporter and functional studies using EPR
spectroscopy, it has been shown that the TMD coupling helix interacts with the NBD Qloop, where both of these mutation sites are located. When MBP docks onto the transporter,
the coupling helix engages this region, resulting in a movement of the Q-loop glutamine
towards the ATP binding site, where it participates in interactions with the required
magnesium ion. Thus, this region not only senses the presence of the SBP through
transmembrane signalling, it also participates in conformational changes by an inward
rotation of the coupling helices. The placement of two labels across this interface would
presumably provide information about NBD-NBD distances as well as information about
signal transduction in the intact system.
A second pair of mutations (F14C and I393C, colored in orange) probed
conformational changes across the consensus NBS. F14C was placed adjacent to the
Walker A motif of the N-terminal NBD. I393C was placed adjacent to the signature
sequence of the C-terminal NBD. In studies of the maltose transporter, the helical
subdomain of one monomer undergoes a rotation towatds the complementary RecA-like
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subdomain of the other monomer to facilitate ATP binding. This process is stimulated by
MBP docking onto the TMD. This pair of mutations would probe this conformational
change in RbsA.
A third pair (cyan) of mutations probed conformational changes across the
degenerate NBS. R132C essentially mimicked the position of I393C in the degenerate site
adjacent to its signature sequence. Meanwhile, a C-terminal domain cysteine, V268C, was
introduced in nearly an identical position as F14C. A construct designed with a nearby
native cysteine, C264, could not be expressed as either a single mutant or paired with
another nearby engineered cysteine.
In addition to these pairs of mutations, other cysteines were engineered to test the
validity of the models. For instance, the interface where A443C and S189C (colored red)
were introduced is not sensitive to conformational changes based on studies of intact ABC
transporters. These single mutations were thus used as controls for model validity.
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Figure 3-6: Sites of cysteine mutations for site directed spin labeling. Top-down view of
RbsA model. For double mutant experiments, three pairs were engineered: 1) consensus
site pair F14C/I393C; 2) Q-loop pair H85C/S333C; and 3) degenerate site pair
D141C/C264. Control mutations were made to test model validity using non-interacting
sites of S189C and A443C, a docking surface mutation at Y308C, and an active site
mutation N89C. Double mutant pairs were used for distance measurements.
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Finally, a single mutation was placed at N89C (red) as a probe of N-terminal domain ATP
binding and activity. This region would undergo conformational changes during the
catalytic cycle in other transporters. Thus, the spin label would be expected to report upon
conformational changes in nucleotide bound states, and in the absence of nucleotide.
Activity of cf-RbsAC was measured at wild-type levels, and introduction of serines
had no effect on complex assembly. Assembly was used as a general test prior to labeling
for pursuing mutations to the next steps. The listed mutations were all successfully
expressed, assembled, and demonstrated activity within 50% of wild-type range after
labeling. Several other mutants were tested but either did not express or assemble properly.
These were not used.
Labeling efficiency of all of these was greater than 90%, based on comparison with
the standard curve for the DTNB assay. Proteins were concentrated and tested in conditions
described earlier for EPR experiments.

3.6.3 Model Validation Using Non-interacting Protein Regions
To test whether the homology model was realistic, single mutations were
introduced at sites where conformational changes and protein-protein interactions were not
expected. This hypothesis was based on understanding of structural changes of ABC
transporters from several crystal structures of the maltose transporter. Using this as a
rationale, single cysteine mutations were engineered in the N-terminal NBD at S189, and
in the C-terminal NBD at A443 (FIGURE 3-7A).
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EPR experiments were performed in several different conditions, using the cofactor
combination Mg-ATP-VO4 with both the RbsABC and RbsAC complexes, the cofactor
combination Mg-ADP with the RbsAC complex, and the combination ATP-EDTA with
RbsABC. No changes in spectral lines were observed due to the introduction of complex
proteins or by different combinations of cofactors (FIGURE 3-7B). Measured spectra were
essentially identical for every condition tested with a mutation data set. All data were
normalized to the highest concentration of spin label as determined by double integration
of EPR spectral lines to calculate the area under the curve.
As an additional control for the C-terminal NBD, a second single mutation was also
introduced at a site not expected to produce an NBD-TMD interaction, Y308C (FIGURE
3-6). This mutation was located on the RecA-like subdomain as part of a β-barrel that
formed the outer surface of the domain. In structures of BtuCD and MalFGK2, this region
remains outside of the interaction surface throughout the catalytic cycle.
As expected, no changes were observed in the Y308C spectra in any cofactor
combination nor due to the addition of RbsB (FIGURE 3-8). These results suggest the
model is valid and the interactions tested thus far are canonical.

147

Figure 3-7: EPR spectra for A443C and S189C single mutations on RbsA. A) Schematic
diagram of RbsA with expected initial (top) and final (bottom) positions of labels going
from apo- to ATP-bound state of RbsA. B) A443C mutant spectra with cofactor/protein
combinations. C) S189C mutant spectra with cofactor/protein combinations. Combinations
tested include RbsAC with Mg-ATP-VO4, RbsABC with Mg-ATP-VO4, and RbsAC with
Mg-ADP.
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Figure 3-8: EPR spectra for Y308C single mutation on RbsA. A) Schematic diagram of
RbsA with expected initial (top) and final (bottom) positions of label going from apo- to
ATP-bound state of RbsA. B) S189C mutant spectra with cofactor/protein combinations.
Combinations tested include RbsAC with Mg-ATP-VO4, RbsABC with Mg-ATP-VO4,
and RbsAC with Mg-ADP.
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3.6.4 Conformational Changes at the TMD-NBD Interface
The Q-loop is the conserved major site of interaction between ABC transporter
TMD coupling helices and the NBD, linking substrate availability with hydrolysis. To
probe Q-loop conformational changes, mutations were introduced as a pair to Q-loop
residues H85 (N-terminus) and S333 (C-terminus) (FIGURE 3-9A). These corresponded
to roughly identical positions. Neither amino acid position participates directly in ATP
hydrolysis, as seen in other ABC transporter structures. The mutant transporter assembled
like normal after labeling and produced wild-type levels of activity.
The cofactor combination ATP-EDTA simulates a pre-hydrolysis conformation.
Using this combination in the presence of RbsB, the EPR spectrum of the 85-333 labeled
transporter produced features with strongly mobile lines (FIGURE 3-9B, green line), at
least by the standard of labeled proteins. When the same combination of proteins is used
to form the vanadate-trapped RbsABC complex, a sharp reduction in amplitude of the
mobile spectral feature was observed (blue line). This was accompanied by a slight
increase in amplitude in the immobile portion of the spectrum. This change could be
observed in both the +1 and -1 peaks following normalization of the spectra using the center
line of the most intense data set.
The cofactor combination Mg-ADP simulates the pos-hydrolysis, post-transport
conformation, and produces during purification the RbsAC complex. Using this cofactor
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Figure 3-9: EPR Spectra for the H85C/S33C double mutant of RbsA. A) Schematic
diagram showing expected initial and final positions of labeled side chains going from apoto ATP-bound state of RbsA. B) EPR spectra for cofactor/protein combinations of the 85333 mutant transporter. Conditions tested include RbsABC with ATP-EDTA (green),
RbsABC with Mg-ATP-VO4 (blue), and RbsAC with Mg-ADP (purple). Mobile (m) and
immobile (i) portions of spectra labeled.
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combination with the labeled 85-333 RbsAC complex resulted in an increase in amplitude
of the +1 and -1 spectral lines compared with the Mg-ATP-VO4 state (purple line).
However, the amplitudes of these peaks was less than those observed for the ATP-EDTA
cofactor combination. Thus, three different types of spectra were recorded for three
different cofactor combinations.
In addition, RbsAC in the presence of Mg-ATP-VO4 was tested, but no difference
was observed between this spectrum and the RbsABC combination with Mg-ATP-VO4
(data not shown).

3.6.5 Conformational Changes at the Consensus Site
EPR spectroscopic measurements of the maltose transporter reveal a rotation of the
helical subdomain towards its complementary RecA-like subdomain to bind and hydrolyze
ATP. To probe similar conformational changes in the single active site of RbsA, cysteine
mutations were introduced across the interface to produce a double mutant using F14C and
I393C mutations (FIGURE 3-10A). The mutant 14-393 transporter assembled like normal
during purification and displayed activity within reasonable range of the wild-type
transporter.
Four different conditions were tested for the 14-393 mutant transporter. Using the
cofactor combination ATP-EDTA in the presence of RbsB produced a spectrum with
relatively mobile spectral features at the +1 and -1 lines (FIGURE 3-10B, green line).
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Figure 3-10: EPR spectra for the F14C/I393C double mutant of RbsA. A) Schematic
diagram showing expected initial and final positions of labeled side chains going from apoto ATP-bound state of RbsA. B) EPR spectra for cofactor/protein combinations of the 14393 mutant transporter. Conditions tested include RbsABC with ATP-EDTA (green),
RbsAC with Mg-ATP-VO4 (red), RbsABC with Mg-ATP-VO4 (blue), and RbsAC with
Mg-ADP (purple). Insets show enlarged spectral features of +1 and -1 peaks, with labeled
mobile (m) and immobile (i) portions.
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Two different vanadate-trapped conditions were tested, using RbsAC and RbsABC. These
conditions had previously been tested with other mutants and had produced no difference
in spectra between the RbsAC and RbsABC combinations. However, a comparison of these
two spectra for the 14-393 double mutant revealed a significant different. The vanadatetrapped RbsAC spectrum (red line) is nearly indistinguishable from the ATP-EDTA
spectrum, with only a slight reduction in the mobility of the spin label in the former
condition. However, the RbsABC vanadate-trapped conformation produced a spectrum
(blue line) with both reduction of the mobile portion and broadening of the +1 and -1
spectral lines. This type of broadening is characteristic of spin-spin interaction, suggesting
close proximity of the two spin labels at position 14 and 393. These spectra also suggested
a difference in conformation between the RbsAC and RbsABC states, though the cofactor
combinations were the same.
Finally, the cofactor combination of Mg-ADP was tested with RbsAC for the 14393 double mutant. This combination produced spectral lines (purple) identical to the
ATP-EDTA conformation, and suggested a lack of any spin-spin interaction.

3.6.6 Probing Consensus Site Conformational Changes Using a Single Label
In addition to the 14-393 double mutant used earlier, conformational changes of the
consensus site were also probed at other locations using single labels. These were
motivated by the attempt to resolve the subdomain rotations typical of active NBDs during
the hydrolysis cycle.
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Several mutants were tested in this location. The N89C mutation was well-tolerated,
assembled efficiently, and had relatively normal levels of activity. This was labeled as
before (FIGURE 3-11A). Three different conditions were tested: 1) RbsABC with the
cofactor combination ATP-EDTA; 2) RbsABC with Mg-ATP-VO4; and 3) RbsAC with
Mg-ADP.
Small spectral changes were observed for this mutant with different cofactor
combinations. In the ATP-EDTA combination, the spectra were relatively mobile
(FIGURE 3-11B, blue line). With Mg-ATP-VO4 bound, a slight reduction in amplitude
is observed in the +1 peak (red line). This reduction was not observed in the Mg-ADP
cofactor combination (green line). The lack of spectral changes suggested either improper
probe placement or a lack of significant conformational changes during hydrolysis at this
portion of the active site.

3.6.7 Probing Conformational Changes at the Degenerate Site
Finally, to probe conformational changes at the site that did not hydrolyze ATP,
spin labels were introduced at homologous positions as F14C/I393C. Unlike the consensus
site, the degenerate site did not readily tolerate cysteine mutations, and a construct
containing the native cysteine C264 could not be expressed. The double mutant
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Figure 3-11: EPR spectra for the N89C single mutant. A) Schematic diagram showing
expected initial and final positions of labeled side chains going from apo- to ATP-bound
state of RbsA. B) EPR spectra for cofactor/protein combinations of the N89C mutant
transporter. Conditions tested include RbsABC with ATP-EDTA (blue), RbsABC with
Mg-ATP-VO4 (red), and RbsAC with Mg-ADP (green).
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R132C/V268C could be expressed and was shown to assemble normally and be active in
detergent (FIGURE 3-12A).
Three different conditions were tested for the 132-268 double mutant. The
vanadate-trapped RbsABC complex produced spectral features with relatively mobile +1
and -1 lines (FIGURE 3-12B, blue line). When the same mutant was tested in the presence
of Mg-ADP, nearly identical spectral lines were produced (red line). In the ATP-EDTA
condition, a slight increase in mobility was observed (green line). In all cases, the spectra
were noisy compared with those for other double mutants, suggesting a labeling
inefficiency. No broadening suggestive of spin-spin interactions was observed in any
spectrum.

3.6.8 Distance Measurements Using Short Distances
For all double mutants, protein samples were labeled both with MTSL only and
with a mixture of diamagnetic probe and MTSL (4:1 ratio). This labeling scheme allowed
for direct measurements of the sum of singles (non-interacting) spectra required for
distances by the method described by Altenbach and colleagues (2001). Single labeled
measurements, performed in identical conditions as described above, were then
deconvoluted from the respective double-MTSL measurements made before.
Deconvolutions were performed using the “Short Distances” program written by C.
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Figure 3-12: EPR spectra for the R132C/V268C double mutant of RbsA. A) Schematic
diagram showing expected initial and final positions of labeled side chains going from apoto ATP-bound state of RbsA. B) EPR spectra for cofactor/protein combinations of the 132268 mutant transporter. Conditions tested include RbsABC with ATP-EDTA (green),
RbsAC with Mg-ATP-VO4 (red), RbsABC with Mg-ATP-VO4 (blue).
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Altenbach. Distances were determined from the resulting broadening function following
deconvolution.
Distance measurements were made for all cofactor conditions tested before
(TABLE 3-2). Most measuremed distances were outside of the range of spin-spin
interactions that could be detected by this method. For the 85-333 double mutant, both the
Mg-ADP and ATP-EDTA cofactor combinations resulted in distances over 20 Å. For the
vanadate-trapped state, this same mutant resulted in a distance of 12.8 Å, with a distribution
of 4.2 Å. These measurements were consistent with qualitative analyses of each spectrum,
and suggested a closure of domains upon ATP binding.
Distance measurements made for the 14-393 double mutant also showed spin-spin
distances beyond the measureable limit for both the Mg-ADP and ATP-EDTA states. In
the vanadate-trapped state, this mutant transporter produced distances of 12.4 Å, with a
distribution of 2.6 Å. These results were consistent with those described for the 85-333
mutant, and with the qualitative analyses of these spectra.
Finally, distances made for the degenerate site double mutant 132-268 showed
distannces outside the measureable for all cofactor combinations tested. No change was
observed for the vanadate-trapped state. The results were consistent with qualitative
observations of these spectra, and inconsistent with the measurements of the other two
mutants.
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Table 3-2: Summary of distances measured for each double mutant. Condition for each
mutant given in table. All cofactor concentrations were 1 mM.
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3.7 Discussion
RbsA was homology modeled using the Phyre2 server, which identified several
templates with 100% confidence that successfully modeled all but 20 amino acids of RbsA.
These amino acids were mostly present within the linker region between the N- and Cterminal domains, for which no homologue exists in the PDB currently.
These results suggests that the three-dimensional topology of RbsA is generally
canonical for ABC transporters, and studies by EPR spectroscopy can provide reasonable
insights into RbsA function despite the absence of a high-resolution three-dimensional
structure.
The Phyre2 server also contains an application that can predict ligand binding sites.
The methodology for this has been discussed earlier. Of note is the prediction of a single
ATP binding site in the consensus NBS of RbsA. This is likely due to the prevalence of
ABC structures in the PDB with canonical binding sites and the absence of those with noncanonical degenerate sites, particularly with ligand bound. This may also be a function of
the differences in the RbsA degenerate site compared with the degenerate sites of proteins
for which structures exist, such as TM287-288. These proteins contain a defined
substitution pattern, with a glutamine in place of the conserved switch histidine and a
glutamate in place of the conserved D-loop aspartate. These side chains appear to support
a closed, substrate-bound state of the degenerate NBS. RbsA, in contrast, has a serine in
place of the switch histidine and appears to be missing the D-loop entirely (an RGVG motif
is present at the region usually where this is found). Currently, no solved structure exists
with a similar substitution pattern in a degenerate site.
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The model for RbsA appears to be reasonable, based on mutations introduced at
control sites where conformational changes and protein-protein interactions are not
expected Spin labels were introduced into positions on the outer and lower surfaces of
RbsA away from regions participating in hydrolysis and transport. These labels reported
no changes due to cofactors or the presence of RbsC and RbsB. In a global sense, the
modeled protein could be trusted to guide labeling and better understand RbsA
conformational changes by this method.

3.7.1 NBDs are Pinched Together Upon ATP Binding
It appears that RbsA functions in a manner similar to MalK. Labels placed at the
NBD-TMD interface (85-333 mutant) demonstrate that the NBDs pinch together in the
intact transporter with Mg-ATP-VO4. This is shown by the significant reduction in
amplitude of the +1 and -1 spectral lines for this experiment, demonstrating reduced spin
label mobility. This cofactor combination is expected to produce the outward-facing state
of the transporter. In this state, it should be expected the coupling helix is docked into the
Q-loop and the NBDs are fully engaged in binding ATP.
The amplitude of these same peaks then increases for the Mg-ADP bound state,
demonstrating increased spin label mobility. This suggests a retraction of the TMD
coupling helix and possible disengagement of the NBDs away from one another. It has
been speculated that this represents either an inward-facing or outward-occluded state of
the transporter (Dawson & Locher, 2006), based on crystallographic evidence. In either
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case, it would be expected that the substrate had been released from the SBP and TM gating
was driving it inwards. The increased mobility supports this situation.
Finally, the amplitude of the +1 and -1 peaks increased further for the ATP-EDTA
cofactor combination. In co-purification studies, this combination resulted in complete
dissociation of RbsA from RbsC (Clifton, et al., 2015). It is not clear if such dissociation
is seen in the context of this experiment. Co-purification studies would fail to capture lowaffinity transient interactions, while EPR can sensitive to these depending on placement of
the spin labels (Erramilli, Simon, Clifton, & Stauffacher, 2016). However, the increase in
amplitude certainly supports a model where the TMD is disengaged from the NBD and
the NBDs have rotated away from one another in the absence of bound cofactors. Thus,
these observations are consistent with what is thus far understood about RbsABC assembly.

3.7.2 RbsB Promotes Conformational Changes in RbsA
It has previously been shown that vanadate-trapping can be used to purify both the
RbsABC and RbsAC complexes, depending on what proteins are included. It was thus not
expected that structural differences in the NBDs and TMDs existed between these two
complexes. Vanadate is a potent nanomolar inhibitor of ATPases and forms a very stable
post-hydrolysis trap.
However, EPR experiments of the 14-393 mutant transporter are discriminate
structurally between these two protein combinations despite identical cofactor
combinations used. Vanadate-trapped RbsAC only shows a slight reduction in spin label
mobility compared with either the Mg-ADP cofactor combination or the ATP-EDTA
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cofactor combination. This is expected based on what is known about NBD-NBD
association during nucleotide binding. Unexpectedly, a significant spectral difference is
observed upon introduction of RbsB, showing not just decreased spin label mobility but a
pronounced broadening typical of at least some degree of spin-spin interaction. This
suggests that the docking of RbsB to RbsC is promoting a further rotation of the
subdomains of RbsA towards one another, and provides a mechanism for increased
hydrolysis activity in RbsA due to RbsB. These results are also consistent with what is
known about ABC transporter function, that an inward rotation of the helical subdomain
towards its complementary RecA-like subdomain drives ATP hydrolysis and links TMDNBD conformational changes.
The Mg-ADP RbsAC spectrum shows similar features to the RbsAC Mg-ADPVO4 state. This cofactor combination results in a RbsAC complex, with RbsB dissociating
post-ATP hydrolysis. This suggests the helical subdomain rotates away from the RecAlike subdomain following RbsB release, and supports either an inward-facing or outwardoccluded state of the transporter.
Finally, the ATP-EDTA combination results in a spectrum with the highest spin
label mobility for this data set. This supports a model where the NBDs of RbsA are
disengaged fully in the absence of bound cofactor. This may also represent the state of
RbsA in the absence of associated RbsC.
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3.7.3 Summary of EPR Experiments
Overall, these results provide the data to construct a transport mechanism that is
consistent with what is known about ABC transporter function, yet has certain caveats.
These caveats arise both from these experiments, the substrate binding studies, and the sum
total of previous observations regarding ribose transporter proteins. In the search for
general mechanisms, ABC transporter research has led to the identification of at least two
divergent phenotypes of importers, each with structural and mechanistic differences
adapted for the nature of their partner proteins and the transported substrates. A transport
model taking into account all of the available data about RbsABC will be discussed in
Chapter 5.
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CHAPTER FOUR: CRYSTALLIZATION TRIALS AND
PHAGE DISPLAY FOR STRUCTURAL STUDIES

4.1: The Challenges of Crystallizing Membrane Proteins
X-ray crystallography remains the gold standard method for determining protein
structures at high resolution. The rate determining step for solving structures with this
method remains obtaining large, well ordered crystals hardy enough to tolerate X-rays for
sufficient exposures to collect a complete data set. Until alternative structure determination
methods gain broad applicability, a high-throughput crystallization trial remains the best
approach for obtaining such crystals to solve protein structures using their X-ray diffraction
patterns.
There is a well-known lag in the progress of membrane protein structure
determination compared with their soluble counterparts (FIGURE 4-1). This lag is based
on predictions from the 1970s regarding the pace of protein structure determination (White,
2004). To date over 117,000 X-ray structures of over 37,000 unique proteins have been
deposited to the Protein Data Bank (source: pdb.org). Of these, roughly 1,000 structures
of slightly more than 600 membrane proteins have been solved and deposited in this
repository, representing less than one percent of stored coordinate files. Nearly one-third
of the genomes of many organisms, from the simplest bacteria to man, code for membrane
proteins (White, 2004).
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Figure 4-1: The progress of membrane protein structure determination (White 2004). The
expected growth is based on the growth rate of protein structure determination from the
date of the first structure (1960) to 1978, when 132 structures had been determined.

167
This lag can be accounted for both by the challenge of expressing and stably purifying
membrane proteins and the difficulties in crystallizing them in their detergent reconstituted
states (Ostermeier & Michel, 1997). A variety of modern technologies have been
developed for the purification and handling of membrane proteins in vitro and
improvements to crystallization and synchrotron technology have overcome significant
barriers to studying membrane proteins (Bill, et al., 2011). These improvements have only
slightly improved the rate of progress for determining membrane protein structures.
The primary challenge remains obtaining well-ordered crystals of membrane
protein. The growth of such crystals is retarded by the significant bolus of detergent
molecules that surround solubilized membrane proteins. This shell often masks extrinsic
regions potentially suitable for the generation of protein-protein contacts required to form
well-ordered crystals. Further, these shells prevent accessibility to potential contact sites
within hydrophobic transmembrane domains, required for forming more stable type I
membrane protein crystals (Ostermeier & Michel, 1997).
A second problem associated with detergents is their insufficiency in replicating
the membrane environment, often leading to instability of transmembrane regions. These
issues have been addressed in part by the development of synthetic detergent molecules
that better mimic lipids (Moraes, Evans, Sanchez-Weatherby, Newstead, & Stewart, 2014).
More recently, crystallization using lipid-based media have been popularized and shown
to be applicable to a variety of membrane protein systems (Caffrey, 2015). A successful
membrane protein crystallization trial thus requires the application of as many of these
methods as is reasonably possible. The worthiness of such an endeavor is well-established
and should be pursued whole-heartedly for all and any membrane proteins at this time.
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Crystals of the ribose transporter complexes suited to X-ray diffraction experiments
have remained elusive to obtain, despite extensive trials. The efforts to obtain such crystals
have involved a variety of techniques, from optimization of purification conditions to the
type of crystallization medium (detergent, bicelles, lipidic cubic phase) and, more recently,
the application of phage-display synthetic antibody technology for the generation of
crystallization chaperones. This chapter describes these efforts and provides a record of the
current progress towards the ultimate goal of obtaining a high-resolution structure of the
full ribose transporter complex. We next discuss the basis for each method briefly before
moving to the experimental details and current results.

4.2 The Optimization of Ribose Transporter Expression and Purification
Efforts to improve the yield of RbsAC from cell cultures to facilitate extensive
crystal screening have been documented in Chapter 2. These efforts improved expression
of RbsAC 10-15 fold over previous methods, and provided the necessary amounts for highthroughput screening using a variety of crystallization methods.
It had previously been determined, following screening during purification, that
DDM was the optimal detergent for extraction and purification of RbsABC (Clifton, 2005).
This mild detergent is simultaneously the most popular for membrane protein purification
and poorly compatible with crystallization experiments, as it forms micelles documented
to be 70-120 kDa in size when solubilizing transmembrane segments (Oliver, et al., 2013)
(Clifton, et al., 2016). A well-established correlation exists between detergent chain-length
and micelle size, with longer chain detergents proving to be more tolerable to a variety of
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membrane proteins. The choice of long versus short alkyl chain is, however, made only by
experimental trials, and short detergents often have destabilizing effects on membrane
proteins by inserting between transmembrane helices and break inter-helica interactions.
A host of synthetic detergents have recently been developed and have aided
crystallization efforts of difficult targets (Chae, et al., 2010). Several of these detergents
were screened for optimization of RbsABC for crystallization. Most notably, double-tailed
detergents that have proven efficacy with G-protein coupled receptor signalling complexes
were tested for compatibility with RbsABC. Further purification of RbsABC and other
ribose transporter complexes by gel filtration chromatography was also pursued and
optimized for buffer content. These included the pursuit of complex-stabilizing catalytic
mutants in lieu of trapping with phosphate analogs such as orthovanadate, and substituting
more stable analogs such as aluminum and beryllium fluorides.

4.3 Ribose Transporter Crystallization Trials
High-throughput crystallization trials of orthovanadate- and aluminum fluoridetrapped RbsABC, RbsAC, and RbsBC were pursued using several dozen commercial
screens (Qiagen, Molecular Dimensions, Anatrace) and in a variety of media (FIGURE 42). These included screens optimized for membrane protein crystallization. A significant
deterrant to membrane protein crystallization is the phase partitioning effects of
precipitants on detergents (Koszelak-Rosenblum, et al., 2009). These phase separations
result in membrane protein denaturation, yet many membrane proteins have crystallized
near the boundaries of these partitions. This knowledge has resulted in the development of
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sparse matrix crystal screens with formulations optimized for the phase boundaries of
popular purification detergents. These screens typically utilize salt concetrations ranging
from 0.05 to 0.4 M and polyethylene glycol (PEG) concentrations ranging from 2 to 22%,
as well as a bias towards shorter-chain PEG reagents (source: Hauptman-Woodward
Institute). These and many other screens were employed for crystallization trials with
coverage of many common and uncommon protein precipitants.
In addition, lipid-based crystal screening was also employed. This involved
screening with both bicelles and lipidc cubic and sponge phases. Bicelles are bilayered
micelles, forming from a mixture of short-chain detergent and lipids (FIGURE 4-2B). The
typical formulation for such studies involves combining dimyristoyl phosphatidylcholine
(DMPC) and the detergent CHAPSO at ratios ranging from 2.5:1 to 3.5:1 (Ujwal & Bowie,
2011). These mixtures are then combined with purified membrane proteins, which
preferentially reconstitute into the lipid bilayers. While not well-defined modules such as
nanodiscs, bicelles are compatible for crystal screening and typically aggregate to form
three-dimensional bilayer systems that allow the growth of type I membrane protein
crystals. Bicelle-reconstituted ribose transporter was screened using many of the same
commercial crystal screens described above.
Recently, lipidic cubic and sponge phases have become popular choices for the
growth of membrane protein screening. These methods involve reconstitution of
membrane proteins into three-dimensional bilayer systems (FIGURE 4-2C) formed from
monoolein lipids. Reconstitution of membrane proteins into lipidic cubic phase (LCP)
involves mixing the protein solution with molten lipids, which are subsequently cooled and
hydrated during mixing to produce protein incorporated LCP. During crystallization, the
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LCP is perturbed by local dehydrations induced by precipitant solutions, resulting in phase
changes that allow the growth of type I membrane protein crystals in the lamellar lipid
phase (Caffrey, 2015) (FIGURE 4-2D). The sponge phase represents an additional
hydrated phase of LCP with larger pores thought to be accommodating for membrane
proteins with large extrinsic domains, such as ABC transporters and large signalling
complexes. Much like with detergents and bicelles, LCP-based crystallization was pursued
for the trapped RbsABC complex using many of the same crystal screens described above.
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Figure 4-2: Membrane protein crystallization environments. A) Traditional, detergentbased (orange) solubilization and crystallization. Protein is green. B) Bicelles are short
bilayer patches (red) solubilized by short-chain detergents (orange). C) Lipidic cubic
phases are three-dimensional bilayers that form reservoirs for membrane proteins to diffuse
and crystallize. D) LCP phase diagram. Hydration (40-50%) results in cubic phase at room
temperature. Introduction of precipitant causes local dehydration, resulting in lamellar (Lα)
phase. Figures adapted from Cherezov lab website.
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4.4 Crystallization Chaperones from Phage Display Technology
Crystallization chaperones encompass a variety of proteins and protein-fragments
that increase the probability of crystallization of a target large molecule (Koide, 2009).
These chaperones are designed to to reduce the conformational heterogeneity of a protein
sample and alter the surface chemistry to improve the likelihood of crystal contact
formation. Chaperones can also provide phasing information for molecular replacement
based structure determination.
Numerous examples demonstrate the success of this method, including many
notable examples of membrane proteins crystallized with chaperones. These include the
full-length potassium channel KcsA, the β-adrenergic receptor, and the bacterial drug
extruder AcrB, all crystallized with bound antibody or engineered protein fragments that
stabilized the protein or provided valuable contact surfaces to promote crystal growth.
Given the size of the detergent micelle and the buried surface area of transmembrane
segments, the latter feature is of particular value for the crystallization of many membrane
proteins.
Traditionally, the generation of crystallization chaperones has involved animal
immunization to produce monoclonal antibodies, a process that is slow and expensive for
the production of milligram quantities of protein required for high-throughput
crystallization trials. Modern methods have relied on either semi-synthetic antibodies,
cloned from the cDNA from animal sources and produced in bacteria, or fully synthetic
antibodies using recombinant DNA technology. The latter method takes advantage of
degenerate oligonucleotides in the polymerase chain reaction (PCR) to produce libraries
with theoretical diversities of 1010 or higher. This allows the generation of antibodies with
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a tremendous variety of complimentarity-determining regions (CDRs) for the recognition
of a vast number of epitopes.
The most common approach with synthetic antibody technology is the use of phage
display for screening target binders. This involves the expression of the heavy- and lightchain Fab portion of antibodies as part of phage DNA. One chain is engineered with an
extended linker region that fuses it to a surface protein. The second is expressed as a soluble
protein and the two dimerize spontaneously and are subsequently expressed on the phage
surface. This allows for convenient and rapid screening to identify high-affinity binding
partners (FIGURE 4-3). Library diversity is achieved by positional variation of CDR
regions, formed by the six combined loops of the heavy- and light-chains of the Fab
molecule (Sidhu & Koide, 2007). Thus, recombinant DNA technology has allowed for
complete independence from the natural immune system for antibody production.
The process for screening and identifying high-affinity binders using phage display
has been well-established (Paduch, et al., 2013). Typically, target molecules are
immobilized and screened through several rounds of selection. By reducing the amount of
target immobilized in each round, a handful of robust binding partners can be selected for.
Interestingly, selection for membrane proteins in detergent proved difficult by this method.
This difficulty was ascribed to the peturbation of membrane protein structure by detergent,
resulting in conformational heterogeniety that prevented successful and reproducible
selection of antibodies by phage display. This problem was solved by the application of
nanodisc technology to reconstitute membrane proteins into well-defined modules. These
modules could then be fed into the phage display pipeline to generate binders with great
specificity (Dominik, et al., 2016). Re-screening the best binders in detergent-reconstituted
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membrane proteins allowed for the application of this technology to a format amenable to
crystallization trials.
By collaborating with researchers in the Kossiakoff laboratory at the University of
Chicago, antibody binders specific to ribose transporter proteins were screened and
selected for using a phage display library and a recently established membrane protein
methodology (Dominik & Kossiakoff, 2015). The selection strategy involved individual
screening of RbsA and RbsB, detergent-based screening of RbsAC and RbsBC, and
nanodisc-reconstituted screening of RbsABC in the vanadate-trapped state. Although a
process for reconstituting RbsABC successfully into nanodiscs has been described in an
earlier chapter, this method had yet to be developed at the time of this phage display
screening. The motivation for a rigorous nanodisc method stemmed in part from the lack
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Figure 4-3: Sequence of phage display selection protocol. The phage display antibody
library is incubated with immobilized target. Non-binding phages are washed off, and
specific binders are removed and the sub-library is amplified in bacterial hosts. The process
is repeated with the sub-library for several rounds, following which specific binders are
validated as purified Fab fragments against targets in vitro.
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of reconstitution success during this time. However, some progress was made at this time
and these ribose transporter nanodiscs were screened as described in the upcoming sections.
Binders from these selections were then expressed and purified from bacterial sources and
are being applied to crystallization trials. The progress of these trials will be discussed in a
later section.

4.5 Methods and Materials
In the following sections, the methods and materials for ribose transporter
purification, crystallization in detergents and lipids, and for the generation of antibody
chaperones are described.

4.5.1 Detergent Screening for RbsABC by Size-exclusion Chromatography
RbsABC was purified as previously described (Clifton, et al., 2015). Following
purification by affinity chromatography using Ni-NTA resin, the complex solutions were
either dialyzed or buffer-exchanged to remove imidazole. All required cofactors were
included in the dialysis/exchange buffers. Buffer exchange was performed by a
combination of PD10 desalting columns (BIO-RAD) and centrifugal spin filters with the
appropriate MWCO (Amicon) using buffer without imidazole. Proteins were concentrated
to final sample volumes of 500 µL (typically 40-50 µM) for the Superdex200 10/30 or 2.0
mL for the Superdex200 16/60 and spun for 10 minutes on a table-top centrifuge
(Eppendorf) at maximum RPM (14k) to clear aggregates. Centrifuged samples were
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transferred to fresh autoclaved 1.5-mL Eppendorf tubes and typically did not contain
visible signs of precipitation.
Samples were injected into either the Superdex200 10/30 or 16/60 GL columns preequilibrated with at least two column volumes of buffer containing 20 mM Tris-HCl pH
8.0, 200 mM NaCl, 20% glycerol, 1 mM each of cofactors, and one of the following
detergents at concentrations 2-3 times the published CMC values: DDM (0.05%), C12E8
(0.02%), LMNG (0.02%), UDM (0.03%), and Fos-choline 12 (0.1%). All detergent
products were purchased from Anatrace. Progress of the elutions was monitored by
computer using built-in A280 detection. Fractions were collected using either 1-mL
volumes (for the 10/30) or 2-mL volumes (for the 10/300) and analyzed by SDS-PAGE.

4.5.2 Ribose Transporter Crystallization Trials
All three ribose transporter complexes were screened in detergent-solubilized states
using DDM. Following Ni-NTA purification, complexes were further purified by gel
filtration chromatography using the Superdex200 16/60 GL. The purification buffer was as
described above with the appropriate cofactors, where required. Fractions containing
monodisperse protein complexes were combined and concentrated to a range of protein
concentrations, from 50 – 200 µM. Glycerol was then removed by overnight dialysis in
buffer containing the required cofactors.
Crystallization experiments were setup with a variety of membrane protein sparse
matrix crystal screens, including MemGold1, MemGold2, MemStart, MemSys, MemFac,
and MORPHEUS (Molecular Dimensions). Other screens, such as JCSGI-IV, Classics 1-
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2, and Pro-complex (Qiagen), were also employed for crystal screening. Both sitting drop
and hanging drop crystallization experiments were pursued using several protein
concentrations (50 – 200 µM) and three different screening temperatures (4, 12, and 20°C).
Drop volumes consisted of 200 nL protein with 200 nL of precipitant solution. Experiments
were monitored daily for two weeks, then weekly for six months, then monthly thereafter.
Screens that resulted in over 80% protein precipitation were re-screened at lower protein
concentrations.
In addition to detergent-based screening, in meso screening was also pursued using
RbsABC with either orthovanadate or aluminum fluoride as a trapping agent. Aluminum
fluoride was substituted for vanadate following gel filtration using two rounds of dialysis
for 4-8 hours each. Aluminum fluoride was prepared as previously described (Oldham &
Chen, 2011).
For bicelles, a mixture of DMPC and CHAPSO was prepared as previously
described (Ujwal & Bowie, 2011). Bicelle solutions were prepared in water at pH 7.0 at
35% final concentrations using a DMPC/CHAPSO ratio of 2.8:1. RbsABC was
concentrated to 50 – 200 µM and mixed with the bicelles solution at a 4:1 ratio. This
solution was kept on ice overnight to allow complete reconstitution. Crystallization
experiments were setup in hanging-drop trays using 200 nL protein and precipitant
volumes. Trays were screened at 4, 20, and 37°C.
For LCP, pure monoolein lipids (Avanti) were heated to 100°C for 5-10 minutes.
Molten lipids were transferred to a pre-warmed Hamilton syringe and mixed with RbsABC
solution (prepared as above) at a 1:1 final ratio. RbsABC (protein concentration: 50 – 75
µM) had previously been transferred to a second syringe, and the two syringes were
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connected as previously described (Caffrey, 2015) taking great care to prevent the
formation of air bubbles. Mixing was performed for several minutes by moving the syringe
pistons back and forth to produce cubic phase. This resulted in a clear solution containg
protein-incorporated LCP. When glycerol was present in the protein solution, a graycolored solution was produced with small precipitates, suggesting incompatibility.
Sandwich-plate crystallization experiments were setup using the same screens
mentioned above. Drop volumes contained 50 nL protein solution and 300 nL precipitant.
Trays were stored at room temperature to prevent temperature-induced phase changes of
monoolein lipids. Bicelle and LCP trays were monitored for several months as described
above. Crystals were screened using UV-fluorescence detection and by home source X-ray
diffraction, wherever possible.

4.5.3 Phage Display Antibody Selection for Ribose Transporter Proteins
The following sub-sections describe steps in phage display selection for complexes
and individual components of the ribose transporter. The selection strategy involved
labeling individual components RbsA and RbsB separately using biotin linkers (NHSbiotin for RbsA and RbsB and maleimide-biotin for RbsA). In addition, MSP was
biotinylated using NHS-biotin for selection in nanodiscs. These labels contained linker
regions of 20-25 Å (EZ-Link-NHS-PEG4-Biotin and EZ-Link-SS-PEG2-Biotin, both
purchased from Thermo), providing the appropriate length to prevent steric hindrance of
antigenic sites by magnetic beads.
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Six separate selection experiments were designed: 1) NHS-RbsA, 2) maleimidelinked RbsA (mal-RbsA, for convenience), 3) NHS-RbsB, 4) mal-RbsA with RbsC (and
cofactors), 5) NHS-RbsB with RbsC, and 6) RbsABC in biotinylated nanodiscs (with
cofactors). In addition, an additional selection involving RbsABC in nanodiscs with an
excess of RbsA and RbsB (to promote complex formation) was performed, for a total of
seven phage display experiments. All selection experiments were performed in the
Kossiakoff lab at the University of Chicago. RbsABC nanodiscs and empty nanodiscs were
prepared as described in Chapter 2 using biotin-labeled MSP1D1 for RbsABC and
unlabeled MSP1D1 for empty nanodiscs.

4.5.3.1 Biotinylation of Ribose Transporter Components and MSP
RbsC, RbsA, and RbsB were purified using his-tagged constructs as previously
described (Clifton, et al., 2015). TCEP-HCl was used as a cysteine reducing agent for RbsA
and was removed by buffer exchange immediately prior to biotinylation. Both proteins
were concentrated to 20 – 25 µM prior to labeling. Protein concentrations were measured
using the Bradford Assay and determined against a BSA standard curive.
All labels were first dissolved in DMSO to produce stock solutions with final
concentrations of 20 mM. The stock solutions were then diluted 10-fold in protein buffer
prior to labeling. A 10-fold excess of the desired biotin label (NHS-biotin for MSP, RbsA
and RbsB, maleimide-biotin for RbsA) was added to each protein. Labeling was performed
at room temperature for 30 minutes and, for the NHS reaction, quenched by the addition
of 5 mM final Tris-HCl pH 7.5. Excess label was removed by PD10 desalting columns,
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and proteins were further purified by gel filtration chromatography using a Superdex200
10/30 GL column. Fractions containing labeled protein were pooled, concentrated to 10
µM, and flash frozen at -80°C.
Prior to selection, the efficiency of biotinylation was evaluated by pull-down
experiments using streptavidin-coated magnetic beads (Streptavidin MagneSphere
Paramagnetic Beads, Promega) and a pull-down stand (Promega). Beads (100-200 µL)
were washed three times with the requisite protein buffer. Beads were briefly incubated
with target proteins, washed three times, and then boiled in SDS-PAGE sample buffer for
five minutes. In addition, for selection experiments using labeled RbsA and RbsB in
complex with RbsC, protein-bead samples were further incubated with RbsC (and
cofactors) and washed three times to remove excess RbsC. Beads were boiled as above.
All samples were subsequently analyzed by SDS-PAGE.

4.5.3.2 Phage Library Sorting
Seven independent sorting experiments were performed as described above. All
selection experiments were performed using sAB Library E (Miller, et al., 2012). For
experiments involving only soluble protein components, four rounds of selection were
performed. For experiments involving complexes and nanodiscs, an additional fifth round
was pursued, as described (Dominik, et al., 2016). For experimental convenience, all
buffers, except for nanodiscs, contained the same components: 25 mM Tris-HCl pH 7.5,
200 mM NaCl, 0.05% DDM, and 1 mM each of magnesium, ATP, and orthovanadate
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(Buffer A). For nanodiscs, DDM was excluded from the buffer (Buffer B). In addition, all
buffers were supplemented with 1% BSA.
In addition to choice of labeling, the sorting strategy included both competitive and
subtractive selection. For RbsABC nanodisc samples, empty unlabeled nanodiscs were
used throughout the selection process as soluble competitors to subtract nanodisc-binding
phages. In addition, excess RbsC was maintained throughout sorting for complex-specific
phage selection. This strategy was intended to combat the complex destabilizing effects of
high-affinity phage binders and bias towards phages recognizing epitopes away from
surfaces involving RbsAC and RbsBC complex formation. A similar strategy was
employed in RbsABC nanodiscs to maintain an excess of soluble, unlabeled RbsA and
RbsB.
Each round of selection was performed as previously described (Dominik &
Kossiakoff, 2015). On the first day of the selection phages were precleared with
streptavidin beads. The first two rounds were performed by immobilizing target proteins
using 200 nM samples. This was reduced in rounds 3-5 to 20 nM. Competitors were
maintained throughout as described above. Bound phages at the end of each selection were
eluted as described for either soluble proteins (Paduch, et al., 2013) or nanodiscs (Dominik
& Kossiakoff, 2015). Following round 3 and through round 5, an aliquot of phage-infected
cells was plated for each selection in 10-fold serial dilutions to evaluate enrichment from
round to round. Plates were imaged and stored each morning.
Selection for NHS-RbsA and mal-RbsA was stopped after four rounds. All other
samples completed five rounds of selection. Following the final round of sorting, single
phage colonies from all the selections were picked randomly and streaked onto separate
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plates. These colonies were then grown overnight and used to prepare glycerol stocks.
Glycerol stocks were subsequently frozen for long-term use. sABS were named according
to labeling strategy. From the RbsA alone selection, sABs were named NAR (NHS-RbsA)
or MAR (mal-RbsA) followed by their position on the plate. From the RbsB selection,
sABs were named NBR. For selection performed with RbsA in the presence of RbsC, sABs
were named MARC. For selection performed with RbsB in the presence of RbsC, sABs
were named MBC. For selection performed with RbsABC nanodiscs, sABs were named
NDC. A map of the master plate with named phages can be found in the RESULTS section.

4.5.3.3 Primary Single-Point Phage ELISA Experiments
Single-point phage ELISA was used as the primary validation step for binding
affinities of synthetic antibodies in the phage format, and was performed as previously
described (Dominik & Kossiakoff, 2015). The night before each ELISA experiment,
phages were amplified from the glycerols stocks by infection and subsequent overnight
cultures. Amplified phage particles were diluted ten-fold for ELISA experiments. As above,
both Buffer A and Buffer B contained 1% BSA.
ELISA plates were coated overnight with Neutravidin (2 mg/mL) and blocked with
either Buffer A or Buffer B, and then washed with buffer three times. Experimental wells
were coated with 20 nM labeled proteins. Phages were allowed to bind and then washed
three times with buffer. Plates were incubated with HRP-conjugated anti-M13 antibody
and then washed three times with buffer. TMB solution was prepared and added and,
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following 2 minutes for development, blocked by the addition of HCl. The absorbance of
each well was measured at 450 nm.
Each sAB clone with A450 signal above 0.2 (four times above background) was
selected for sequencing. Phages from these wells were streaked onto a fresh plate and
grown overnight. The plate was sent for colony PCR. Unique clones were selected and
grown overnight. Glycerol stocks were prepared from these amplifications and stored
frozen.

4.5.3.4 Secondary Single-Point Phage ELISA
As an additional validation, secondary ELISA in the phage format was performed
to identify complex- and conformation-specific binders. ELISA experiments were
performed for labeled RbsA and RbsB in the presence of RbsC and either RbsBC or RbsAC
with cofactors present in all buffers. In addition, epitope mapping was performed for RbsA
using the N-terminal NBD construct [ (Clifton, 2005), (Armstrong, Tabernero, Zhang,
Hermodson, & Stauffacher, 1998)] as both a soluble competitor and as a labeled protein in
ELISA experiments. The N-terminal domain construct was purified as previously
described (Clifton 2005), and labeled using the same biotinylation strategy described above.
All generated phages were tested against these sample conditions to identify unique
epitopes for cloning. As above, A450 values were used to evaluate phage binding.
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4.5.3.5 Cloning and Purification of unique sABs
Several unique sABs from each selection strategy were chosen for cloning on the
basis of ELISA signal strength and location of epitope. Twenty-one sAB genes were
amplified by PCR and then sub-cloned into the expression vector pSVF4 as previously
described (Paduch, et al., 2013). Fourteen of the cloned sABs were then transformed into
BL21-DE3 cells and expressed and purified as previously described (Paduch 2013). Of
these, purified synthetic antibodies that expressed at sufficient levels were dialyzed
overnight following purification (50 mM Tris-HCl pH 7.5, 100 mM NaCl), concentrated
to 50 – 100 µM, and frozen at -80°C in 500 µL aliquots until further use.

4.5.3.6 Antibody-Antigen Complex Formation in Vitro
Synthetic antibodies were tested for the ability to form complexes with RbsA,
RbsABC, and RbsB. Complex formation was evaluated by gel filtration chromatography
using a Superdex200 10/30 GL column. All complex buffers contained cofactors as needed.
RbsABC-sAB complex formation was tested in detergent (0.05% DDM). Elution was
monitored by A280. Fractions (1 mL) were collected and evaluated by SDS-PAGE.
Complex formation with RbsA was tested in the presence of magnesium, ATP,
vanadate and the following sABs: NAR09, NAR10, MA22, and MA36. In addition, the
following sABS were used in combination to test the success of epitope mapping: NAR09
and NAR10, NAR09 and MA22, and NAR10 with MA22.
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Complex formation witih RbsB was tested with the sAB NBR51 in the absence of
cofactors. For RbsB experiments, buffer without DDM and containing only 10 mM TrisHCl, pH 8.0, was used for all SEC experiments.
Complex formation with RbsABC was tested with all of the above sABs
individually in the presence of magnesium, ATP, and vanadate, and also with the sABs
MAC70 (RbsA with RbsC), NDC91, and NDC92, from the selection with nanodiscs.
To form complexes, sABs were added at a 1.25:1 molar excess over protein or
protein complexes and mixed and briefly incubated on ice. 500 µL samples from each
complex formation sample was injected. Binding was evaluated by shifts of the protein
elution profiles to lower retention volumes and the presence of sAB bands (25 kDa) on
SDS-PAGE. All gel filtration experiments were run for 1.5-2 column volumes to allow
elution of unbound sABs. Following completion of experiments, columns were cleaned by
1 mg/mL pepsin solution in 50 mM acetic acid (2 CVs) followed by 0.5 M NaOH (3-5
CVs) and 5-10 CVs of water.

4.6 Results
Results from detergent-optimization, crystallization trials, and phage display
sorting are presented in individual sections below.

4.6.1 Detergent-Optimization Results
Five different detergents were screened for buffer optimization. These included
DDM, which has been tested extensively but not previously used in gel filtration
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experiments. Elution profiles for four other detergents were compared to DDMreconstituted RbsABC in the presence of cofactors.
DDM-reconstituted RbsABC eluted at approximately approximately 12.5 mL from
the Superdex200 10/30 (FIGURE 4-4, blue curve). RbsABC was subsequently exchanged
during gel filtration into LMNG at a concentration 3 times over CMC (FIGURE 4-4, green
curve). Ribose transporter proteins primarily eluted in the void volume (~7.5 mL) and
precipitated in the fractions shortly after, indicating poor compatibility. Tests in
concentrations ranging from CMC to an order of magnitude higher did not produce better
results (data not shown).
RbsABC was also exchanged into Fos-choline 12 in a similar fashion (FIGURE 44, red curve). The complex appeared to be destabilized and RbsA and RbsB eluted at higher
retention volumes. RbsC eluted in the aggregate fraction. A small amount of complex
appeared to elute at the expected retention volume but could not be detected using
Coomassie-staining SDS-PAGE.
The detergents UDM and C12E8 were tested using the Superdex200 16/60. On this
column, DDM-reconstituted RbsABC eluted at roughly 60 mL retention volume
(FIGURE 4-5, blue curve). RbsABC exchanged into UDM eluted in the void volumne,
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Figure 4-4: Elution profile of RbsABC in the detergents DDM, LMNG, and Fos-choline
evaluated using Superdex200 10/30 GL column. Void volume = 7.5 mL.
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Figure 4-5: Elution profile of RbsABC in the detergents DDM, UDM, and C12E8,
evaluated using a Superdex200 16/60 column. Void volume = 38 mL.
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suggesting aggregation (FIGURE 4-5, red curve). Fractions containing these proteins
developed precipitation shortly after elution. RbsABC in C12E8 (FIGURE 4-5, green
curve) eluted in part in the void volume and in part at a lower retention volume than
expected (48 mL). Fractions containing RbsABC were tested for activity but found to show
no RbsC-stimulated activity in RbsA, as is expected in detergent (data not shown). This
suggested a destabilizing effect of C12E8 on RbsC. Further optimization using C12E8 was
not pursued.

4.6.2 Crystallization Trials of the Ribose Transporter Complexes
Following extensive screening, only one RbsABC crystallization condition
provided protein crystals (FIGURE 4-6). These crystals arose from the Pro-complex
screen using RbsABC in bicelles at 200 µM concentration, and precipitant conditions
included 25% polyacrylic acid sodium salt (PAANa) and 0.1 M potassium dihydrogen
phosphate buffer. Crystals were evaluated by UV fluorescence, which confirmed the
content was protein. The crystals were fragile and disappeared within two weeks. Attempts
to harvest the crystals failed.
Optimization of these crystals was pursued using a grid screen, with PAANa
ranging in concentration from 10 to 40% and buffer pH ranging from 6.5 to 9.0. Protein
concentration was varied from 50 to 200 µM, with crystal size and number varying
proportional to protein concentration. Small crystals reappeared shortly after setup, but
were again fragile and disappeared within 1-2 weeks. Further screening has not yet been
attempted.
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Figure 4-6: RbsABC crystals in PAANa and dihdyrogen phosphate. Above: brightfield
image at 200X maginifcation. Below: UV fluorescence image (measured at 340 emission
at same magnification).
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4.6.3 Results of Phage Display Library Sorting
Results for sorting experiments have been broken into sections for convenience.
Results are presented in the following sections.

4.6.3.1 Control Pull-down Experiments of Labeled Proteins
Following RbsA and RbsB labeling with biotin reagents, excess unreacted label
was removed using desalting columns and gel-filtration chromatography (data not shown).
NHS-RbsA, mal-RbsA, and NHS-RbsB were then tested for efficiency of labeling by
sample pull-down experiments using streptavidin paramagnetic beads. The proteins were
tested alone and then for their ability to retain RbsC during pull-down experiments. As a
control, unlabeled RbsC was also tested with beads for non-specific binding.
For all experiments, the following samples were prepared and analyzed by SDSPAGE. Experimental buffers included cofactors and detergent in all cases for convenience.
The initial protein sample was run in lanes marked “input”. Following incubation of the
sample with beads and subsequent pull-down, a sample was collected and marked “flowthrough”. These beads were washed three times; wash 3 was collected and run on the gel.
Samples were then incubated either with RbsC or a buffer blank (marked “detergent wash”).
The flow-through was again collected and ran on the gel (FT2). The beads were again
washed three times; wash 3 was collected and run on the gel. Finally, the remaining beads
were dissolved in SDS sample buffer, boiled, and subsequently loaded and run on the gel.
This fraction is marked “beads”.
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In FIGURE 4-7, pull-down results from NHS-labeled RbsB and RbsA are shown
using a stain-free gel visualized by protein fluorescence emission detection. Bands for
RbsA in the beads fraction are readily visible, along with streptavidin (lane 9). In addition,
excess, unbound RbsA is also visible in the flow-through (lane 10).
RbsB was not visible by this detection method. This result is expected given an
analysis of the RbsB amino acid sequence reveals a complete absence of aromatic amino
acids. To visualize RbsB, Coomassie staining followed by imaging was employed
(FIGURE 4-8). Following imaging, RbsB became readily apparent in the beads fraction,
demonstrating a successful pull-down.
Further, analysis of the beads fraction with the RbsC control (lanes 14 and 15 in
both 4-7 and 4-8) demonstrated RbsC does not bind non-specifically to streptavidin beads
(lane 15). In all lanes containing streptavidin, a second band is apparent; this is a
streptavidin dimer.
In lanes 1-6 of FIGURE 4-9, mal-RbsA was tested for successful pull-downs and
visualized by stain-free gels using protein fluorescence. The RbsA band is apparent in the
beads fraction (lanes 2), with a smaller amount of unbound mal-RbsA present in the flowthrough. The darker streptavidin monomer and dimer bands are also apparent.
In lanes 8-12, the ability of NHS-RbsB to pull-down RbsC was tested. The input
was omitted here. In the beads fraction, bands for RbsC and streptavidin are readily
apparent. However, RbsB once again required Coomassie staining to visualize. These
results are shown in FIGURE 4-10. Bands for RbsB, RbsC, and streptavidin can be found
in the beads fraction (lane 8). Excess, unbound RbsC is also present in the flow-through
following incubation with NHS-RbsB (lanes 11 in 4-9 and 4-10).
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Finally, the ability of both NHS-RbsA and mal-RbsA to pull-down RbsC was tested
and visualized on stain-free gels using protein fluorescence (FIGURE 4-11). In the beads
fraction of both (lanes 1 and 6), bands for RbsA, RbsC, and streptavidin are clearly visible.
Excess RbsC in the flow-through is present, as expected. These results demonstrated that
proteins were successfully labeled and able to pull-down unlabeled RbsC in a similar
fashion to purification with affinity chromatography. Based on these successful pull-downs,
phage display experiments were subsequently performed.
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FIGURE 4-7: Pull-down of NHS-RbsB and NHS-RbsA. RbsB and RbsA labeled with
NHS-PEG4-Biotin. 1 = RbsB Input, 2 = RbsB-NHS + Beads (final), 3 = FT following
RbsB pull-down, 4 = W3 following pull-down, 5 = FT2 following detergent wash, 6 = W32, 7 = Standards, 8 = RbsA Input, 9 = RbsA-NHS + Beads (final), 10 = FT1, 11 = W3-1,
12 = FT2, 13 = W3-2. Fractions from Control Reactions with RbsC run on each gel (gel 1
– Input and beads fraction; gel 2 – FT1 and W3-1 fraction; gel 3 – FT2 and W3-2 fractions).
14 = RbsC Input, 15 = RbsC + beads (following wash steps).
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Figure 4-8: Coomassie staining of pull-down of NHS-RbsB and NHS-RbsA. RbsB is now
visible by staining. RbsB and RbsA labeled with NHS-PEG4-Biotin. 1 = RbsB Input, 2 =
RbsB-NHS + Beads (final), 3 = FT following RbsB pull-down, 4 = W3 following pulldown, 5 = FT2 following detergent wash, 6 = W3-2, 7 = Standards, 8 = RbsA Input, 9 =
RbsA-NHS + Beads (final), 10 = FT1, 11 = W3-1, 12 = FT2, 13 = W3-2. Fractions from
Control Reactions with RbsC run on each gel (gel 1 – Input and beads fraction; gel 2 – FT1
and W3-1 fraction; gel 3 – FT2 and W3-2 fractions). 14 = RbsC Input, 15 = RbsC + beads
(following wash steps).
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FIGURE 4-9: Pull-down of mal-RbsA and NHS-RbsB incubated with RbsC. RbsA is
labeled with mal-PEG2-Biotin and RbsB is labeled with NHS-PEG4-Biotin. 1 = RbsA
Input, 2 = RbsA-Mal + Beads (final), 3 = FT following RbsA pull-down, 4 = W3 following
pull-down, 5 = FT2 following detergent wash, 6 = W3-2, 7 = Standards, 8 = RbsB + RbsC
+ beads (final), 9 = FT1, 10 = W3-1, 11 = FT2 after RbsC, 12 = W3-2. Fractions from
Control Reactions with RbsC run on each gel (gel 1 – Input and beads fraction; gel 2 – FT1
and W3-1 fraction; gel 3 – FT2 and W3-2 fractions). 13 = RbsC FT, 14 = RbsC W3.
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FIGURE 4-10: Coomassie staining of pull-down of mal-RbsA and NHS-RbsB incubated
with RbsC. RbsB is now visible by staining. RbsA is labeled with mal-PEG2-Biotin and
RbsB is labeled with NHS-PEG4-Biotin. 1 = RbsA Input, 2 = RbsA-Mal + Beads (final),
3 = FT following RbsA pull-down, 4 = W3 following pull-down, 5 = FT2 following
detergent wash, 6 = W3-2, 7 = Standards, 8 = RbsB + RbsC + beads (final), 9 = FT1, 10 =
W3-1, 11 = FT2 after RbsC, 12 = W3-2. Fractions from Control Reactions with RbsC run
on each gel (gel 1 – Input and beads fraction; gel 2 – FT1 and W3-1 fraction; gel 3 – FT2
and W3-2 fractions). 13 = RbsC FT, 14 = RbsC W3.
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Figure 4-11: Pull-down of NHS-RbsA and mal-RbsA, both incubated with RbsC. RbsA is
labeled with NHS-PEG4-Biotin in lanes 1-5 and with mal-PEG2-Biotin in lanes 6-10. 1 =
RbsA-NHS+ RbsC + Beads (final), 2 = FT1 , 3 = W3-1, 4 = FT2 after RbsC addition, 5 =
W3-2, 6 = RbsA-Mal + RbsC + Beads (final), 7 = FT1, 8 = W3-1, 9 = FT2 after RbsC
addition, 10 = W3-2, 11 = standards. Fractions from Control Reactions with RbsC run on
each gel (gel 1 – Input and beads fraction; gel 2 – FT1 and W3-1 fraction; gel 3 – FT2 and
W3-2 fractions). 12 = RbsC FT2, 13 = RbsC W3-2.
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4.6.3.2 Phage Display Library Sorting Results
Phage display sorting was performed for the following targets: 1) NHS-RbsA, 2)
mal-RbsA, 3) NHS-RbsB, 4) mal-RbsA with RbsC, 5) NHS-RbsB with RbsC, 6) RbsABC
in biot-MSP1D1 nanodiscs, and 7) RbsABC in biot-MSP1D1 nanodiscs with excess RbsB
and RbsA for competitive selection. For samples 4) and 5), RbsC was added at every step
to ensure complex formation with target protein was maintained. A similar technique was
employed for sample 7) with RbsB and RbsA. All sorting was performed in buffers with
cofactors and detergent, except for nanodisc sample buffers, which contained only
cofactors.
Soluble proteins were immobilized at target concentrations of 200 nM at the start
of selection, while nanodiscs were immobilized at 2 µM. Where required, RbsC was added
at final concentrations of 1 µM. All protein concentrations were determined by Bradford
assays. For the second round of selection, target concentration was reduced 2-fold. For the
final rounds of selection, target concentration was reduced 10-fold from starting
concentrations. In addition, empty, unlabeled nanodiscs were employed as soluble
competitors for subtractive selection during these rounds. Following round 3, control pulldowns without proteins of phage sub-libraries were also tested for specific binding.
Following round 4 of selection, phages from each selection and control were
amplified and plated as serial dilutions (10-1 to 10-4) on LB media containing ampicillin, as
previously described (Dominik 2015) (FIGURE 4-12). Dilutions were streaked on plates
to resolve individual colonies produced by sublibrary infection.
Selection for samples 1, 2, 4, and 5 showed significant enrichment of phages over
background levels. Significantly higher numbers of colonies were present in samples with
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target (+) than without (-). Library sorting for these samples was halted at this point and
phages were carried to the next step. Unexpectedly, sample 3, which contained soluble
RbsB, showed little enrichment of phages over background levels.
Selection proceeded an additional round for samples 3, 6, and 7 and samples were
similarly plated (FIGURE 4-13). Following this round, serial dilutions of sample 3 showed
significant enrichment of phages over background levels, indicating a successful selection
strategy. Both samples 6 and 7 showed little enrichment over samples containing either
empty nanodiscs or no protein.
At the completion of selection, sublibraries were produced for each target that
showed significant enrichment over background levels, except for nanodisc samples.
Phages from both round 3 and round 4 of selection (or round 4 and round 5 for nanodiscs)
were used to infect E. coli cell cultures in the presence of helper phage and subsequently
plated separately on LB-ampicillin media for overnight growth. The following morning,
two dozen colonies from each plate were selected and amplified in 96-well deep block
format overnight. Cells were spun down and phages were isolated and diluted ten-fold for
ELISA experiments. The phages were also replated and colonies were sent for sequencing
to identify unique binders.
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Figure 4-12: Round 4 of phage library sorting. Phages were used to infect cells and serial
dilutions were plated following infection. Top panel: Comparison of selection for samples
1, 2, 3 from pull-downs containing labeled proteins (+) over those with beads alone (-).
Bottom panel: Same comparison, for samples 4, 5, 6, and 7.
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Figure 4-13: Round 5 of phage library sorting. Phages were used to infect cells and serial
dilutions were plated following infection. Top panel: Comparison of selection for sample
3 in pull-downs with (+) and without (-) proteins. Bottom panel: Comparison of selection
for samples with proteins (+), samples with empty nanodiscs (N-), and samples without
labeled proteins (-).
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4.6.3.3 Initial Validation Using Phage ELISA
ELISA experiments were performed for phage sublibraries using 20 nM target
concentration to immobilize protein on wells. ELISA experiments were performed in a
format mirroring selection. NHS-RbsA, mal-RbsA, NHS-RbsB, and RbsABC nanodiscs
were immobilized on ELISA plates. Much like for selection samples 4) and 5), RbsC was
added throughout ELISA experiments. Excess RbsA and RbsB were also employed for
ELISA experiments of selection sample 7). Following several rounds of washing, bound
phages were detected using HRP-conjugated anti-M13 antibody. Background wells lacking
proteins were prepared and tested for all phages.
Selections for NHS- and mal-RbsA showed significant enrichment of phages
following round 4, as evaluated by the improvement in ELISA signal for these sublibraries
(FIGURE 4-14, top and middle panels) over background levels (red = protein; black =
phage only controls). Similarly, NHS-RbsB sublibraries showed significant enrichment
following rounds 4 and 5 (FIGURE 4-14, bottom panel). For NHS-RbsB, samples from
rounds 3, 4, and 5 were used due to limited numbers of colonies yielded after overnight
plating.
Interestingly, selections with mal-RbsA and NHS-RbsB yielded different ELISA
results compared with selections for these proteins alone (FIGURE 4-15). For mal-RbsA,
few high quality binders were produced following selection with RbsC as a soluble
competitor (4-15, top panel). For NHS-RbsB (bottom panel), enrichment following round
3 was significantly improved due to the presence of RbsC as a soluble competitor.
Finally, ELISA results for nanodisc samples (FIGURE 4-16) showed very few
binders with signal elevated above background levels. This was the case both for selection
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with RbsABC nanodiscs (top panel) and for RbsABC nanodiscs with RbsA and RbsB as
soluble competitors. This was unsurprising given the lack of enrichment previously seen
in the sorting experiments.
Following ELISA experiments, signals were cross-referenced to sequencing results
and sorted according to signal strength and uniqueness of CDR amino acid identities. Based
on these experiments, 12-24 high- to medium quality binders were chosen from each
selection sublibrary, for a total of 95 from all selections combined and frozen as glycerol
stocks. These phages were named based on their selection strategy and numbered according
to their positions on the master plate (SPS1; see FIGURE 4-17).

4.6.3.4 Secondary ELISA for Additional Validation of Targets Prior to Cloning
Given limited resources for expression, purification, and crystal screening of
protein-sAB complexes for structure determination, secondary validation of phage ELISA
was pursued using the master population of unique binders chosen from the initial ELISA
experiments and sequencing results. Phages from master plate glycerol stocks were used
to infect E. coli cells and grown overnight at 37°C with shaking. The following morning,
cells were pelleted and phages were transferred to a separate plate. Ten-fold dilutions of
phage stocks were prepared for use with ELISA experiments.
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Figure 4-14: Phage ELISA of sublibraries for rounds 3 and 4 (and round 5 for RbsB) from
selection samples 1, 2, 3. For RbsA-NHS, round 3 is A1 - H3 and round 4 is A4 - H6. For
RbsA-mal, round 3 is A7 – H9 and round 4 is A10 – H12. For RbsB, round 3 is A1 – H3,
round 4 is A3 – H4, and round 5 is A5 – H6. Sample signal given in red. Phage only wells
(black) lack target protein. Dotted line is typical background level.
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Figure 4-15: Phage ELISA of sublibraries for rounds 3 and 4 from selection samples 4 and
5. For RbsA-mal with RbsC, round 3 is A1 - H3 and round 4 is A4 - H6. For RbsB-NHS
with RbsC, round 3 is A7 – H9 and round 4 is A10 – H12. Sample signal given in red.
Phage only wells (black) lack target protein. Dotted line is typical background level.
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Figure 4-16: Phage ELISA of sublibraries for rounds 4 and 5 from selection samples 6 and
7. For RbsABC (Sample 6) in biot-MSP1D1, round 4 is A1 – H3 and round 5 is A4 to H6.
For RbsABC (Sample 7) in biot-MSP1D1 with soluble competitors, round 4 is A7 – H9
and round 5 is A10 – H12. Sample signal given in red. Phage only wells (black) lack target
protein. Dotted line is typical background level.
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Figure 4-17: Map of Phage Master Plate from Ribose Transporter Sorting Experiments.
Top panel: Selected wells from phage ELISA experiments (see Figures 4-14 – 4-16). Wells
are color-coded to match selection experiment. Orange = NHS-RbsA, Yellow = mal-RbsA,
Blue = NHS-RbsB, Pink = mal-RbsA with RbsC, Purple = NHS-RbsB with RbsC, NDC =
combined phages from nanodisc sublibrary.
Bottom panel: Wells renamed according to selection strategy for convenient reference.
Color-coding from top panel is preserved. NAR01-NAR21 = phages from NHS-RbsA,
MA22-MA45 = phages from mal-RbsA, NBR51-NBR67 = phages from NHS-RbsB,
MAC70 = phages from mal-RbsA with RbsC, MBC71-MBC82 = phages from NHS-RbsB
with RbsC, NDC91-99 = phages fron nanodiscs. Plate is stored in Kossiakoff lab and is
named “SPS1”.
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4.6.3.4.1 Identifying Complex-Specific Binders – Part 1
Complex-specific phages were tested for using a competition binding ELISA. In
these experiments, labeled RbsA (both NHS and mal), NHS-RbsB, and newly labeled
NHS-RbsC were immobilized onto ELISA plates. Cognate binding partners were included
as soluble competitors throughout the ELISA experiments in the presence of 1 mM
magnesium, ATP, and orthovanadate.
The first set of experiments tested the following sub-population of phages from the
master plate, given by columns: 3, 4, 6, 7, 9, and 10 (FIGURES 4-18 – 4-20). This selection
sampled phages from each sub-population from every sorting experiment. Each phage was
tested using 11 different immobilized proteins and complexes. The conditions, given with
their color-coding and pattern used on ELISA bar graphs, are l) NHS-RbsA (blue, solid);
2) mal-RbsA (blue, dotted); 3) NHS-RbsB (red, solid); 4) NHS-RbsC (green, solid); 5)
NHS-RbsA + RbsC (blue, thin stripes); 6) mal-RbsA + RbsC (blue, thick stripes); 7) NHSRbsB + RbsC (red, checked); 8) NHS-RbsC with RbsA (white with green border); 9) NHSRbsC with RbsB (green and white stripes); 10) mal-RbsA with RbsBC (dark blue, solid);
and 11) NHS-RbsB with RbsAC (purple).
Initially, high background signal was observed for all experiments. This was
attributed to the presence of orthovanadate, which turns yellow when HCl is added. HCl
quenches the color development reaction of HRP. For these data sets, all background signal
was subtracted using phage-only wells. For subsequent ELISA experiments, vanadate was
reduced 10-fold in concentration with no detriment. This has previously been shown to be
tolerable to RbsABC complex formation (Clifton, et al., 2016).
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Phages obtained from RbsA sorting experiments (columns 3, 4, and 6)
demonstrated no cross-reactivity with other immobilized proteins. These phages also
produced robust ELISA signals in wells where immobilized RbsA was included with
cognate complex proteins. However, no signal was obtained from wells containing
immobilized RbsB or RbsC where RbsA was included to form complexes.
Phages obtained from RbsB sorting experiments produced strong signals where
RbsB was immobilized. Strong ELISA signals were also produced in wells that contained
mal-RbsA immobilized with RbsBC and cofactors. However, many RbB phages from the
NBR subpopulation also produced strong signals in wells containing only RbsA,
suggesting cross-reactivity and incomplete selection.
Immobilized RbsC produced no ELISA signal in wells where it was the only protein.
Interestingly, in wells with RbsC and binding partners, ELISA signals arose only phages
from nanodisc selections (NDC), suggesting complex recognition. These phages also
recognized RbsA and RbsB when RbsC was present.
Many results were ambiguous due to the background signal of vanadate. In the
following experiments, vanadate concentrations were reduced.
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Figure 4-18: Single-point phage ELISA testing columns 3 and 4 from SPS1 Master Plate
(See figure 4-17). The conditions, given with their color-coding and pattern used on ELISA
bar graphs, are l) NHS-RbsA (blue, solid); 2) mal-RbsA (blue, dotted); 3) NHS-RbsB (red,
solid); 4) NHS-RbsC (green, solid); 5) NHS-RbsA + RbsC (blue, thin stripes); 6) malRbsA + RbsC (blue, thick stripes); 7) NHS-RbsB + RbsC (red, checked); 8) NHS-RbsC
with RbsA (white with green border); 9) NHS-RbsC with RbsB (green and white stripes);
mal-RbsA with RbsBC (dark blue, solid); and 11) NHS-RbsB with RbsAC (purple).
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Figure 4-19: Single-point phage ELISA testing columns 6 and 7 from SPS1 Master Plate
(See figure 4-17). The conditions, given with their color-coding and pattern used on ELISA
bar graphs, are l) NHS-RbsA (blue, solid); 2) mal-RbsA (blue, dotted); 3) NHS-RbsB (red,
solid); 4) NHS-RbsC (green, solid); 5) NHS-RbsA + RbsC (blue, thin stripes); 6) malRbsA + RbsC (blue, thick stripes); 7) NHS-RbsB + RbsC (red, checked); 8) NHS-RbsC
with RbsA (white with green border); 9) NHS-RbsC with RbsB (green and white stripes);
mal-RbsA with RbsBC (dark blue, solid); and 11) NHS-RbsB with RbsAC (purple).
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Figure 4-20: Single-point phage ELISA testing columns 9 and 10 from SPS1 Master Plate
(See figure 4-17). The conditions, given with their color-coding and pattern used on ELISA
bar graphs, are l) NHS-RbsA (blue, solid); 2) mal-RbsA (blue, dotted); 3) NHS-RbsB (red,
solid); 4) NHS-RbsC (green, solid); 5) NHS-RbsA + RbsC (blue, thin stripes); 6) malRbsA + RbsC (blue, thick stripes); 7) NHS-RbsB + RbsC (red, checked); 8) NHS-RbsC
with RbsA (white with green border); 9) NHS-RbsC with RbsB (green and white stripes);
10) mal-RbsA with RbsBC (dark blue, solid); and 11) NHS-RbsB with RbsAC (purple).
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4.6.3.4.2 Identifying Complex Specific Binders – Part 2
The remaining phages were tested by single-point ELISA in a similar fashion,
employing similar testing conditions. These conditions, given with their color-coding and
pattern used on ELISA bar graphs, are l) NHS-RbsA (blue, solid); 2) mal-RbsA (blue,
dotted); 3) NHS-RbsB (red, solid); 4) NHS-RbsC (green, solid); 5) NHS-RbsA + RbsBC
(blue, thin stripes); 6) mal-RbsA + RbsC (blue, thick stripes); 7) NHS-RbsB + RbsAC (red,
checked); 8) NHS-RbsC with RbsA (white with green border); 9) NHS-RbsC with RbsB
(green and white stripes); 10) mal-RbsA with RbsBC (dark blue, solid); and 11) NHSRbsC with RbsA and RbsB (purple). Phages from columns 2, 5, and 8 were tested using
this conditions with cofactors (FIGURES 4-21 and 4-22).
In addition, phages from part 1 with high background signal were re-tested using
the reduced vanadate concentrations. These included primarily RbsB phage subpopulations,
which were tested to determine if cross-reactivity signals were simply a consequence of
vanadate background. Testing conditions were identical to those described above
(FIGURE 4-23).
The results for untested phages were consistent with those observed in the previous
ELISA experiments (FIGURE 4-21). Wells with immobilized RbsA produced strong
ELISA signals from RbsA phage subpopulations, as expected. These phages showed no
cross-reactivity with wells containing immobilized RbsB or RbsC, including where RbsA
was present as a soluble cofactor.
Untested phages from the RbB subpopulation showed less cross-reactivity with
wells containing immobilized RbsA alone (FIGURE 4-22). These phages gave moderate
ELISA signals for wells with immobilized RbsB. Interestingly, these same phages gave
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robust ELISA signals in wells with soluble RbsBC present as a cofactor, suggesting the
ability to bind to RbsB in the context of ribose transporter complexes.
Retested phages from RbsB sorting experiments also showed reduced crossreactivity with RbsA-alone wells (FIGURE 4-23, top panel). However, relatively high
ELISA signals for these same wells were obtained with phages from RbsBC sorting
experiments (FIGURE 4-23, middle panel and MBC subpopulation).
Finally, wells with immobilized RbsC with and without cognate binding partners
gave almost no signal in any ELISA experiments, including from nanodisc phage
subpopulations.
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Figure 4-21: Single-point phage ELISA testing columns 2 and 5 from SPS1 Master Plate
(See figure 4-17). These conditions, given with their color-coding and pattern used on
ELISA bar graphs, are l) NHS-RbsA (blue, solid); 2) mal-RbsA (blue, dotted); 3) NHSRbsB (red, solid); 4) NHS-RbsC (green, solid); 5) NHS-RbsA + RbsBC (blue, thin stripes);
6) mal-RbsA + RbsC (blue, thick stripes); 7) NHS-RbsB + RbsAC (red, checked); 8) NHSRbsC with RbsA (white with green border); 9) NHS-RbsC with RbsB (green and white
stripes); 10) mal-RbsA with RbsBC (dark blue, solid); and 11) NHS-RbsC with RbsA and
RbsB (purple).
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Figure 4-22: Single-point phage ELISA testing column 8 from SPS1 Master Plate (See
figure 4-17). These conditions, given with their color-coding and pattern used on ELISA
bar graphs, are l) NHS-RbsA (blue, solid); 2) mal-RbsA (blue, dotted); 3) NHS-RbsB (red,
solid); 4) NHS-RbsC (green, solid); 5) NHS-RbsA + RbsBC (blue, thin stripes); 6) malRbsA + RbsC (blue, thick stripes); 7) NHS-RbsB + RbsAC (red, checked); 8) NHS-RbsC
with RbsA (white with green border); 9) NHS-RbsC with RbsB (green and white stripes);
10) mal-RbsA with RbsBC (dark blue, solid); and 11) NHS-RbsC with RbsA and RbsB
(purple).
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Figure 4-23: Single-point phage ELISA re-testing columns 7, 9, and 10 from SPS1 Master
Plate (See figure 4-17). These conditions, given with their color-coding and pattern used
on ELISA bar graphs, are l) NHS-RbsA (blue, solid); 2) mal-RbsA (blue, dotted); 3) NHSRbsB (red, solid); 4) NHS-RbsC (green, solid); 5) NHS-RbsA + RbsBC (blue, thin stripes);
6) mal-RbsA + RbsC (blue, thick stripes); 7) NHS-RbsB + RbsAC (red, checked); 8) NHSRbsC with RbsA (white with green border); 9) NHS-RbsC with RbsB (green and white
stripes); 10) mal-RbsA with RbsBC (dark blue, solid); and 11) NHS-RbsC with RbsA and
RbsB (purple).
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4.6.3.4.3 Mapping RbsA using Single Point ELISA
Initial ELISA experiments showed the highest quality binders were available for
RbsA. Since an N-terminal domain structure of RbsA has previously been determined
(Armstrong, Tabernero, Zhang, Hermodson, & Stauffacher, 1998), epitope mapping using
phage ELISA was performed to test if any phages bound to the C-terminal domain. The
goal was to determine if antibodies exist that could stabilize this region, making it more
amenable for crystallization.
The N-terminal domain construct for RbsA (residues 1-244) was previously
designed and shown to express stably at high levels (Clifton, 2005). This construct was
purified as previously described and subsequently labeled with both NHS and maleimide
linkers, as done before for full-length RbsA. The maleimide linker took advantage of the
single cysteine present on the N-terminal domain (NTD).
Phages were prepared as described earlier. ELISA plates were prepared and coated
with either no protein, NHS-RbsANTD, mal-RbsANTD, or NHS-RbsAFL (for full-length
RbsA). Binding was tested in the presence of cofactors, as before, taking care to use
reduced vanadate concentrations. All phage subpopulations produced from RbsA sorting
experiments were tested for binding to either RbsANTD or RbsAFL. As negative controls,
some phages from RbsB sorting were included.
Of the 45 phages tested from the RbsA subpopulation, 23 produced signals for
either RbsANTD labeled version (FIGURES 4-24 and 4-25). Of this group of phages,
only 9 produced signals resembling those produced for full-length RbsA. As an additional
control, soluble NTD RbsA was included as a competitor in a separate ELISA experiment.
These results were identical to those produced for immobilizing NTD RbsA (data not
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shown). In addition, no cross-reactivity with RbsB phages was observed. This suggested
the population included phages specific for full-length RbsA or NTD-RbsA, and perhaps
some that bound only to the C-terminal domain. Experiments with the C-terminal domain
were not pursued as no stably expressing construct has yet been identified.

4.6.3.5 Cloning into Expression Vectors and Purifying Phages
With considerations for time and resources, a small group of phages from the initial
population of 95 were chosen for cloning into expression vectors, as described in the
methods section. The choice was based on strength of ELISA signal, diversity of epitopes,
and recognition of ribose transporter complexes. Cloning was performed using a previously
described protocol. Successful cloning reactions were confirmed by sequencing results
using primers specific for both heavy- and light-chains.
Twelve clones were then expressed and purified using previously described protocols
(Paduch 2013). Of these, eight expressed at sufficient levels to carry over to in vitro studies
(NAR09, NAR10, MA22, MA36, NBR51, MAC70, NDC91, and NDC92). Three of these
expressed at significantly high levels and were expressed and purified in greater amounts,
in anticipation of crystallization experiments. Interestingly, of the four with low expression
levels, two were from MBC subpopulations and two from nanodisc sorting experiments.
Additional optimization of poorly expressed sABs was not pursued at this time.
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Figure 4-24: Single-point phage ELISA using immobilized RbsA-NTD. ELISA signals
compared for: 1) phage alone (black); 2) NHS-labeled RbsA-NTD (blue); 3) maleimidelabeled RbsA-NTD (red); and 4) NHS-labeled RbsA-FL (full-length, green). Phages from
all RbsA subpopulations (columns 1-6 of SPS1 master) were tested. See Figure 4-17.
ELISA was performed as described earlier.
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Figure 4-25: Single-point phage ELISA using immobilized RbsA-NTD. ELISA signals
compared for: 1) phage alone (black); 2) NHS-labeled RbsA-NTD (blue); 3) maleimidelabeled RbsA-NTD (red); and 4) NHS-labeled RbsA-FL (full-length, green). Phages from
all RbsA subpopulations (columns 1-6 of SPS1 master) were tested. See Figure 4-17.
ELISA was performed as described earlier.
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4.6.3.6 In Vitro Complex Formation Experiments
Following sAB purification, the ability of reformatted antibodies to recognize
epitopes in vitro was tested using gel-filtration chromatography. Prior to injection, sABs
were added to proteins at a molar excess, mixed, and incubated briefly. Binding was
evaluated by shifts to lower retention volumes on the chromatogram.
RbsA was tested with NAR09, NAR10, MA22, and MA36. In addition,
combinations of antibodies were tested based on epitope-mapping results from RbsA-FL
versus RbsA-NTD. Combinations included NAR09 with NAR10, NAR09 with MA22, and
NAR10 with MA22. These tests were motivated by improving RbsA crystallizability and
increasing the complex size for potential applicability to cryo-EM studies.
RbsA eluted from size-exclusion columns at lower retention volumes in the
presence of all tested antibodies (FIGURE 4-26A). RbsA alone eluted at 14.9 mL run
volume, while RbsA with sABs eluted at approximately 13.8 mL. Fractions were analyzed
by SDS-PAGE and revealed the presence of additional bands at 25 kDa (data not shown),
indicating co-elution of sABs. These bands corresponded to the heavy and light chains,
which run separately after addition of SDS sample buffer.
Combinations of antibodies were also tested for binding to RbsA (FIGURE 4-26B).
Antibodies were combined at the same molar excess over RbsA, mixed, and injected onto
the column after brief incubation on ice. Both the NAR09/MA22 (4-26B) and the
NAR10/MA22 (not shown) combinations eluted at the same volume as RbsA with single
sABs, suggesting both could not bind at the same time. However, the NAR09/NAR10
combination eluted at a slightly lower retention volume (13.2 mL). Analysis of the fractions
by SDS-PAGE was, as expected, ambiguous for the presence of two sABs. The column
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was subsequently recalibrated with known standards. The known 158 kDa standard eluted
at approximately 13.3 mL. This would also represent the rough molecular weight of RbsA
(55.3 kDa) plus two antibodies (50 kDa each). Additional analyses using RbsA and sABs
in the presence of cofactors have not yet been pursued.
All eight purified sABs were also tested for binding to the detergent-reconstituted
RbsABC complex in the presence of cofactors. All antibodies were concentrated to higher
concentrations using 10 kDA MWCO spin filters to combat dilution effects when
combined with RbsABC. The stock concentration following this procedure was generally
80 – 100 µM. As before, sABs were added to RbsABC, mixed, and then allowed to
incubate briefly on ice. Samples were injected onto the SEC and 1 mL fractions were
collected. Binding of sABs to RbsABC was evaluated by analysis of chromatograms for
shifts to lower retention volumes and then by SDS-PAGE.
Of the 8 antibodies, only one, NBR51, resulted in a shift on the chromatogram to a
lower retention volume (FIGURE 4-27A). SDS-PAGE analysis of the elution fractions
revealed the presence of heavy- and light-chains in the elution fraction with RbsABC. The
result was unexpected, as the sABs were produced in RbsB sorting and had previously not
bound to complexes during ELISA experiments.
As a control step, NBR51 binding to RbsB alone during gel-filtration experiments
was tested. RbsB elutes at ~15.9 mL of the run volume. Addition of NBR51 produced no
noticeable shift of RbsB (FIGURE4-27B) and eluted from the SEC in the second column
volume, as other unbound sABs typically have done. The results strongly suggested
NBR51 was binding non-specifically to RbsABC, and perhaps interacting with the
hydrophobic detergent core. Protein elution profiles are typically symmetrically distributed
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when the molecules are monodisperse; the asymmetric peak shift caused by NBR51
addition likely meant this was not the case.
Additional tests of sAB binding and characterization have yet to be pursued and
will be completed at a later date.
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Figure 4-26: Superdex200 10/30 GL elution profiles of RbsA (blue) with antibodies either
singly (A) or in combination (B).
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Figure 4-27: A) Superdex200 10/30 GL elution profiles of vanadate-trapped RbsABC (blue)
and in the presence of antibodies (color-coded above). B) Superdex200 10/30 elution
profile of RbsB (red) and in the presence of NBR51 (blue).
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4.7 Discussion
Crystallization trials of ribose transporter complexes have yet to produce
diffraction-quality crystals despite extensive screening in a variety of media, from
detergents to lipids. While protein crystals have been achieved, the identity of these crystals
has yet to be determined. This awaits the growth of hardy, harvestable crystals that can be
tested by X-ray diffraction methods. Optimization trials are currently being pursued to
improve the quality of these crystals.
The inability of RbsABC to tolerate different detergents is disappointing, if
unsurprising. The only detergent that appeared to produce a well-behaved elution on sizeexclusion chromatography was C12E8. Additional optimization may result in a condition
where this detergent can be used for RbsABC crystallization. While DDM remains the
most popular detergent for membrane protein crystallization and more crystals obtained
with this detergent than not, the success rate as a whole is pedestrian at best and wanting
for better methods. Newer, lipid-like detergents are available that may be worth pursuing.
Screening RbsABC in different LCP lipids is also currently in progress. Alternatively,
cloning RbsABC from other organisms may prove to be a more successful pursuit, and
these experiments should be attempted in the near future.
The results from phage display sorting are promising, and have at least produced
three high-quality binders for the NBD, RbsA, for which no structure currently exists.
Unsurprisingly, it appears these antibodies recognize regions of RbsA involved in proteinprotein interactions, based on the absence of antibody binding to ribose transporter
complexes, and thus these sites are expected to be highly antigenic. Crystallization trials
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of RbsA-Fab complexes will soon be pursued in the hopes that some crystals can be
obtained. Further characterization of these current binders will also be pursued.
The question of whether RbsA binds one or two antibodies remains unanswered.
Analytical ultracentrifuge experiments and multi-angle light scattering are both available
tools that can address these ambiguities. These extend the size of RbsA significantly and
may aid crystallization trials.
In addition, epitope mapping using purified sABs will soon be pursued to identify
other unique phage binders to reformat and clone into expression vectors. These will
provide additional crystallization reagents and hopefully produce a handful that can
recognize and bind specifically to the RbsABC complex. No antibodies from the current
batch that were expressed and purified recognize the transport complex. It appears NBR51
does not recognize RbsB, and likely interacted with the detergent or transport complex by
non-specific hydrophobic interactions. This is not an uncommon property of these
antibodies (Dominik, 2015). ELISA results pointed to the potential of MBC subpopulations
that appeared to recognzie complexes. Attempts to express two clones from this group
failed. Several others remain and will be cloned and expressed in the hope that some can
be produced in quantities sufficient for crystallization experiments.
An additional possibility will be to pursue a new selection. Nanodiscs had
previously not been optimized at the time selection was pursued. Unsurprisingly, binders
from that selection are poor-quality and do not specifically recognize any ribose transporter
proteins. Indeed, the most successful selection appears to be for RbsA alone, which
produced 45 high-quality binders that have no cross-reactivity with other proteins.
Currently only 5 of these were produced in high quantities, and more will be cloned,
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expressed, and purified as needed. The nanodisc selection experiments will be pursued
again in the near future to obtain high-quality crystallization chaperones for RbsABC.
Ultimately, the difficulty in crystallizing RbsABC may arise from conformational
heterogeneity. Antibodies may resolve this issue. In addition, identifying high-quality
binders for RbsABC may extend the range of the complex for structural studies by cryoEM. The current complex size is 150 kDa; binding one or two antibodies extend the
complex into a size range that make these experiments somewhat practical. These options
will be pursued with enthusiasm in the near future in the hopes of finally obtaining a highresolution map of the complex.
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CHAPTER FIVE: A MODEL FOR RIBOSE TRANSPORT

5.1 The Ribose Transport Cycle
The ultimate goal of this study is to better understand the function of this unusual
ABC transporter at high resolution. While we still await a crystal structure to provide this
level of detail, assembly experiments and EPR data have provided sufficient mechanistic
information required to construct a transport model for the ribose transporter. In the search
for general principles of ABC transporter function, perhaps this knowledge can be applied
to other unusual ABC systems.
Assembly experiments have demonstrated that three different transport complexes
can be isolated depending on the protein and cofactor combinations used (Clifton, et al.,
2015). In the absence of cofactors, the RbsBC complex is isolated, and RbsA is dissociated
from the inner membrane complex. In the presence of non-hydrolyzable analogs or
nucleotide and orthovanadate, the full transport complex RbsABC is isolated. In the
presence of Mg-ADP, the RbsAC complex is isolated, with RbsB dissociating from its
binding site on RbsC. Despite the unusual set of complexes and the single active NBD of
RbsA, these complexes assemble in a canonical manner: one molecule of RbsB docks onto
a transmembrane domain homodimer formed by RbsC, which associates with one molecule
of RbsA consisting of two NBDs (Clifton, et al., 2016).

234
SDSL EPR experiments of RbsB show that in the cofactor-free RbsBC complex,
the lobes of RbsB remain at least partially together in the closed state of the protein. In the
vanadate-trapped full complex, the lobes of RbsB are driven completely apart, a state where
ribose is released following hydrolysis. Finally, the Mg-ADP bound state of the transport
complex shows the lobes of RbsB close together once again, a conformation that likely
drives RbsB dissociation from the transport complex. These results are consistent with the
assembly experiments and provide a pathway for ribose release from RbsB due to ATP
hydrolysis (Erramilli, Simon, Clifton, & Stauffacher, 2016).
SDSL EPR experiments of RbsA now demonstrate that the NBDs of RbsA undergo
closure in the vanadate-trapped RbsABC complex. Further, the presence of RbsB promotes
subdomain rotation, providing the structural basis for RbsB stimulated hydrolysis activity
of RbsA. This transmembrane signalling, where the SBP regulates the hydrolysis cycle of
the NBDs, is typical for ABC importers and demonstrates canonical behavior for the
consensus site of RbsA. During this process, it appears ATP is bound but not hydrolyzed
at the degenerate site, which may provide cooperativity for ATP hydrolysis in RbsA. This
RbsB- and ribose-stimulated hydrolysis and cooperativity are demonstrated in ATPase
activity assays from nanodiscs.
Post-hydrolysis, the NBDs dissociate in the Mg-ADP bound conformation. This
likely represents the inward-facing state of the transporter, but could also represent the
outward-occluded conformation. This ambiguity cannot be resolved with a high-resolution
crystal structure. RbsA then appears to dissociate from RbsC when the bound nucleotide
is removed. Whether this state is physiological remains unclear. Given cellular ATP
concentrations, it is likely that nucleotide is rapidly recycled, and may briefly result in a
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full or partial dissociation of RbsA from RbsC. This would resolve a significant conflict in
this system: how RbsA traffics to and associates with the cell membrane in the absence of
RbsC. If the need for this is obviated by rapid nucleotide exchange, then the model is
complete until higher resolution information can be obtained.
Assuming rapid exchange of nucleotide and a constant association of RbsA with
RbsC, a transport model can be described as follows. Ribose-bound RbsB docks onto the
Mg-ATP bound state of the inner membrane RbsAC complex, likely in an intermediate
conformation resembling the pre-translocation state of the maltose transporter or the
cytoplasmic-occluded conformation of BtuCD. This docking promotes domain closure in
RbsA and ATP hydrolysis by the single active site, and simultaneously drives the lobes of
RbsB apart, releasing ribose to transporter. Here the transporter is clearly in the outwardfacing state, with the NBDs of RbsA tightly associated, the coupling helices of RbsC fully
engaged with their complementary Q-loops, and RbsB stably forced into an open
conformation. The γ-phoshpate is then released, destabilizing the NBD-NBD interactions
of RbsA and leading to an inward-facing or outward-occluded state. This results in
conformational changes in RbsC sufficient to transport ribose into the cytoplasm. RbsB
follows the conformational changes of RbsC, with its lobes pinching together until its
interaction with RbsC is destabilized and it dissociates. The transport cycle is completed,
nucleotide is exchanged, and the transporter awaits a freshly-loaded RbsB to initiate the
next cycle (FIGURE 5-1).
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5.2 What about RbsC?
The RbsB and RbsA data complement each other and provide a structural
mechanism for linking ribose release from RbsB with stimulation of ATP hydrolysis in
RbsA. The observations from these experiments, however, stand in contrast to what is
currently known about RbsC.
RbsC has a predicted ten transmembrane helices per monomer, based on cysteine
scanning mutagenesis. Its closest homolog is BtuC, with which it shares 25% identity.
Comparison of the model generated from cysteine scanning mutagenesis with the structure
of BtuC shows a conservation of structure that is reasonable (Stewart & Hermodson, 2003).
For instance, the coupling helix of RbsC, defined by a conserved EAA motif found in all
ABC transporters, lies between TM helices 6 and 7. This is a typical feature of Type II
ABC importers. Type I importers typically contain the coupling helix between TM helices
4 and 5. In addition, the scanning experiments reveal a large loop between TM helices 5
and 6. In the structure of Type II importers, this loop forms a short TM helix, termed 5a,
that forms the periplasmic gate for these transporters. Since it is primarily located within a
solvent-exposed vestibule that forms the receiving site for the transported substrate, it is
expected that this region have solvent accessible cysteines. Thus, it is likely the gating for
RbsC occurs in a highly similar manner as BtuC and other type II importers
Given the similarity, this exposes a conundrum that cannot be resolved by the
current structural understanding of type II importers. While rigid-body motions of the
TMDs drive the conformational changes for maltose transport (and other type I importers),.
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Figure 5-1: Transport cycle for ribose transporter. Grey bar is cell membrane. Ribose is
brown pentagon, ATP is blue circle, and ADP is purple circle. RbsB is green, RbsC is red,
and RbsA is colored by catalytic domain (orange) and helical domain (light blue). Left to
right: RbsB captures ribose and delivers it to RbsC, which stimulates RbsA to bind ATP
while driving open RbsB simultaneously, releasing ribose to the outward-facing
translocation channel. ATP is bound at both consensus and degenerate sites. ATP is
hydrolyzed by the consensus site, and interactions stabilizing the helical and catalytic
domains in the consensus site are destabilized. As the helical domain disengages, this
drives RbsC to an inward-open conformation and simultaneously resulting in RbsB
dissociation. Nucleotide is then recycled and the cycle begins again.
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the conformational changes of type II importers are typically limited to rotations of
the gating helices to allow alternating access of the translocation channel to the periplasm
and cytoplasm. These movements facilitate substrate delivery down a channel that lacks a
clear binding site, unlike the maltose transporter and other type I importers.
The lack of rigid body movements of type II TMDs also limits the conformational
changes possible for their cognate binding proteins. Typically, the SBPs for these systems
also undergo limited conformational changes to bind and release their substrates. Their
affinity for these substrates is typically lower compared to SBPs found in type I importers.
On the other hand, the SBPs bind the TMDs with low nanomolar affinity. Consequently,
substrate release is driven by the increased affinity of the SBP with the TMD. This is
accomplished by a slight rotation of the lobes away from one another.
While the RbsB-RbsC interaction is patterned in a type II manner, it is clear both
from crystal structures of RbsB and the EPR data that RbsB undergoes fairly significant
conformational changes during the transport cycle, from ribose binding to subsequent
release. No obvious pathway exists for the TMDs of a type II system to undergo such
significant changes, which would certainly require rigid body rotations.
It is also clear that RbsA undergoes fairly significant conformational changes. Here,
however, both type I and type II importers are similar. Cytoplasmic gating in the latter
system, provided by coupling helices and TM helical translations, drives fairly large
conformational changes, similar to those observed in type I importers. The inward rotations
reported from EPR experiments by RbsA support this model. How hydrolysis at a single
active site of RbsA fuels conformational changes in RbsC remains unclear.
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5.3 Type I, II, Or Something Else?
Three types of bacterial ABC importers have recently been identified. These
include two models of canonical ABC importers based on structure-function studies of the
maltose (type I) and vitamin B12 (type II) transporters. A third type of importer, the ECF
transporters, have recently been included in ths family as a separate class of importer. These
are very different structurally from the former two classes and operate by a different
alternating access mechanism, though also fueled by ATP-hydrolysis in dimeric NBDs.
Is this type-setting sufficient, or can these proteins even been described in terms of
types? As studies of increasing sophistication of the two types have been conducted, the
major difference appears to be structurally. In both cases, regulation of hydrolysis is driven
essentially by the binding protein, linking ATP utilization with transport in an efficient
manner. The structures of the TMDs and SBPs used by each type provide the essential
functional difference. Type I TMDs pair with SBPs from clusters with flexible hinge
regions. This pairing results in rigid body rotations of type I TMDs to drive open the
binding protein, releasing substrate into a well-defined binding pocket within the TMD.
This transient site releases substrate as the TMD shifts from outward open to inward open,
which also destabilizes its interaction with the SBP.
Type II TMDs pair with SBPs from clusters with rigid hinges. The SBPs dock into
grooves in the TMDs, inducing a slight rotation of SBP lobes to release the substrate into
the translocation channel. Rearrangements of the gating helices allow the substrate to slide
down the translocation channel. These gates are the basis for alternating access in these
systems.
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It appears the ribose transporter has a mismatch of type I SBP with type II TMD.
How the SBP interacts with the TMD is an open question, and one that will require a highresolution structure to answer. Whether other such systems exist is a matter of improved
knowledge of the TMDs of putative ABC importers. Few systems exist with a RbsA-type
protein, and it remains to be seen whether the ribose transporter is a molecular oddity or
provides clues that lead to a fundamental understanding of many other ABC transporters.
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APPENDIX

A.1 Purification of TEV Protease
TEV protease was expressed from glycerol stocks procured as a gift from the
Mesecar Research Lab at Purdue University. The protein was purified with TALON resin
using the protocol from their lab. Following purification, TEV protease fractions were
pooled and dialyzed overnight into 50 mM Tris-HCl, pH 8.0, 25% glycerol, 5 mM EDTA,
2 mM DTT. The final concentration, determined by A280 using the estimated extinction
coefficient, was typically 0.8 – 1.4 mg/mL TEV protease. The sample was transferred as
1 mL aliquots into 1.5 mL Eppendorf Tubes, which were flash frozen in liquid nitrogen
and stored at -80ºC.

A.2 Summary of RbsA Catalytic Mutations
A full list of RbsA mutations and their impact on transporter function can be found
on the following page. All mutations were produced by Huide Zhang by site-directed
mutagenesis. Transport was assayed in liposomes using C-14 labeled ribose. Swarm
assays were performed on solid media made with ribose as the sole carbon source.
Chemotaxis was studied using a capillary-based technique that assayed cell migration due
to ribose. Cell lines used for this study are indicated and stored at -80 ºC.
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Table A-1: Summary of RbsA Catalytic Mutations, adapted from Huide Zhang.

pecies

Position

Ribose
Swarm
Plate

Wildtype
K43R
S44A
Q86A
S143A
D166A
E167Q
E167A
H199A
H199R
R291A
R291K
L395P
L395V
E421Q
E167Q/
E421Q

-

100

100

100

100

Complex
Assembly
(MgATPVO4)
ABC

Walker A
Walker A
Q-loop
Signature
Walker B
Walker B
Walker B
H-loop
H-loop
Walker A
Walker A
Signature
Signature
Walker B
Walker B

0
0
0
100
100
0
0
0
0
40
60
40
50
10
0

10
10
35
0
60
-

5-10
10
85
100
10
0
10
75
0
40
85
-

0
0
60
90
0
0
10
0
0
75
90
30
50
0

BC
BC
BC
ABC
BC
ABC
ABC
ABC
BC
ABC
ABC
BC
ABC
ABC
ABC

Peak
Ribose
Chemotactic
Transport
Response

ATPase
Activity

VITA
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